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Dengue, an Aedes mosquito-borne flavivirus, is the most common vector-borne viral 
infection worldwide. Infections result in around 100 million (95% credible interval:  67 - 
136 million) clinical episodes and 10.5 million (95% uncertainty intervals: 4.1 – 22.7 
million) hospitalizations annually, mostly within the Asia Pacific region. There are four 
closely related viral serotypes, all of which cause severe disease. First infections are often 
mild/asymptomatic but subsequent infections with heterologous serotypes more 
frequently result in severe episodes and hospitalisations. National surveillance systems 
are not designed to estimate the full disease burden and the value of preventive measures 
is therefore poorly defined. 
In 2014 the first dengue vaccine, CYD-TDV, was licensed having demonstrated 
significant efficacy against all four serotypes in study participants aged 2 – 16 years. 
Subsequent analyses after 5 years’ follow-up revealed a more complex vaccine profile 
with superior protection in individuals seropositive for dengue, but an elevated risk of 
hospitalized dengue in seronegative vaccine recipients. Population-level benefit-risk is 
therefore dependent on epidemiological criteria and WHO recommends its use only under 
certain conditions or following confirmation of individual serostatus.  
This thesis describes a body of epidemiological research designed to improve 
understanding of these conditions. Studies were intended to fill important knowledge gaps 
identified following discussions with local vaccine policymakers and experts. My role, 
working within a multidisciplinary team, was to understand identified gaps and develop 
and implement a corresponding research agenda to fill them. I designed and contributed 
to protocols, provided oversight to their implementation working with local research 
teams, analysed and interpreted the resulting data and drafted the manuscripts included 
in this thesis which were published between 2016 and 2020.  
These studies used different methods: we analysed existing data sources to improve 
estimates of symptomatic dengue disease burden; measured age-stratified dengue 
seroprevalence in children in India and Indonesia; estimated force-of-infection (the annual 




seven Asian countries; and conducted a prospective surveillance study to plan future 
dengue vaccine effectiveness research. After refining these methods for dengue, we 
extended them to Japanese encephalitis, another mosquito-borne flavivirus. 
Using data derived from active case ascertainment from the placebo arm of a paediatric 
clinical trial, wherein parents were contacted weekly and reminded to report to study sites 
in case of febrile illness in their children, we identified a crude dengue attack rate of 
4.6%/year. Only 29% of these events were clinically diagnosed as dengue by study 
investigators, indicating that most symptomatic disease fails to satisfy existing case 
definitions. This active case ascertainment captured a greater proportion of symptomatic 
dengue than national passive surveillance systems. The ratio between these two rates 
(“expansion factor”) can be used to estimate the full disease burden from passive 
surveillance reports and we calculated factors ranging from 0.5 – 31.7, depending on 
country and case definition.  
Large seroprevalence surveys in India and Indonesia confirmed very high rates of 
paediatric infection: by the age of 10 years, 73% of children in India and 79% in Indonesia 
had been infected at least once. We also identified serological evidence for circulation of 
multiple dengue serotypes in both countries. We used these and other serological data 
to estimate force-of-infection which varied widely between countries from 1.7% 
(Singapore) to 24.1% (the Philippines), with significant heterogeneity within countries. 
The force of infection of Japanese encephalitis was much lower (varying from 0.8% in 
Malaysia to 5.2% in Vietnam) but this demonstration of transmission in urban areas was 
an important finding in areas where Japanese encephalitis vaccination is not routine. After 
conducting a hospital-based surveillance study to plan future dengue vaccine 
effectiveness studies in Malaysia, we concluded that test-negative case control studies 
are not feasible due to small numbers of test-negative controls; and that case control 
studies for dengue vaccines could be significantly biased by underlying differences 
between cases and controls. 
In summary, these studies demonstrated intense but heterogeneous dengue 
transmission across multiple Asia-pacific countries. These levels of transmission are 




level but, due to heterogeneity in endemicity, more local approaches would likely be 







Dengue fever is a disease caused by a virus passed between people by the bites of 
infected “tiger” mosquitoes. The disease is often not serious, causing only mild fever, but 
can cause more serious illness and severe cases need to spend time in hospital and in 
rare cases, they can die. The mosquitoes which transmit the disease can only live in 
warm, humid climates, so cases are concentrated in tropical areas and most occur in 
Asia. There are four types of dengue caused by slightly different viruses. After infection 
with one virus people develop life-long immunity and so it is possible to become sick a 
maximum of four times in somebody’s life. The total number of cases which occurs 
globally is not known because many of the cases are never diagnosed. 
There is one vaccine available which can prevent dengue, but the vaccine can cause 
people who have never had dengue before to have a higher likelihood of more severe 
cases when infected. The WHO therefore recommends the vaccine should only be used 
in populations with a high probability of having been previously infected. This thesis 
describes research which was conducted to help understand which areas of Asia have 
the most dengue and therefore would be the most appropriate places to use the dengue 
vaccine. I reanalysed data which had been generated from other studies and worked with 
study teams to collect new data to make estimates of the number of people becoming 
sick with dengue each year. We estimated the number of people who had been historically 
infected, by looking for specific antibodies indicating previous dengue infection in the 
blood of healthy people and conducted similar calculations for Japanese encephalitis, a 
similar virus causing disease in Asian countries. Finally, we conducted a study in 
Malaysian hospitals, to help us plan future studies to monitor how well dengue vaccines 
are working.  
We estimated that around 5% of children in some Asian cities became sick due to dengue 
every year. However less than 1/3 of those cases were correctly diagnosed. Our method 
of actively looking for dengue identified many more cases – up to 30x more – than were 




We found that by the age of 10 years, 73% of children in India and 79% in Indonesia had 
circulating dengue antibodies indicating they had been infected with dengue before. It 
was possible from these and other data to calculate the proportion of children who 
became infected annually, which varied from 1.7% of children (in Singapore) to 24.1% (in 
the Philippines). Japanese encephalitis infections were much less common, but we still 
identified circulating virus in urban areas where it had been believed the virus was rare. 
While planning a study to monitor if dengue vaccines prevent disease as they should, in 
Malaysia, we found those studies would be easily affected by methodological problems 
and proposed solutions to fix those problems.  
In summary, these studies demonstrated that dengue circulates very widely and that 
children are infected frequently across multiple Asia-pacific countries. While vaccines 
could help to minimize this disease, not all areas would be suitable for vaccine use without 
prior population testing and governments will need to consider the best methods of 
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Self-critical review  
Introduction  
Dengue is the most common vector-borne viral infection worldwide, and the neglected 
tropical disease responsible for the highest number of deaths and life years lost.1,2 A 
mosquito-borne flavivirus, infections result in around 100 million clinical episodes, and 
likely results in 10.5 million hospitalizations annually.3–5 Approximately 75% of the at-risk 
population resides within the Asia Pacific region where the primary vectors (Aedes 
aegypti and Ae. albopictus) and dengue virus have become widely dispersed over recent 
decades following social, environmental, and demographic changes resulting in cyclical 
outbreaks every 3-5 years.6–8 The disease is caused by one of four closely related dengue 
viral serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) all of which circulate in tropical 
Asian countries.9 Infection results in a wide and unpredictable range of clinical 
presentations from mild/asymptomatic flu-like illness, progressing to acute, febrile, and 
severe/haemorrhagic disease and rarely, death.6,10 Disease prevention efforts with 
mosquito control have been largely unsuccessful and recent decades have witnessed 
increased disease frequencies and expanded ranges of transmission.5,11,12 Dengue is 
now endemic in over 120 countries worldwide, with almost half of the global population at 
risk.1,5 
Population-level risk factors for high disease frequencies include urbanization, high 
population density and presence of Aedes mosquito vector breeding sites.13 At the patient 
level, disease severity depends upon the presence of heterologous antibodies from a 
previous infection, viral characteristics, and the age and genetic background of the 
infected individual.14 Until 2009, the World Health Organization (WHO) recommended 
classifying clinical episodes as classical dengue fever (DF), dengue haemorrhagic fever 
(DHF) and dengue shock syndrome (DSS).6 While this classification remains in clinical 
use in some countries, a new system was proposed by WHO in 2009 primarily to improve 





An important feature of pathogenesis, particularly important for the design of vaccination 
strategies, infection with one serotype provides only transient cross-protection against the 
others and second infections have a higher likelihood of being symptomatic and/or 
severe.16,17 This phenomenon predisposes individuals to more severe disease during 
chronological and/or immunological windows of sub-neutralizing antibody concentrations, 
probably by a mechanism known as antibody dependent enhancement (ADE), or other 
mechanisms, arising from infection with heterologous viral serotypes.16–19  Following a 
given infection the likelihood of suffering mild or more serious symptoms is therefore a 
complex function of ecological and immunological factors with time-varying risk windows, 
determined by the underlying transmission intensity. Immunological interaction with other 
flaviviruses may also affect disease severity and complicate diagnosis.20,21  
In most scenarios, national surveillance systems which provide the majority of dengue 
epidemiological data underestimate disease burden due to the non-specific clinical 
presentation of dengue; unavailability and limitations of confirmatory diagnostic tests; and 
health system issues that result in incomplete reporting.3,5,22,23 More reliable estimates 
are required to guide disease control programs, allow rational allocation of resources, and 
to assess the impact of new interventions such as dengue vaccination. Accordingly, 
estimating the full disease burden was one of the WHO’s three objectives in the 2012 
Global Strategy for Dengue Prevention and Control 2012–2020.5  
Several methods used to improve the accuracy of dengue burden estimates including 
capture-recapture studies, expert consensus-based approaches, statistical and/or 
cartographic models incorporating dengue occurrence data or their covariates, regression 
methods incorporating independent variables from neighbouring countries, and 
derivations from seroprevalence data.3,24–26 Most influentially, a 2013 study by Bhatt et 
al. used a cartographic modelling approach combining demographic and epidemiological 
data, adjusted for clinical severity and determinants of dengue incidence to estimate a 
global burden of 390 million (95% credible interval: 284–528 million) infections in 2010, 
of which 96 million (67–136 million) were symptomatic.3 About 70% of the global burden 
of apparent infections were in Asia, with India contributing 34% of the total. Overall, this 




in Hong Kong where >300,000 episodes were estimated in the absence of notified 
episodes, and underestimate it in others: in the USA, the study predicted zero dengue 
transmission whereas local transmission occurs along the US-Mexico border and in 
Florida.27,28 
While case fatality rates are low, morbidity is high and no specific treatment exists. A 
vaccine could therefore have significant economic as well as public health value. Dengue 
vaccine clinical development has been ongoing for many decades and, despite the 
availability of other flavivirus vaccines, has been complicated, most importantly by the 
requirement for vaccines to provide balanced immunity to all four serotypes.29 In 2014 the 
first dengue vaccine was licensed (Dengvaxia®; Sanofi Pasteur) indicated for vaccination 
of individuals aged from 9 – 60 years in most countries.30,31 Important additional 
information about this vaccine was published in 2015 indicating its superior efficacy in 
children seropositive for dengue,32 and an elevated risk for hospitalized dengue in 
seronegative vaccine recipients.33 These findings further complicate the decision to 
introduce dengue vaccination into public health programmes because vaccine 
performance and safety are products of complex epidemiological indicators which, in 
endemic countries in which the vaccine could provide most value, are often poorly 
defined. Important data gaps include: age-specific seroprevalence data and sub-national 
heterogeneity in endemicity; the frequency, severity and cost of symptomatic episodes; 
and the relative economic benefits of dengue vaccination compared with other healthcare 
interventions.  
As with any new vaccine, post-licensure monitoring of safety and effectiveness will be 
needed but, because effectiveness monitoring of a dengue vaccine has never been 
conducted, robust study designs have not been validated. Case control studies have been 
widely used for vaccine effectiveness (VE) monitoring, including for vaccines against 
influenza;34 Japanese encephalitis;35 whooping cough,36 and pneumococcal 
pneumonia.37 The test-negative design is a variant whereby suspected cases with 
negative laboratory results – and who are therefore considered absent of the outcome of 
interest – are used as controls. This design has been used extensively for evaluating the 




been conducted to understand potential biases associated with these study 
designs,39,45,46 but never for dengue. Given the clinical and epidemiological specificities 
of dengue, uncertainties exist in terms of clinical presentation and diagnosis, healthcare 
practice and underlying epidemiology exist which warrant a preparatory study.47  
Japanese encephalitis virus (JEV) is another mosquito-borne flavivirus, transmitted by 
Culex mosquitoes (of which Culex tritaeniorrhynchus is the most important) , distributed 
across east, south-east and south Asia existing in zoonotic cycles with pigs and ardeid 
birds in which humans are incidental, dead-end hosts.48,49 Most infections are 
asymptomatic or mild and are unlikely to be diagnosed as Japanese encephalitis (JE) 
due to a combination of low level of clinical suspicion and infrequent use of laboratory 
confirmation.50,51 Symptomatic episodes are severe including encephalitis and 
neurological disorders, convulsions, prolonged seizures, respiratory abnormalities and 
spasms.50  In hospitalized individuals around 30% will die, and around 50% of survivors 
will suffer severe residual neurological disease.50,52,53 Several licensed vaccines with 
excellent efficacy [of 80% – 99% following complete schedules] are available and 
vaccination is recommended both for those living in and traveling to endemic areas.54 
Under-recognition of disease contributes to under-vaccination and the full range of 
transmission exceeds the geographic areas where vaccination is routine.48,54  
A 2011 JE global disease burden estimate reviewed existing literature and extrapolated 
based on country archetypes to estimate 67,900 incident symptomatic cases per year 
across affected countries.55 A revised estimate in 2020 incorporated age-stratified 
notification rates, force of infection (FOI) estimates and vaccination coverage in a 
modelling study to estimate 100,308 cases (95% CI: 61,720–157,522) after considering 
the protective benefits of vaccination.56 These relatively modest case numbers mask the 
contribution of JE to long-term encephalitis complications,57 which contributed to up to 1 
million DALYs per year.51 The disease also causes peaks in morbidity and mortality over 
a short period of time during focal outbreaks, which result in long-term disability and 
suffering, for example in Northeast India.58  
Evidence of the range and intensity of transmission is limited and, for the reasons 




measure JEV infection frequency – and minimize bias – were conducted, including in 
naïve US servicemen, in East Asia in the 1940s – 1960s59,60 and, more recently, have 
been performed to understand levels of seroprotection.61 Following our work on dengue 
FOI estimation, upon realizing that JEV and dengue serology data were both available 
from an age-stratified paediatric population, we adapted the analytical methods for 
dengue to describe JE endemicity and the implications of serological cross-reaction on 
such assessments.  
The economic value of a vaccine is broadly equal to the burden of disease, including the 
societal aspects and long-term sequalae, that vaccination would prevent.62 This thesis 
describes a body of work which contributes to understanding of dengue and JE frequency, 




Thesis structure and scope 
Dengue vaccine development has been ongoing for several decades. As the reality of a 
dengue vaccine became closer several years ago, policymaking organizations began to 
consider the necessary and/or ideal conditions for dengue vaccine use in endemic areas, 
and the information needed to direct vaccination programmes to populations who would 
benefit most. Many of those consultations focused on dengue epidemiological conditions 
supporting vaccine use which, in developing Asian countries, had previously been 
relatively poorly defined.23 
Notable policy guidance included: an expert meeting in late 2010 of the “Dengue vaccine-
to-vaccination” (Dengue v2V) Asia-Pacific group in Singapore;63 recommended ‘points for 
consideration’ for dengue vaccine introduction, published in 2016, by the Dengue Vaccine 
Initiative;64 and conclusions of a WHO-initiated call for mathematical modellers to 
estimate the long-term public health impacts of dengue vaccination, which reported 
results in 2016.65 These reports documented several key areas for epidemiological 
research: 
1. Documenting complete morbidity and mortality data to quantify and monitor public 
health impacts of vaccination, including proportions of inpatient and severe cases; 
age, geographical and serotype distributions  
2. Dengue seroprevalence estimates to identify areas suitable for vaccination and 
which would provide the greatest public health impact  
3. Protocols supporting the conduct of vaccine-effectiveness studies with appropriate 
case definitions and study methods.  
This thesis is comprised of a series of published works which were conducted to respond 
to the topics outlined above, as described in figure 1. Having developed these methods 
for dengue, we applied some to JE, a closely related endemic flavivirus, in a study which 
shed light on the applicability and limitations of these methods. The component papers 
contribute to discussions around dengue vaccine introduction and effectiveness 
monitoring, across a spectrum of disease severity. The focus of the thesis is on the Asia 




which originally included data from Latin America. Broadly aligned with the themes above, 
the thesis is divided into four chapters followed by discussion; with the individual 
manuscripts in the portfolio supporting one or more chapters of the thesis: 
1. Symptomatic dengue disease burden estimation in Asia  
2. The feasibility of different dengue vaccine effectiveness study designs 
3. Dengue seroprevalence, serotype distributions and levels of endemicity suitable 
for vaccine introduction 
4. Using serological data to infer dengue and JE infection rates and estimate 
seroprevalence at a given age 
5. Discussion, conclusions and recommendations for future research 
The thesis describes a range of studies, methods and results which directly and indirectly 
contributed to decisions around the introduction of the world’s first dengue vaccine in the 
countries which are most-severely affected by the disease.  
Figure 1: Identified epidemiological priorities for dengue vaccine introduction; and 






Ethical approvals and civil society consultations 
All studies described in this thesis underwent local governmental and institutional ethics 
review in the countries where the studies were conducted as indicated in each manuscript 
and clinical trial identifiers are included in appendix 1. Ethics committees provided review 
of informed consent and assent forms which were signed by study participants, parents 
or legal guardians before participation, in compliance with the regulations of each country.  
Participant informed consent forms always clearly identified the study sponsor (Sanofi 
Pasteur) and described the analyses which would be performed with biological specimens 
and data. In addition, participants were asked for consent to use their blood specimens 
for unspecified further research (but never human genetic testing) and they were free to 
decline this permission but remain enrolled in the studies. Participants were also informed 
that their anonymized personal data may be transferred overseas and communicated with 
health authorities in other countries. 
Accordingly, we did not consult with ethics committees when conducting reanalyses 
described in this thesis which were covered by the conditions above, partly because these 
studies were expected to result in a large number of secondary publications due to its 
numerous secondary and exploratory objectives included in the protocols. However the 
environment with respect to data privacy and legal definitions of “anonymous” data within 
the European General Data Protection Regulation may have changed slightly since these 
studies were planned and additional consultations with ethics committees may be 
advisable in case of future analyses. For prospective studies whose primary papers 
contribute to this thesis, consent was explicitly requested to use data for analyses to 
improve understanding of flavivirus epidemiology, and the ethical approvals for those 
studies are included in appendix 2. 
Studies were conducted in accordance with the latest revision of the Declaration of 
Helsinki, the Guidelines for Good Epidemiology Practices,66 and local regulatory 
requirements.  
We did not involve patient and public representatives or civil society at large in the design 




interpreted with local investigators from study cites and sites who, in addition to their 






Chapter 1: Symptomatic dengue disease burden estimation in 
Asia  
Published works contributing to this chapter 
1. Nealon J, Taurel A, Capeding MR, et al. Symptomatic Dengue Disease in Five 
Southeast Asian Countries: Epidemiological Evidence from a Dengue Vaccine Trial. 
PLoS Negl Trop Dis 2016; 10(8):e0004918.67 
2. Wahyono TYM, Nealon J, Beucher S, et al. Indonesian dengue burden estimates: 
review of evidence by an expert panel. Epidemiol Infect. 2017; (May):1–6.68 
3. Nadjib M, Setiawan E, Putri S, et al. Economic burden of dengue in Indonesia. PLoS 
Negl Trop Dis. 2019; 13(1):e0007038.69 
Introduction: symptoms, severity and surveillance 
National dengue surveillance systems in Asian countries are designed for dengue 
outbreak response and detection, and to monitor changes in epidemic activity over time.5 
They monitor the fluctuation of case numbers and dengue serotypes over time but – 
because dengue symptoms are non-specific, confirmatory diagnostics are under-utilized, 
and reporting may not be complete – they under-estimate the full burden of disease.22,23 
More precise data are required to guide disease control, allow rational allocation of 
resources, and assess the impact of new interventions such as dengue vaccination. 
Accordingly, “estimating the true disease burden” constitutes one of the WHO’s three 
objectives in the Global Strategy for Dengue Prevention and Control 2012–2020.5 
Important progress has been made. Notably, prospective cohort studies utilizing active 
surveillance, which yield more complete estimates of symptomatic disease than passive 
surveillance systems,70 have been conducted in association with tropical medicine 
research institutes for many years in Thailand,71 Cambodia,72 Indonesia,73 the 
Philippines,74 and Vietnam.75 These studies are important because they provide high-
quality and granular data which have subsequently been incorporated into other 
comparative, regression-based or expert-informed analyses of disease burden at the 
country or regional levels.76–79 
The first global dengue burden estimates derived from formal quantitative methods were 
published in 2013. Bhatt et al. used data from these cohort studies and other geo-




and socioeconomic covariates into a cartographic model estimating dengue incidence on 
a fine spatial scale, adjusted for clinical severity.3 They estimated a global burden of 390 
million (95% credible interval: 284–528 million) infections in 2010, of which 96 million (67–
136 million) were symptomatic. This was followed in 2016 by another global estimate from 
the Global Burden of Disease group of 58.4 million (95% uncertainty interval: 23.6 – 121.8 
million) symptomatic cases per year.80 The difference in results can be accounted for by 
methods – Bhatt et al. extrapolated from incidence captured in cohort studies whereas 
GBD models used verbal autopsy data and estimated case numbers based on case 
fatality rate of milder cases. Confidence/uncertainty intervals of the estimates overlap, 
and the exercises provide overall confidence in a global symptomatic disease burden in 
the range of 50 – 100 million cases/year. Both estimates provide country-specific data but 
their relevance to local policy is hindered by complex methods, inaccuracies in some 
geographies induced by global assumptions, and unclear relation to local environments 
which local policymakers know well.  
A relatively straightforward estimation of disease burden can be made by multiplying the 
incidence rates (IRs) of disease captured from routine surveillance systems by a 
multiplication or expansion factor (EF) which describes the level of under-estimation of 
symptomatic cases.81,82 In Cambodia, Thailand, and the Philippines, individual studies 
calculated EFs for dengue of between 7.2 and 9.1.78,83 A review using data from all WHO 
regions found dengue EFs in Asia of up to 126, with significant variation among countries 
and over time resulting from differences in underlying epidemiology, surveillance 
practices, and comparative study design.81  
Dengue vaccine clinical trials are conducted with a high degree of operational integrity 
and produce data closely resembling those from epidemiological studies. Participants 
allocated to the placebo group do not receive dengue vaccine, so incidence data from 
these individuals can be interpreted as an observational cohort.84 CYD14 was a phase 
III, observer-blinded dengue vaccine study conducted in 2011–2013 in 10,275 children 
aged 2–14 years in Indonesia, Malaysia, Thailand, the Philippines, and Vietnam.30 In 
Nealon et al. 2016,67 we used this comprehensive dataset to describe dengue incidence 




frequency and severity in five Asian countries. We also made comparisons with national 
surveillance reports to estimate EFs for symptomatic dengue of different clinical 
severities, from which broader burden estimates can be inferred.  
Where robust empirical data are unavailable, expert opinion-based methods have been 
used to estimate disease burden.78,82 Responding to epidemiological data gaps in 
Indonesia, in Wahyono et al., and Nadjib et al., we used an expert consensus method to 
estimate unknown parameters and combined them with subnational-level surveillance 
data to make national-level dengue disease burden and cost-of-illness estimates.  
Aims and objectives 
Aim: to improve dengue disease burden estimates, stratified by severity and setting, in 
Asian countries  
Specific objectives:  
1. Use the control arm of a large vaccine clinical trial to estimate dengue incidence and 
under-reporting according to different case definitions in five Asian countries 
2. Apply expert opinion in a structured consultation to estimate unknown parameters 
needed to calculate dengue under-reporting, and apply these to estimate disease 
burden in Indonesia 
Methods 
Symptomatic disease from surveillance 
In Nealon et al. (2016),67 we used data generated in a randomized, phase 3 dengue 
vaccine trial in children aged 2 – 14 years old in Indonesia, Malaysia, the Philippines, 
Thailand and Vietnam.30 We analysed data from the placebo arm which was equivalent 
to a 25-month epidemiological cohort study. Participants were followed up with active 
surveillance for episodes of fever ≥ 38°C on ≥ 2 consecutive days which were clinically 
diagnosed by investigators as DF or DHF according to WHO 1997 case definitions.85 
Serum samples were taken for virological confirmation of dengue (NS1 ELISA and/or RT-




1. Clinically diagnosed dengue (CDD) as diagnosed, irrespective of the laboratory 
result 
2. Virologically confirmed dengue (VCD), irrespective of the clinical diagnosis 
3. Clinical VCD (cVCD) where a clinical diagnosis was laboratory-confirmed 
4. Undifferentiated fever VCD (UF-VCD) where a laboratory-confirmed febrile 
episode was not diagnosed as dengue by the investigator 
Site- and age-weighted incidence densities of each outcome and their 95% CIs (based 
on the gamma distribution) were calculated for each of three age groups (< 5 years; 5 
−10 years; and > 10 years) by dividing the number of cases satisfying each case definition 
observed in the study by the number of person-years of observation.86 We compared 
these observed rates with average annual rates reported from passive surveillance at the 
sub-national level (from districts, provinces, or cities) encompassing each clinical trial 
centre, after adjusting for population changes and demographic limitations.87–91  
EFs and their CIs were calculated by dividing the adjusted ID captured during CYD14 for 
each case definition by the IRs reported by the national passive surveillance systems.92 
We additionally described hospitalization rates in participants satisfying different case 
definitions; and the positive and negative predictive value and sensitivity/specificity of 
clinical diagnoses, using VCD as the gold standard.  
Indonesia-specific estimates 
The Indonesian estimates generated above lack the specificity required for more granular 
and locally accepted health economic analyses, including the frequency of mild cases 
which never report to healthcare facilities. In Wahyono et al.68 we used the estimates from 
Nealon et al.(2016), and other available data sources to inform a Delphi panel (a 
structured process which aims to achieve a convergence of expert opinion through review 
of iterative group estimates93) aiming to estimate the burden and characteristics of 
dengue at the national level in Indonesia.  
Fourteen multi-disciplinary experts from across Indonesia were presented updated 
information on dengue epidemiology and sources of uncertainty, before being asked to 




Q1: What percentage of dengue cases enter a healthcare facility to seek treatment?  
Q2: Of all dengue cases entering a healthcare facility, what proportion are 
diagnosed as dengue? 
Q3: Of dengue cases diagnosed in a healthcare facility what proportion are then 
reported in the routine Indonesian dengue surveillance system statistics? 
Q4: Of dengue cases entering an Indonesian healthcare facility, what proportion 
are hospitalized for any duration?  
Q5: Among all dengue cases entering healthcare facilities, what proportion are 
seen in the public sector if: a) hospitalized; b) outpatient (i.e., ambulatory) 
 
Anonymous responses were collected, presented and discussed. Participants were 
invited to revise their opinions twice based on the opinions expressed. Medians of final 
round votes were used for analysis, and a bootstrapping resampling method (200 
samples) employed to provide variability based on the theoretical non-parametric 
distribution of observed values, enabling estimation of medians and their 95% CIs.94 
These medians were used to estimate: 1) the total number of symptomatic dengue cases 
occurring in Indonesia; 2) the overall EF of total: reported cases; 3) EFs stratified by 
hospitalized or ambulatory cases; and 4) the proportion of cases seen in public vs private 
facilities. National level estimates were calculated by multiplying these EFs by the number 
of reported dengue cases in Indonesia, from 2006 – 2015.95 
In Nadjib et al.,69 we used Indonesian provincial passive surveillance data, adjusted by 
factors estimated in Nealon et al.(2016), and Wahyono et al., to make provincial- and 
national-level dengue burden estimates of cases requiring hospitalization, by:  
𝐶𝑎𝑠𝑒𝑠ℎ𝑜𝑠𝑝 = 𝐶 ∗  𝐸𝐹𝑡 ∗  𝑃ℎ 
 
and for non-hospitalized cases by: 
 





Where 𝐶 is the total number of reported cases at provincial or national level; 𝐸𝐹𝑡 is the 
overall Indonesian expansion factor estimated in Nealon et al. (11.5) and 𝑃ℎ is the 
estimated proportion of cases requiring hospitalization from Wahyono et al. (60%). 
 
Results 
Symptomatic disease from surveillance 
Between June and December 2011, 3,424 children were enrolled in the placebo arm of 
the CYD14 study contributing 6,933 person-years of observation time. There were 3,099 
febrile episodes of which 319 (10.3%) were VCD. This proportion varied in each country 
from 6.3% (Malaysia) to 12.3% (Indonesia). The overall crude annual VCD attack rate 
was 4.6%, varying from 2.2% (Malaysia) to 6.6% (Philippines); outcome frequencies 
according to different case definitions are provided in table 1.1. 
 
Table 1.1 Number and proportions of febrile episodes (in brackets) of febrile episodes 





















Indonesia 623 357 1232 44 (12.3) 26 (7.3) 33 (9.2) 18 (5.0) 59.1 3.6 
Malaysia 465 332 937 21 (6.3) 9 (2.7) 11 (3.3) 12 (3.6) 42.9 2.2 
Philippines 1166 1420 2370 156 (11.0) 16 (1.1) 19 (1.3) 140 (9.9) 10.3 6.6 
Thailand 392 388 792 47 (12.1) 35 (9.0) 36 (9.3) 12 (3.1) 74.5 5.9 
Vietnam 778 602 1602 51 (8.5) 6 (1.0) 9 (1.5) 45 (7.5) 11.8 3.2 
Totals 3,424 3,099 6,933 319 (10.3) 92 (3.0) 108 (3.5) 227 (7.3) 28.8 4.6 
n = number of participants 
Of the 319 VCD cases, 92 (29%) cases were diagnosed by investigators as dengue. This 
proportion varied widely among countries, from 10.3% (Philippines) to 74.5% (Thailand). 
Adjusted dengue incidence densities in the CYD14 study were considerably higher than 
the rates captured by the national systems and varied according to the case definition 




(range: 2,048 [Malaysia] to 10,960 [Philippines]), UF-VCD (range: 1,192 [Indonesia] to 
10,290 [Philippines]), CDD (range: 701 [Philippines] to 4,383 [Thailand]), and cVCD 
(range: 261 [Vietnam] to 4,262 [Thailand]).  
The IRs for all dengue cases (per 100,000 p/y) reported to national routine surveillance 
systems for the study locations during the study period varied by country from: 64.7 
(Malaysia); 263 (Indonesia); 497 (Thailand); 509 (Vietnam); and 954 (Philippines) (Table 
1.2). 
Table 1.2. Dengue incidence rates from routine surveillance systems and adjusted 
incidence densities (95% CIs in italics) of disease according to different case definitions 





Incidence densities captured from active surveillance, by 
case definition 
 







996 - 3,153 
2,479 
1,483 - 3,963 
1,192 
602 - 2,269 
Malaysia 64.7 
2,048 
1,099 - 3,720 
671 
288 - 1,851 
777 
367 - 1,961 
1,377 
567 - 2,993 
Philippines 954.4 
10,960 
8,673 - 13,620 
677 
262 - 1,439 
701 
281 - 1,461 
10,290 
8,055 - 12,890 
Thailand 496.7 
5,938 
4,273 - 8,059 
4,262 
2,914 - 6,055 
4,383 
3,015 - 6,194 
1,676 
808 - 3,065 
Vietnam 509.2 
2,784 
1,813 - 4,238 
261 
94 - 1,083 
840 
156 - 2,371 
2,523 
1,580 - 3,964 
 
These different rates gave rise to EFs of 5.5−31.7 for VCD, 0.5−10.4 for cVCD, and 





Table 1.3. Expansion factors for VCD, cVCD, and CDD over the active phase of the 
CYD14 study. 
Country VCD [95% CI] cVCD [95% CI] CDD [95% CI] 
Indonesia 11.5 [7.4, 17.3] 6.9 [3.8, 12.0] 9.4 [5.6, 15.1] 
Malaysia 31.7 [17.0, 57.5] 10.4 [4.5, 28.6] 12.0 [5.7, 30.3] 
Philippines 11.5 [9.1, 14.3] 0.7 [0.3, 1.5] 0.7 [0.3, 1.5] 
Thailand 12.0 [8.6, 16.2] 8.6 [5.9, 12.2] 8.8 [6.1, 12.5] 
Vietnam 5.5 [3.6, 8.3] 0.5 [0.2, 2.1] 1.7 [0.3, 4.7] 
 
Overall, 126 (4.1%) of the acute febrile episodes in the cohort were hospitalized, varying 
between countries from 1.2% (Vietnam) to 8.8% (Thailand). Hospitalization rates varied 
by case definition: 61 (19.1%) of the 319 VCD episodes; 62 (57.4%) of the 108 CDD 
cases; and 24 (96.0%) of the 25 VCD cases diagnosed as DHF, were hospitalized. These 
proportions varied between countries. The median duration of clinical symptoms was 5.0 
days [min; max: 2.0; 38.0] for cases of UF-VCD; 6.0 [2·0; 38·0] for VCD and 8.0 [2.0; 
31.0] for CDD.  
The positive predictive value (PPV) of clinical diagnosis, using VCD as the gold standard, 
was 85.2% (95% CI 77.1−91.3) and the negative predictive value (NPV) was 92.4% 
(91.4−93.3). The sensitivity of clinical diagnosis was 28.8% (95% CI 23.9−34.2) and the 
specificity was 99.4% (99.1−99.7).  
Indonesia-specific estimates 
Delphi panel participants estimated that of all symptomatic Indonesian dengue episodes, 
57.8% (95%  CI: 46.6–59.8) enter healthcare facilities to seek treatment; 39.3% (32.8–
42.0) are diagnosed as dengue; and 20.3% (95% CI 16.1–24.3) are subsequently 
reported in the surveillance system. These estimates gave an overall EF of 5.0; 
hospitalized EF of 1.6; and ambulatory EF of 34.0 which, when combined with passive 
surveillance data, equates to an annual average (2006–2015) of 612,005 dengue cases, 
and 183,297 hospitalizations (figure 2). In the ten years from 2006 – 2015 we estimated 




facilities;  2,476,067 (CI: 1,986,082 – 2,577,322) dengue diagnoses and 1,832,969 (CI: 
1,665,785 – 2,052,687) hospitalizations, 1,164,543 of which are seen in the public sector.  
Figure 2: Estimated annual number of dengue cases and hospitalizations in Indonesia 
following adjustment of surveillance reports with EFs, and their 95% confidence intervals 
(CIs), 2006 - 2015 
 
In Nadjib et al., a cost-of-illness study, a slightly different method was used, incorporating 
empirical under-reporting estimates from our clinical trial reanalysis.67 Final estimates of 
the disease burden combined the value from expert opinion that 60% of dengue cases 
were hospitalized; with our empirical observation of 11.5-fold under-reporting to generate 
final expansion factors for hospitalized (EFH; 7.65) and ambulatory dengue (EFA; 45.90). 
Provincial level totals aggregated to a national Indonesian symptomatic dengue burden 





Conclusions and critical assessment 
We estimated the incidence rate of symptomatic dengue episodes in 5 Asian countries 
according to case severity and other characteristics, after adjustment for disease under-
reporting in passive surveillance data. We found that systematic laboratory confirmation 
of febrile episodes gives rise to approximately 3.5-times more cases than clinical 
confirmation according to existing case definitions and practices. When comparing with 
rates reported from surveillance systems, active surveillance captures up to 30-times as 
many episodes. Because most passive disease surveillance systems in Asia rely almost 
entirely on clinical diagnosis,23,96 a substantial proportion of symptomatic dengue disease 
is unrecognized and therefore unreported. Of dengue diagnoses, most were virologically 
confirmed, resulting in a PPV of clinical diagnosis of 85.2%. However, the sensitivity of a 
clinical diagnosis was 28.8%, reflecting the considerable proportion of VCD which was 
not clinically diagnosed as dengue. This is likely because local DF or DHF reporting case 
definitions had not been satisfied, even when investigators suspected dengue as the 
underlying aetiology of mild or non-specific febrile episodes. These episodes are unlikely 
to result in hospitalization or death but can be important for public health both from an 
overall health economic perspective, and because mild cases have been shown to 
contribute significantly to transmission.97 
In Indonesia specifically, our results confirm previous reports that dengue is significantly 
under-reported and provide granularity which was previously lacking. However, the 
overall magnitude of under-reporting (5-fold) was modest in comparison with other 
studies. Notably, Undurraga et al. estimated under-reporting factors of 7.6 from a 
literature review and regression-based extrapolation to neighbouring countries;25 Toan et 
al. found factors of 36 – 126, comparing published cohort studies with passive 
surveillance data on WHO websites;81 Kosasih et al. empirically measured a factor of 43 
from a factory-based cohort;98 and we identified a factor of 11.5 from the control arm of a 
clinical trial.67 Global dengue burden modelling studies estimated national burdens from 
which Indonesian EFs of 57 and 106, respectively, can be derived3,80 and in 2019, O’Reily 
et al. combined the estimates above to generate national-level estimates of 7.8 million 




The magnitude of these under-reporting differences observed in Indonesia and elsewhere 
is difficult to reconcile and highlight a clear difference between studies extrapolating from 
local data or experience; vs those which use mathematical models, applying incidence 
estimates across a broad geographical scale. For example, O’Reily et al. used a model 
incorporated data from prior studies including ours, describing dengue i) occurrence, ii) 
incidence and iii) FOI to generate estimates of endemicity on a 5x5km cartographic scale, 
and adjusted the likelihood of suffering dengue of a given case definition by the population 
of the entire country. Modelling initiatives also allow the application of milder case 
definitions – corresponding to events which cannot easily be identified in real-life studies 
– thereby increasing sensitivity. Bhatt et al. use a case definition of apparent dengue with 
“sufficient severity to modify a person’s regular schedule, such as attending school”.3 The 
authors liken this to a definition used in cohort studies but our clinical trial required fever 
of ≥38°C for inclusion, a definition which is likely more specific. The GBD study used what 
is probably a more severe case definition for mild cases corresponding to “infectious 
disease, acute episode, moderate” with a mean duration of 6 days but with no definition 
of fever.80  
In contrast, the local experts participating in our Delphi panel, mostly clinicians, are likely 
familiar with more severe, less common presentations of medically-attended dengue. 
Global models are of undoubted global policy value but make strong assumptions which 
are not applicable to every geography and contrast with our local approach comparing 
age-specific rates from the provincial or lower administrative levels. O’Reily et al. 
estimated 1.1 million (220,000 -  2.9 million) hospitalized cases implying that – even of 
dengue cases requiring hospitalization – only 12% are reported in national statistics.99 
Considering the level of clinical suspicion applied to dengue and the frequent use of 
confirmatory diagnostics in hospitalized settings in Indonesia, this scale of under-
reporting seems inplausible.100 Complex modelling methods reporting extremely high 
disease burdens are also of questionable local policy relevance because they differ so 
dramatically from local realities. Allocation of resources is decided based on competitive 
healthcare priorities and adoption of these model-based burden estimates would require 
resource reallocation to prevent dengue, a decision which would be irrational without 




Ours was the first study using local, age-stratified incidence and passive surveillance data 
to allow precise incidence estimates according to different case definitions and improve 
understanding of the full spectrum of dengue disease. Using identical protocols and 
laboratory methods in different countries provides confidence the results are comparable. 
Local experts from all included countries were included as study authors, improving our 
ability to interpret the results and their policy-relevance. However, we included only 
~3,400 children across five countries, a sample size inadequate to generate precise 
estimates of more severe, less frequent outcomes observed, and a strict definition of fever 
was applied, resulting in a relatively specific case definition. Generalizability is also limited 
because sites were chosen for their historically high reported dengue burdens; results 
from lower-endemic areas may differ.101 We also cannot exclude the impact of these 
ongoing clinical studies on case reporting or under-ascertainment; if active studies 
increased the proportion of cases captured in surveillance this would bias 
underestimation estimates towards the null.  
In summary, these analyses were performed to inform policy and strengthen evidence for 
public health decisions, including financing for dengue control efforts such as vaccination. 
They enrich available evidence indicating that passive surveillance systems greatly 
underestimate dengue burden and emphasize that burden estimates are highly sensitive 
to case definitions.  
Critical reflection  
The initial work (Nealon et al. 2016) in this chapter was driven by my realization that 
available data from a clinical trial could be used to generate high-quality EFs, according 
to different case definitions, and therefore make granular descriptions of under-reporting 
and burden estimates. Whilst multipliers like this had been calculated before including for 
influenza102 and dengue,25 I believe this had not been done before from clinical trial data, 
and the approach was subsequently replicated in Latin America103 and then from 
influenza trials104 which has validated the approach. The advantage of using clinical trial 
data is the rich data set, originating from rigorous active surveillance, which can be readily 
exploited for epidemiological analysis. Lack of external validity is the limitation; sites are 




not always reflect real-life treatment realities: for example in our study dengue diagnosis 
as a proportion of VCD was lowest in Philippines, but investigators indicated this is simply 
because cases had not satisfied the strict case definitions in the protocol, rather than due 
to uncertainty about the diagnosis. The sophistication of the techniques we employed is 
inferior to those used by global modelling consortia who have published on the topic. 
Their incorporation of serological data is an important difference, giving rise to incidence 
rates several times higher than observed in local medical practice and these global data 
are therefore highly sensitive to assumptions of the frequency of symptomatic infections, 
and the associated case definitions. 
In Indonesia, the expert panel approach required extensive planning and organization, 
and the integrity of the Delphi process depends on the expertise of panellists. Practicing 
physicians who are local experts are not always experts on epidemiological research 
methods and the requirement to spend adequate time to explain, in local language, 
cannot be over-stated. Some estimation parameters are also challenging even for experts 
to guess and this is an inherent weakness of the approach.  
My contribution to both of these papers was as the lead researcher. After conceiving the 
ideas for the studies, I worked with a team to design protocols and analysis plans, 
designed spreadsheets for data collation and analysis, contributed to statistical analyses 
and drafted both manuscripts. This involved close relationships with local collaborators 
who provided local surveillance data for analyses; and for the multi-country study,67 
individual co-authors were responsible for collating data from their respective countries. 
The Delphi panel meeting in Indonesia was organized by the local team but design of the 
meeting agenda, creation of most presentation materials, questions and analysis plan 
were led by me, with support from co-authors. In both papers, co-authors provided 
valuable contributions to discussions, provided review and feedback and local 
interpretation and context. More complex statistical analyses (e.g., bootstrapping to 
generate confidence intervals) were conducted by a statistician. In terms of learning, most 
analyses were conducted in MS Excel and large spreadsheets quickly became unwieldly, 
difficult-to-follow and carried the risk of introducing errors. A major learning was on the 




labelled and organized. The tables and results in Nealon et al. 2016 are lengthy and can 
be confusing; they could have been simpler, with some data relegated to supplementary 
materials. Because we used multiple data sources including national surveillance data for 
these analyses, permissions from ministries of health and many individuals and 
institutions was needed which took significant time. For this and to enhance 
understanding of the results in the context of the healthcare systems from which they 






Chapter 2: The feasibility of different dengue vaccine 
effectiveness study designs 
Published works contributing to this chapter 
Nealon J, Lim W-Y, Moureau A, et al. Feasibility of case-control and test-negative designs 
to evaluate dengue vaccine effectiveness in Malaysia. Vaccine. 2019;37(39):5891-5898.  
Introduction: dengue vaccine effectiveness studies 
The previous chapter discussed dengue disease burden, with reference to vaccine 
introduction. A number of dengue vaccines are in clinical development and after their 
introduction in public vaccination programmes, evaluations of their real-world 
performance will be needed.105–107 Post-licensure dengue VE studies have not been 
published and, given the clinical and epidemiological specificities of dengue, challenges 
may be expected which warrant preparatory studies.47 These include the ability to recruit 
dengue patients satisfying relevant case definitions; availability of laboratory capacity to 
confirm infection with adequate specificity and sensitivity; and the practical infrastructure 
to identify and recruit suitable control participants.  
There are several methods for monitoring VE which may be suitable for dengue. A 
workshop of international experts took place in 2014 to discuss the underlying principles; 
participants agreed that case-control (CC) and test-negative (TN) designs should be 
considered for this purpose.108 CC studies are established methodologies for assessing 
associations between vaccine exposure and infectious disease outcomes including for 
influenza;34 Japanese encephalitis;35 whooping cough,36 and pneumococcal pneumonia37 
and have been used to evaluate dengue risk factors.109,110 The TN design is a variant of 
the CC study whereby suspected cases with negative laboratory results – and who are 
therefore considered absent of the outcome of interest – are used as controls, and has 
been used extensively for evaluating the effectiveness of influenza vaccines38–41 and 
other vaccines.42–44 The TN design has advantages in reducing bias in control 
recruitment, and has been used to understand dengue risk factors.111 
In Malaysia, dengue outbreaks occur nationwide with increased risk in urban and peri-




occur year-round, and reported case numbers have doubled since 2010.112,113 In 
anticipation of vaccine introduction, we assessed the feasibility of conducting CC and TN 
studies for dengue VE evaluation, in Malaysia.114 Because the vaccine was not yet in use, 
we used both study designs to measure associations between socio-demographic and 
environmental risk factors and dengue outcomes. We considered hospitalized/severe 
dengue as policy-relevant and specific endpoints, so we conducted hospital-based 
dengue surveillance for a period of one year, matching cases to control participants who 
were hospitalized for a non-dengue condition. Feasibility was assessed based on the 
ability to recruit adequate numbers of suspected cases, laboratory-confirmed cases and 
controls to demonstrate VE under a hypothetical scenario. Associated logistical, clinical, 
and laboratory aspects were documented, and we described biases and challenges which 
could result. Finally, we proposed modifications to improve the design of future dengue 
VE studies. 
Aims and objectives 
Aim: Assess appropriate case definitions, operational processes and study designs for 
future dengue VE evaluations. 
Specific objectives:  
1. To identify the risk factors for hospitalized and severe dengue using CC and TND 
study designs 
2. To evaluate the sensitivity and specificity of different dengue case definitions and 
laboratory tests to enhance the design of dengue VE studies 
Methods 
Study sites and participant enrolment 
Enhanced surveillance for suspected dengue cases was conducted starting October 
2016, for a period of 12 consecutive months, among hospitalized patients at three large 
tertiary care hospitals operating within the Malaysian Ministry of Health system. The 
hospitals are all located in urban/peri-urban areas and are centres of excellence for 




Participants were enrolled following screening from medical and paediatric wards during 
weekdays and within working hours by study coordinators. Eligibility was assessed based 
on clinical history, physical examination and following discussions with attending 
physicians. Typically in Malaysia, individuals are suspected of dengue based on clinical 
signs and symptoms and, at these referral centres, it is likely that most participants had 
already received either IgM/IgG and/or non-structural antigen 1 (NS1 Ag) rapid diagnostic 
tests (RDT) and/or a previous clinical diagnosis of dengue at primary care clinics or 
hospital emergency departments. Children suspected of dengue are typically admitted, 
whereas adults will be hospitalized only following a poor or worsening clinical condition. 
Participants were classified according to the following case definitions: 
• Suspected dengue: patients on whom the attending clinician makes a diagnosis of 
probable dengue according to clinical history, physical examination and results of 
routine diagnostic tests which may have been used.  
• Virologically-confirmed dengue (VCD): suspected dengue cases virologically 
confirmed by the central laboratory using dengue RT-PCR and/or NS1 Ag ELISA. 
• Severe dengue: a patient presenting with fever of 2-7 days plus any of the 
following: severe plasma leakage, severe haemorrhage or severe organ 
impairment, as derived from raw clinical data, based on WHO 2009 case 
definitions.6 
• Controls (for case control study): patients who were identified in hospital wards by 
study staff, hospitalized for conditions not likely to be dengue, age- and 
geographically matched to VCD cases. 
• TN controls: suspected dengue cases who tested negative for dengue by both RT-
PCR and NS1 Ag. 
Suspected dengue cases aged 9 to 25 years (reflecting the population most likely 
targeted by public vaccination campaigns), acutely ill and suspected of dengue infection; 
admitted to the study hospital within 5  days (extended to seven days, nine months into 
the study) of fever onset and resident in the hospital catchment area were invited to join 
the study. For each laboratory-confirmed dengue case, study teams attempted to identify 




dengue infection, with a final diagnosis other than dengue and admitted within one month 
(before or after) of laboratory confirmation of the case. Controls were individually age-
matched to cases in three age groups: 9 to 12 years; 13 to 17 years; and 18 to 25 years; 
and geographically-matched based on the catchment areas of district health offices. The 
sample size was based on a hypothetical effectiveness objective comparing the odds 
ratio (OR) of having a virologically confirmed, hospitalized dengue episode between 
vaccinees and non-vaccinees. Assuming 70% of suspected cases test positive, 50% 
vaccine coverage within the target population and 50% VE, the TN design would require 
223 cases and 96 TN controls. A CC design would require 88 cases and 352 controls 
(with a case:control ratio of 1:4) or 110 cases and 220 controls (with a 1:2 ratio).  
Data collection and laboratory analysis 
A questionnaire was administered to all participants, completed by legal guardians for 
children, including socio-demographic information, reported dengue histories of 
participants and household contacts, other risk factor data (e.g., household and 
neighbourhood vector control practices; time spent outdoors) and flavivirus (dengue, 
Japanese encephalitis or yellow fever) vaccination history. Final discharge diagnoses 
based on routine clinical practice were retrieved from electronic medical records. For 
suspected cases, dengue was confirmed by RT-PCR and NS1 Ag ELISA in a central 
study laboratory. The results of routinely-performed dengue diagnostic testing, which 
could include RDTs and ELISAs detecting IgM, IgG and NS1 Ag, before or during 
hospitalization, were also recorded. 
Statistical analysis 
Socio-demographic characteristics of VCD cases and controls were compared for both 
designs. Univariate logistic regression models were used to estimate associations 
between confirmed dengue and risk factors using the CC (in which only participants with 
at least 1 matched control were included, by conditional logistic regression) and TN study 
designs. Variables with a P-value <0.2 on univariate analysis were included in a final 





Dengue discharge diagnoses were compared with WHO 2009 case definitions, including 
severity assessment, as derived from participants’ clinical data.6 The sensitivity and 
specificity of each diagnostic test used in routine practice were calculated using RT-PCR 
and/or NS1 Ag ELISA positive test results as the reference standard, with confidence 
intervals computed using the normal approximation method. 
Results 
Characteristics of study participants 
We recruited 327 participants. There were 155 suspected of dengue within 5 days of fever 
of whom 18 were aged 9-12 years; 48 were aged 13-17 years, and 89 were aged 18-25 
years (study flow chart in figure 3). The planned sample size was not met in any age 
group. Many suspected cases were ineligible to participate because they were not aged 
9 – 25 years old; had experienced onset of fever >5 days previously; because parents 
were unavailable to provide informed consent; and/or birth certificates – prerequisites for 
study participation – were not available.  
Figure 3: Study flow chart for a dengue VE feasibility assessment in Malaysia. VCD = 
virologically confirmed dengue. 
 
Of the 155 suspected dengue cases, 124 (80%) were VCD. Three participants had 
missing RT-PCR results and we therefore recruited 28 TN controls. To match 124 




controls were recruited and some cases lacked controls: 90 cases were matched with 1 
or 2 controls. Time between case and matched control recruitment was on average 74 
days. Table 4.1 compares the characteristics of control participants recruited for the CC 
study and TN controls. Significant differences between groups were observed in the sex 
distribution; and proportion of participants reporting family history of dengue within the 
past month. 
Table 4.2 summarises the socio-demographic characteristics of study participants. 
Differences in baseline characteristics between cases and controls were observed in the 
sex distribution: of VCD cases, 43 (34.7%) were female in comparison with 98 (57.0%) 
controls and 6 (21.4%) TN controls. There were also differences in reported recent 
dengue history in the household (32 [25.8%] cases; 6 [21.4%] TN controls and one [0.6%] 
case control) and reports of recent neighbourhood fogging (68 [55.3%] VCD; 11 [40.7%] 
TN controls and 64 [37.2%] case-controls).  
Table 4.1 Comparison of control and test-negative control study participants’ 
characteristics. Numbers (%; SD for Mean age). P-values derived from chi-squared test 








N 172 28 - 
Mean age, years (SD) 19 (4.3) 18 (3.7) 0.247 
Sex       
M 74 (43) 22 (79) 
<0.001 
F 98 (57) 6 (21) 
Site       
Ipoh, Perak 59 (34) 5 (18) 
0.190 Selayang, Selangor 62 (36) 14 (50) 
Sungai Buloh, Selangor 51 (30) 9 (32) 
Education level       
No formal or primary 14 (8.1) 2 (7.1) 
0.204 Secondary 114 (66) 23 (82) 
Tertiary 44 (26) 3 (11) 
Type of dwelling       
Individual house 127 (74) 17 (61) 
0.152 




Number of family members in household   
≤ 3 31 (18) 7 (25.0) 
0.534 
4 – 5 54 (31) 11 (39) 
6 – 7  59 (34) 7 (25) 
≥ 8 28 (16) 3 (11) 
Household member diagnosed with dengue within the past month?  
No 171 (99) 22 (79) 
<0.001 
Yes 1 (0.6) 6 (21) 
Participant previously diagnosed with dengue?   
Yes 19 (11) 6 (21) 
0.123 
No 153 (89) 22 (79) 
Average time spent outdoors, daily (hours)   
< 4 hours 19 (11) 3 (11) 
0.216 4 hours <= time < 8 hours 122 (71) 16 (57) 
>= 8 hours 31 (18) 9 (32) 
Insecticidal fogging in neighbourhood in the past month?   
    No 108 (63) 16 (59) 
0.725 
    Yes 64 (37) 11 (41) 
 
Utility of case-control and test-negative design for risk factor identification  
In the CC study, two variables remained significant in the final model: respondents who 
reported a recent household dengue contact (OR: 54; 95% CI: 7.3 – 397; P<0.001) and 
those reporting neighbourhood insecticidal fogging in the last month (OR=2.1; 95% CI: 
1.3 – 3.6; P = 0.005) were associated with an increased risk of hospitalized dengue as 
compared to participants without these risk factors. In the TN analysis, no risk factors 
were identified. This might be partially a result of the number of controls (n=28), resulting 
in imprecise estimates. No risk factors associated with severe VCD could be calculated 
as the number of severe dengue cases was too small (n=7). 
Routine laboratory diagnosis of dengue 
The most commonly used dengue confirmatory test in routine practice was the NS1 Ag 
RDT, in 148 (95.5%) of 155 suspected cases, followed by the IgM RDT (110; 71.0%) and 
the IgG RDT (109; 70.3%). The IgM ELISA, IgG ELISA and NS1 ELISA were used in 45 
(29.0%), 31 (20.0%) and 2 (1.3%) participants, respectively.  The NS1 Ag RDT correctly 




(95% CI 86.5 – 96.6%). However, 14 of 27 negative samples were incorrectly classified 
as positive, giving a specificity of 48.1% (29.3 – 67.0%). IgM rapid tests correctly identified 
8 out of 87 VCD cases, a sensitivity of 9.2% (3.1 – 15.3%) and specificity of 81.0% (64.2 
– 97.7%; correctly identifying 17 of 21 negative cases). The IgM ELISA had a sensitivity 
of 47.2% (30.9 – 63.2%; 17/36 VCD cases positive) and specificity of 25.0% (0 – 55.0%; 
2/8 negative cases correctly identified). The NS1 Ag ELISA misclassified both VCD cases 
on which it was used as dengue negative.  
Table 4.2 Numbers (%; SD for mean age) of participants with selected socio-
demographic characteristics and risk factors recruited as VCD cases, controls and test-
negative controls. P-values are in bold font with ORs below, vs the reference category. 













OR (95% CI) 
N 90 172  124 28  
Mean age, years 
(SD) 
18 (4.3) 19 (4.3)  
18 
(4.2) 
18 (3.7)  
Sex    0.003   0.181 
M 57 (63) 74 (43) Ref 81 (65) 22 (79) Ref 
F 33 (37) 98 (57) 0.4 (0.3;0.8) 43 (35) 6 (21) 1.9 (0.7;5.2) 
Site#    -   0.1697* 
Ipoh, Perak 31 (34) 59 (34) - 45 (36) 5 (18) Ref 
Selayang, Selangor 32 (36) 62 (36) - 44 (36) 14 (50) 0.3 (0.1;1.1) 
Sungai Buloh, 
Selangor 
27 (30) 51 (30) - 35 (28) 9 (32) 0.4 (0.1;1.4) 
Education level   0.270   0.110* 
No formal or primary 5 (5.6) 14 (8.1) Ref 10 (8) 2 (7.1) Ref 
Secondary 58 (64.4) 114 (66) 4.4 (0.5;37) 76 (61) 23 (82) 0.7 (0.1;3.2) 
Tertiary 27 (30.0) 44 (26) 5.6 (0.6;50) 38 (31) 3 (11) 2.5 (0.4;17) 
Type of dwelling   0.135*   0.589 
Individual house 58 (64) 127 (74) Ref 82 (66) 17 (61) Ref 
Apartment/ flat/others 32 (36) 45 (26) 1.5 (0.9;2.6) 42 (34) 11 (39) 0.8 (0.3;1.8) 
Number of family 
members in 
household 
  0.596   0.224 
≤ 3 11 (12) 31 (18) Ref 14 (11) 7 (25) Ref 
4 – 5 32 (36) 54 (31) 1.8 (0.8;4.2) 44 (36) 11 (39) 2 (0.7;6.1) 
6 – 7  31 (34) 59 (34) 1.6 (0.7;3.7) 45 (36) 7 (25) 3.2 (1;11) 






dengue within the 
past month?  
  <0.001*ᶻ   0.630 
No 62 (69) 171 (99) Ref 92 (74) 22 (79) Ref 





  0.589   0.202 
Yes 12 (13) 19 (11) Ref 15 (12) 6 (21) Ref 
No 78 (87) 153 (89) 0.8 (0.4;1.8) 
109 
(88) 
22 (79) 2 (0.7;5.7) 
Average time spent 
outdoors, daily 
(hours) 
  0.213   0.280 
< 4 hours 17 (19) 19 (11) Ref 23 (19) 3 (11) Ref 
4 hours <= time < 8 
hours 
57 (63) 122 (71) 0.5 (0.2; 1.1) 77 (62) 16 (57) 0.6 (0.2; 2.3) 
>= 8 hours 16 (18) 31 (18) 0.6 (0.2; 1.4) 24 (19) 9 (32) 0.3 (0.1; 1.4) 
Insecticidal fogging 
in neighbourhood 
in the past month? 
  0.0049*ᶻ   0.174* 
No 39 (43) 108 (63) Ref 55 (45) 16 (59) Ref 
Yes 51 (57) 64 (37) 2.1 (1.3; 3.6) 68 (55) 11 (41) 1.8 (0.8; 4.2) 
# Study site not included in CC design because controls were matched to cases based 
on site. ^ Includes only cases with ≥1 matched control. * Variables included in multivariate 
model. ᶻ Variables retained in final multivariate model. Ref = reference category. 





Conclusions and critical assessment 
We aimed to assess feasibility in recruitment, logistics and laboratory confirmation of a 
traditional CC or TN design to evaluate dengue VE in Malaysia. Rather than identifying 
risk factors, the primary objective was to assess biases, stemming primarily from the 
methods of control recruitment and misclassification of disease and vaccine status, and 
describe these limitations to inform the design of future studies.115 Primarily due to low 
levels of case and control recruitment stemming from our design choices (hospitalised 
dengue is rare in teenagers and younger adults) it is likely that protocol changes would 
be required before embarking on a dengue effectiveness evaluation. Key challenges and 
possible solutions are provided in table 4.2. 
The exposures under assessment were a selection of socio-demographic and 
behavioural risk factors whose distribution was similar in cases and controls, and were 
therefore not identified as risk factors. Two risk factors were identified with the CC 
method: living with household members recently diagnosed with dengue (OR: 54), and 
neighbourhood insecticidal fogging conducted in the last month (OR: 2.1). Reporting bias 
may have contributed to these findings: because these risk factors were captured by 
questionnaire, suspected cases – attuned by their hospitalization with diagnosed dengue 
– perhaps recalled higher frequencies of dengue history or neighbourhood prevention 
than controls. This is a weakness of our approach to examine exposures ascertained 
through self-reporting. Reported rates of household dengue/recent fogging were higher 
in TN controls who had been diagnosed with suspected dengue than case-controls, 
providing some evidence for reporting bias. TN designs can offer logistical advantages 
and reduce confounding by healthcare seeking behaviour, but these advantages could 
be offset by reporting or other biases resulting in biased VE estimates.  
We recruited a lower-than-expected number of suspected dengue cases and controls, 
partly because Malaysia suffered fewer dengue cases in 2017 than in preceding years.116 
But many hospitalized dengue cases were ineligible for study inclusion for other reasons 
and recruitment was challenging. For each VCD case we also failed to recruit two 
matched controls. Our study enrolled adolescents, teenagers and young adults, a healthy 




within large hospitals was challenging. Perhaps the age- and geographical matching used 
here should be relaxed in the future; or alternative methods of control selection such as 
recruitment of community-based controls, could be considered.  
For the TN study, recruitment of controls was low because a higher-than expected (80% 
vs. 70%) proportion of suspected cases was VCD. This may be due to clinical expertise 
and familiarity with dengue in Malaysia and/or frequent use of RDT and subsequent 
decisions to admit based on their results. Indeed, 95.2% of VCD cases had received an 
NS1 Ag RDT as part of their routine care; and 87% of VCD cases had a positive NS1 Ag 
RDT result. The frequency of pre-admission testing and subsequent hospitalization are 
likely influenced by epidemic activity, availability of RDTs at health facilities and hospital 
congestion, effects which have been shown to introduce bias to TN studies of influenza 
vaccines.45 Probably, a TN study would only be efficient if a higher proportion of 
suspected cases tested negative, perhaps by using a less specific case definition, and/or 
enrolment at an earlier stage of the treatment pathway, for example in the clinic before 
RDTs are used. We also failed to recruit large numbers of severe dengue cases, 
representing an important study bias, confining analysis to milder cases and prohibiting 
effectiveness estimation against severe outcomes which may be of particular relevance 
for policymakers and against which vaccine performance may differ. 
Rates of confirmatory diagnostics used in routine clinical practice were variable and of 
inadequate sensitivity/specificity to conclude on infection status. This was most 
concerning for the NS1 Ag RDT which is the most-commonly used dengue diagnostic in 
Malaysia and displayed specificity much lower than reported elsewhere.117 This study 
was not designed specifically to assess diagnostic test performance but nonetheless, the 
observation deserves additional investigation, for example via clinical assessment of 
discordant cases; or programmatic evaluation of RDTs in the field. 
Potential biases identified for future VE studies 
CC studies are vulnerable to a number of biases, most notably due to challenges in 
control selection.115,118 Our approach was to use hospitalized controls, matched to cases 
and recruited within a similar time window. To minimize bias, controls should represent 




independently of the exposure of interest.119 Biased VE estimates would arise if the 
decision to vaccinate was associated with other exposures associated with infection risk, 
such as family dengue history or community fogging which were elevated in cases over 
controls in our study, a problem with our design choice of using socio-demographic 
variables collected by questionnaire as exposures. This effect would likely underestimate 
VE. Due to resource constraints in batching and shipping samples there was an average 
of 74 days between case and control recruitment which may affect the comparability of 
these groups. Rather than awaiting laboratory confirmation it may be beneficial to recruit 
controls immediately following suspected case enrolment to better match on exposure 
risk which may vary over time. Consideration of these and other related biases deserves 
further assessment when patterns of dengue vaccine distribution after launch are better-
understood, including by verifying the accuracy of patient-reported data with family 
members or public health authorities to limit recall bias. We similarly observed gender 
differences between cases and controls, perhaps due to differences in sex distribution 
between dengue wards and the wards used for control identification (e.g., 
gynaecology/orthopaedic surgery). This may constitute a bias because the sex-
distribution of dengue in Malaysia is not equal, with males slightly over-represented,112 or 
if sex is associated with health-seeking behaviour. Matching controls to cases based on 
sex may be advisable in the future. 
This study was conducted in three sites in Malaysia over only one year. Results should 
be generalized only in the context of local epidemiology and treatment practices. Our 
difficulty in recruiting matched hospitalised controls resulted in low statistical power which 
may have prevented identification of risk factors, an effect difficult to describe because 
strong socio-demographic risk factors for hospitalized dengue are unknown. Practical 
limitations also led to lower-than-possible recruitment.  
This was the first detailed and quantitative assessment of the feasibility of a dengue VE 
study. Conducted in a dengue-endemic setting including practical constraints 
encountered in a busy hospital, we concluded it is likely the TN design would not be 
efficient for a dengue VE study unless a less-specific case definition was applied, 




to methods of control recruitment, may be feasible: we recruited 124 confirmed dengue 
cases, an approximate minimum sample size. However, there is a risk of important biases 
and a full bias assessment after vaccination patterns are better understood would be 
needed. These findings will inform the design of dengue vaccine effectiveness studies in 
coming years. 
Critical reflection  
I contributed to study conception and outline protocol development, which was led by a 
multidisciplinary research group. I was then the primary contact with local study teams in 
Malaysia, working with them to identify study sites in Malaysia, finalize the protocol and 
statistical analysis plan, develop operational guidelines and refine the protocol based on 
local hospital working practices. Statistical analyses were conducted by the study 
statistician. I coordinated meetings to interpret study results in the context of local hospital 
practices and drafted the manuscript.  
This study was a component of a dengue vaccine risk management plan, and high-level 
governmental cooperation and collaboration was necessary to conduct a surveillance 
project in multiple government hospitals. We agreed to modify the study protocol to 
include participants with ≤ 7 days’ (instead of ≤ 5 days’) fever due to low recruitment. This 
new definition did not correspond to WHO case definitions, increased workload and 
resulted in ten additional suspected cases, two of whom tested positive for dengue. 
Probably, this modification was not necessary. We identified low performance of routine 
diagnostic tests, a finding which could cause concern. The study was not powered or 
designed to address this research question and it would be prudent to carefully consider 





Table 4.2. – Requirements for a dengue vaccine effectiveness study; challenges 
encountered and potential remedies. 
Study requirement  Challenge encountered Potential remedies 
Sufficient sample size 
and characteristics of 
cases 
Few hospitalized suspected 
dengue cases 
 
− Increase number and/or range of 
study sites (e.g., include emergency 
department) 
− Assess and improve enrolment 
mechanisms 
− Assess local ethics administrative 
requirements and incorporate 
mechanisms to ease enrolment 
Few severe dengue cases 
− Recruit retrospectively using stored 
serum samples and/or medical 
records 
− Assess and improve enrolment 
mechanisms 




Few case-controls recruited 
 
− Consider community-based control 
recruitment (family members; 
neighbours; etc.) 
− Assess logistics of hospital-based 
recruitment during site selection 
− Relax matching criteria based on 
expected exposure status 
Few test-negative controls 
recruited due to high 
confirmation rates in 
suspected cases 
− Enrol suspected cases prior to use 
of rapid tests  
− Recruit from primary health centres 
or otherwise earlier in the patient 
pathway 
Exposure history (e.g., 
exposure to risk factors 
under study) of 
controls representative 
of source population of 
cases 
Duration between case and 
control recruitment may 
introduce bias in exposure 
(during a vaccination 
campaign; or if vaccination 
increases during an 
outbreak) 
− Enrol controls immediately after 
identification of suspected cases 
− Consider community-based control 
recruitment (family members; 
neighbours; etc.) 
− Improve laboratory test turnaround 
time  
Females over-represented 
as controls in CC design 
which could bias results if 
vaccination rates are 
unequal 
− Match controls on sex 
− Recruit from alternative hospital 
wards 
Controls have similar 
outcome risk (e.g., 
reporting to study site 
with hospitalized 
dengue) as cases  
 
Severity of conditions 
suffered by case-controls 
may have differed from 
hospitalized dengue 
− Assess impact of using different 
control populations 
− Use test-negative design after 
assessing misclassification bias 





Chapter 3: Dengue seroprevalence, serotype distributions and 
levels of endemicity suitable for vaccine introduction 
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Introduction: seroprevalence as an indicator of endemicity 
As discussed in the previous chapters, estimates of symptomatic dengue burden are 
affected by case definitions, health-seeking behaviour and health system specificities, in 
addition to underlying infection rates. This results in disparities between reported and 
estimated case numbers of up to >100-fold.81 Serological data, by which antibodies to a 
specific pathogen are detected in circulating blood, present a relatively unbiased view of 
historical infection at the individual level. In unvaccinated individuals antibodies are a 
consequence of natural infection and since age reflects duration of exposure, median age 
of first exposure is an indicator of population level infection frequency which will increase 
in areas of lower endemicity where infections are less likely to have occurred by a given 
age.24 Because many first dengue infections are asymptomatic, the age of individuals’ 
first-infection is rarely determined but this information can be estimated from cross-
sectional serological surveys of healthy individuals conducted across countries, 
continents or time-points enabling comparisons of historical transmission intensity within 
specific populations to plan the optimal age of vaccine introduction.120  
There are four dengue virus serotypes all of which can cause severe disease. Individual 
studies have identified more severe or variable clinical episodes following infection with 
different serotypes 121–125 or according to the order of infection.126 However, many of these 




relationship between infecting serotype and disease severity.127 Nonetheless, the 
distribution of serotypes affects the modelled performance of dengue vaccination due to 
serotype-specific differences in vaccine effectiveness; and also because second 
infections, which have a higher likelihood of being severe, are possible only when 
heterologous serotypes are circulating.65 Individual or multiple serotype-specific infection 
history can be determined by plaque reduction neutralization test (PRNT) assays which 
measure neutralizing antibody responses to individual viral serotypes, though 
interpretation of those data is not straightforward.128,129 
India and Indonesia are the world’s second and fourth most populous countries with a 
combined population of over 1.6 billion, spread across over 19,000 islands, belonging to 
religious and linguistic groups in different stages of economic development. Both are 
dengue-endemic and while reliable burden estimates in each country are highly variable, 
Bhatt et al. estimated 7.6 and 32.5 million cases in Indonesia and India, annually, which 
translates to 41.8% of the global total.3 In both countries, the geographical distribution of 
disease is evolving. Historically considered an urban disease in India, dengue has spread 
to rural areas in recent decades. Whereas individual serotypes were typically isolated 
during outbreaks in the 1960s, more recent reports describe circulation of all four virus 
serotypes, without clear geographical boundaries, and many urban areas are now 
considered hyper-endemic.130 In Indonesia, dengue is most common in urban areas but 
since the 1980s incidence in rural areas, has gradually increased.131 While routine 
laboratory confirmation is uncommon, all four serotypes have been identified during 
dedicated studies in Yogjakarta, Makassar, Surabaya and Jakarta, including during 
outbreaks, and it is likely that all four serotypes circulate across many islands.73,132,133 
At the time of these studies (2011 – 2014), both countries suffered from a lack of dengue 
seroepidemiological data; there had been no studies conducted nationwide or using 
representative sampling methods to describe variations in transmission intensity. In India, 
limited studies had been confined to the Andaman and Nicobar Islands,134 Hyderabad,135 
and Chennai;136 and in Indonesia older data were available from Bandung73 and 
Yogjakarta.137 We therefore performed the first multi-site seroprevalence surveys 




history in healthy children to understand dengue endemicity at the sub-national level and 
provide data to facilitate planning of dengue vaccination strategies.  
Aims and objectives 
Aim: Describe dengue seroprevalence and serotype distributions in India and Indonesia.  
Specific objectives:  
1. Conduct a multi-site cross-sectional survey to measure serotype-specific dengue 
seroprevalence at multiple Indian sites  
2. Conduct a nationally representative, multi-site cross-sectional survey to measure 
serotype-specific dengue seroprevalence in Indonesia. 
Methods 
Common to both India and Indonesia 
Eligible children were identified using specific methods described below, and enrolled 
following collection of written informed consent from parents/guardians and assent from 
older children. Socio-demographic characteristics, significant medical histories and 
information on reported infection history were collected by interview with parents. 5 mL 
blood samples were drawn from children by trained laboratory technicians, nurses or 
clinical investigators and left at room temperature for 1–2 hours before centrifugation; 
serum samples were divided into aliquots and frozen at -20°C or below until analysis at 
central laboratories. Dengue IgG antibody levels were assessed using commercially 
available ELISA kits according to manufacturers’ instructions (Focus diagnostics and/or 
Panbio Diagnostics, both of which have reported sensitivity >98% and specificity 
≥80%138). The titre of dengue serotype-specific neutralizing antibodies of dengue IgG 
positive samples was determined by the PRNT test based on 50% or greater reduction in 
plaque counts (PRNT50).128  
For the interpretation of PRNT50 titres, participants were classified as follows:  




• Monotypic, if antibody titres ≥10 (1/dil) for only one serotype or if titres ≥10 (1/dil) for 
different serotypes with a single serotype having a high titre (>80 (1/dil) titre, and ≥5 
times higher than other titres) 
• Multitypic, if antibody titres ≥10 (1/dil) for different serotypes without a single 
predominant titre. 
Descriptive statistics reported baseline characteristics and dengue IgG and PRNT50 
results. Associations between dengue positivity and socio-demographic covariates were 
assessed using chi-squared tests or t-test (for age); followed by multiple logistic 
regression to identify risk factors associated with serostatus in each country. 
Characteristics specific to each study are described below and summarized in table 2.1. 
Table 2.1. Comparison of dengue seroprevalence studies conducted in India139 and 
Indonesia.140 
 India (DNG10) Indonesia (DNG26) 
Number, characteristics of 
sites 
8, peri-urban/urban 30, urban 
Sampling strategy 
Convenience sample across 
wide geographical area 
Population representative 
across country 
Recruitment sites Households and schools 
Neighbourhood association 
meetings 
Participant age (years) 5 – 10 2 – 18 
Target recruitment per site 323 107 
Rationale for sample size 
Assuming 30% 
seroprevalence for the 
overall study population, 
with precision of 5% and 
95% confidence 
National estimate in each of 
four age groups, adjusted for 
clustering, assuming 25%, 
45%, 55% and 65% 
seroprevalence, 5% precision, 
95% confidence 
Enrolled participants 2,609 3,210 
PRNT50 confirmation of IgG-
positive sera 
All dengue positive samples 





Primary analysis Crude percentage 












India study features 
A convenience sample of eight private (three) or government (five) medical colleges at 
six geographically distinct locations was selected: a) to provide a wide geographical 
distribution across India; b) to represent rural and peri-urban areas; and c) based on the 
site’s recognized ability to conduct epidemiological research. Overall, two sites were 
selected in each of New Delhi and Hyderabad, and one site each in Kalyani (West 
Bengal), Wardha (Maharashtra), Mumbai, and Bangalore. Participants were invited to 
participate either during routine health worker household visits; or at informational 
meetings held at schools. In addition to dengue, samples were tested for JEV.  
Indonesia study features 
Sites were selected based on cluster survey methods used by WHO.141 Based on the 
probability of a subdistrict being selected being proportional to its population size, 30 
urban subdistricts were selected using demographic and geographical data. The main 
health centre (puskesmas kecamatan) in each selected subdistrict was used as the study 
centre for each site. Participants were enrolled following informational sessions at 
monthly neighbourhood meetings and a maximum of one eligible child from each 
household was invited to join the study. 
Results 
India 
In India, 2591 participants (52.6% girls) were included and blood sampled with a mean 
age of 7.9 years. Laboratory results for dengue were available for 2558 participants; 
overall, dengue IgG prevalence was 59.6%, ranging between 23.2% and 80.1% 
according to study site (Table 2.2) and increased from 40.7% in 5-year-olds to 73.4% in 
10-year-olds (figure 4). Participants from one site (Kalyani, West Bengal in Eastern India) 
experienced notably lower dengue exposure than others.  
In multivariable logistic regression analysis, household water storage (OR 5.0, 95% CI 
3.5–7.1) and indoor piped water from the public water supply (OR 1.5, 95% CI 1.2–1.9), 




temporary/non-fixed accommodation* compared to a fixed house (OR 1.5, 95% CI 1.2– 
2.0) were also associated with dengue status. Being resident in Kalyani was associated 
with decreased exposure (OR 0.18, 95% CI 0.10–0.31), while participants from Wardha 
(OR 1.5, 95% CI 1.1–2.1) and Mumbai (OR 2.5, 95% CI 1.7–3.7) had an elevated risk, in 
comparison with Delhi. A reported history of dengue or a family history of dengue was 
reported by 15 (0.6%) and 48 (1.9%) of participants, respectively.  
PRNT50 data were available for 1,512 participants; overall, 89.2%, 92.2%, 93.9%, and 
84.9% had antibody titres ≥ 10 (1/dil) for DENV-1, DENV-2, DENV-3, and DENV-4, 
respectively. Despite the young age of study participants, 48.7% expressed a multitypic 
profile. Overall, JE IgG prevalence was 13.6%.  
Table 2.2. Age and site-stratified dengue IgG prevalence (%) from India139 
Age (years) 5 6 7 8 9 10 Overall 
Kalyani 15.0 14.5 26.5 26.3 27.9 50.0 23.2 
Hyderabad (2) 28.3 48.1 61.4 74.6 77.6 77.6 58.2 
Hyderabad (1)  38.9 52.6 55.6 73.0 70.0 58.3 58.6 
New Delhi (1) 39.0 51.0 62.1 65.0 76.0 70.8 60.2 
Bangalore 61.2 60.6 58.8 70.9 62.8 63.6 62.5 
New Delhi (2) 48.9 63.5 67.2 69.2 71.9 76.1 66.5 
Wardha 46.3 51.0 63.0 81.8 81.1 89.3 69.0 
Mumbai 51.6 68.4 79.0 90.2 88.3 96.7 80.1 
Sites combined 40.7 50.9 58.6 67.4 70.8 73.4 59.6 
 
Indonesia 
In Indonesia, 3,210 participants were enrolled from 30 clusters spread from west to east 
across the country. After exclusions, 3,194 participants, 48% male, were included in the 
analyses, 672 aged 1–4-years-old, 861 aged 5–9, 886 aged 10–14 and 775 aged 15–18-
years-old. Seroprevalence ranged from 26.4% (95% CI: 15.8–37.1) in those aged 1-year-
 





old to 95.3% (89.8–100) in the 18-year-old participants (figure 4). The median age at 
seroconversion was 4.8 years. The overall nationwide seroprevalence was 69.4%, with a 
minimum of 34.6% and a maximum of 87.9% observed per site, and the seroprevalence 
per age group was 33.8% (26.4–41.2) in the 1–4 year-old group, 65.4% (59.1–71.7) in 
the 5–9-year-old group, 83.1% (77.1–89.0) in the 10–14-year-old group and 89.0% (84.0–
94.1) in the 15–18-year-old group. 
Increasing age and female gender were associated with dengue serological status, with 
the odds of seropositivity 22 times higher in participants aged >15 vs those aged 1 – 4 
(p<0.0001) and  values of 71.1% (95% CI: 65.9–76.3) in females versus 67.4% 
(62.4;72.5) in males (p=0.018). In the multivariate model, two variables remained 
associated with dengue serologic status, the participant age group (OR increasing to 21.9 
in the 15 – 18 year age group vs 1 – 4 year olds; p<0.0001) and the number of cases 
diagnosed in the household since the participant was born (OR for >1 vs none, 2.96; 
p=0.0004). 
Multitypic profiles were observed in 50.9% of the participants, a proportion which 
increased with age. Amongst monotypic samples, the highest proportion was reactive 
against DENV-2, followed by DENV-1, and DENV-3, a trend which was most clearly 
observed in the two youngest age groups. 






Conclusions and critical assessment 
We conducted the first multi-site dengue seroprevalence studies in India and Indonesia 
to understand dengue infection risk in two of the world’s most populous countries 
contributing >40% of the world’s dengue burden.3 Overall, 60% of 5 – 10 year old Indian 
and 69% of 2 – 18 year old Indonesian children had been infected at least once and most 
children had been infected by the age of 5 years (Indonesia) and 6 years (India). Children 
expressed neutralizing antibody responses to >1 serotype suggesting most had 
experienced multiple infections, and our results confirmed that all four serotypes circulate 
widely in both countries. These studies did not describe symptomatic disease episodes 
but clearly demonstrate both countries represent hyper-endemic environments in which 
symptomatic episodes are common and severe, and in which effective vaccines would 
provide a significant public health benefit.16 
We conducted a risk factor analysis in both countries, attempting to identify socio-
demographic variables associated with positive serostatus. Increasing age was strongly 
associated with serological status but other explicit socio-demographic risk factors were 
not observed. For example, in India, having household water supply and storing 
household water were both associated with higher odds of dengue positivity. It is likely 
these findings were confounded (e.g., both could be indicators of socio-economic status) 
or were artefacts arising from multiple hypothesis testing. Overall, these data imply that 
strong individual-level risk factors within communities are absent, perhaps unsurprisingly 
for a mosquito-borne disease, and that community-level prevention (e.g., reducing vector 
densities to low thresholds) are needed to reduce outbreak risk.  
 
In both countries, rates of reported dengue history were much lower than the infection 
rate, but more markedly in India where only 0.6% of participants reported a previous 
episode. While only 30 – 50% of primary cases are symptomatic,65 the size of the disparity 
implies a lack of health seeking, lack of recognition of the disease, misclassification of 
dengue as another febrile illness, or lack of reporting. This may be a consequence of a 
broader de-prioritization or under-appreciation of the disease in India: while the observed 




countries of South and Southeast Asia,140,142–144 the officially reported average annual 
incidence of disease is approximately 100-times lower than other countries.145 We should 
assume that dengue burdens reported in the routine surveillance system represent only 
a fraction of symptomatic episodes. 
 
The major limitation of these studies concerns representativeness and, therefore, 
generalizability. In India, we chose 8 sites with geographical spread across the country, 
but sites were not representatively or randomly sampled. In Indonesia, we applied a 
representative sampling method to choose urban sites across the country. We also 
adjusted results for the effects of clustering within sites with a random-effects model, 
providing results and confidence intervals which describe national level seroprevalence 
within urban areas. In both countries, participants were enrolled through community 
meetings which could have resulted in study populations which do not fully represent the 
communities from which they were drawn and results were not adjusted to reflect 
demographic or other characteristics of those who declined to participate. Participant age 
was different in India and Indonesia due to differences in available resources. This 
allowed enrolment of the full paediatric age group in Indonesia in whom differences in 
seroprevalence were considered likely, but neither study was powered to identify sub-
national variation in seroprevalence. Since publication of our data, a more comprehensive 
Indian dengue serosurvey was conducted which tested 12,300 randomly-selected 
participants from 240 urban and rural clusters.146 Overall lower dengue seroprevalence 
was observed, with higher seroprevalence in urban than rural areas. This suggests the 
peri-urban and urban sites included in our study may represent areas of heightened 
dengue transmission and are not representative of the country as a whole. Additionally, 
our study did not recruit randomly, and it is possible participants at higher risk of dengue 
were over-represented in our study. Five of our eight sites were government facilities and 
we did not compare seroprevalence between these and the private institutions involved 
in the study. 
 
Flavivirus IgG assays are also susceptible to providing false-positive results when testing 




phenomenon which could theoretically inflate the positivity rates observed here.21,147 We 
confirmed ELISA results by dengue PRNT to minimize this risk and >97% were confirmed 
positive, but it remains possible that the PRNT50 assay also suffers from cross-reaction.148 
We used ELISAs as a screening assay and have no way of assuring their sensitivity: 
PRNT may have identified an even higher number of exposed children. Within the PRNT, 
cross-reaction between serotypes is likely for samples expressing high neutralizing titres 
and the algorithm applied to define serological profiles is rather subjective.149 While these 
PRNT data from cross-sectional studies provide valuable insights on the circulation of 
multiple serotypes, longitudinal studies are needed to provide additional data on infection 
frequency, serotype dynamics and implications of disease symptomology and 
severity.71,150 
 
In summary these studies both confirmed a high level of dengue infection which is 
compatible with a high burden of symptomatic disease. More granular assessments of 
infection rates across age groups and geography would further strengthen vaccine 
decision-making, and analyses to support this objective are discussed in the following 
section.  
Critical reflection  
For the Indian study, my participation in the study began after raw data had been collected 
and I was therefore not involved in study design. I jointly developed the analysis plan, 
selected the data tables for inclusion in the paper and performed logistic regression 
modelling to identify risk factors, under the supervision of a statistician. I also interpreted 
the results, decided on the manuscript outline and content and drafted the manuscript. 
For the Indonesian study, I contributed to development of the protocol and study design, 
conducted meetings with study partners and local officials to plan conduct of the study, 
responded to ongoing queries from the local study team and was involved in all aspects 
of the data interpretation. I contributed to the manuscript, which was drafted by the first 
authors.  
Major lessons from these studies included the difficulty of selecting a representative 




resources to this, our sample was not representative due to the final selection of houses 
close to healthcare centres. It is possible that translating an English language protocol to 
Bahasa Indonesian language and then training staff at multiple sites introduced 
inconsistencies in field implementation. Our statistical methods were not corrected for 
multiple-testing and I suspect the environmental risk factors for dengue serostatus were 








Chapter 4: Using dengue and Japanese encephalitis 
serological data to infer flavivirus infection rates 
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Introduction: force of infection 
The previous chapters discuss symptomatic and serological evidence of dengue infection, 
and how those data contribute to understanding of dengue epidemiology. Whilst 
symptomatic disease data are often more relevant for policymaking, seroprevalence data 
are less influenced by testing and reporting practices, providing relatively unbiased 
information on historical infections within a population. However, data from dedicated 
serosurveys are rare, generalizing results from one site to another is unreliable and 
estimates often offer limited precision around specific age groups. This is a particular 
problem when considering immunization, because the efficacy of the world’s first dengue 
vaccine (CYD-TDV, Dengvaxia®, Sanofi Pasteur, Lyon, France) is dependent on an 
individual’s infection history.33 The WHO Strategic Advisory Group of Experts (SAGE) 
guidelines recommend vaccination only after individual screening for dengue antibodies 
or, if this is not feasible, where seroprevalence in 9 year-olds exceeds a threshold of 80% 
in sub-national areas of high endemicity.31 Dengue seroprevalence is therefore an 
important determinant of the public health impact, cost effectiveness and acceptability of 




Estimates of age-stratified seroprevalence can be made if underlying information on the 
rate of infection within a population is available.  Assuming transmission intensity is 
constant over time, the rate at which seroprevalence increases with age can provide a 
measure of FOI, or the rate at which susceptible (seronegative) individuals acquire 
infection.151 FOI can be applied under assumptions of constant or varying endemicity, 
incorporating uncertainty to estimate seroprevalence at a given age, to complement 
empirical seroprevalence measurements.152,153  
Dengue FOI is also an important determinant of the characteristics of symptomatic 
disease. Following first infection – which is normally mild or asymptomatic65 – 
homologous antibodies to the infecting serotype are protective, probably for life.154 But 
after a certain duration of time, their presence increases the risk of symptomatic and 
severe disease following infection by a heterologous serotype.16–18 The risk of suffering a 
symptomatic or severe episode is therefore a function of time since previous infection 
and, accordingly, the age-distribution of symptomatic/severe dengue disease is 
dependent on FOI, with more intense transmission resulting in a younger median age of 
symptomatic/severe cases.155 Infection frequency may be constant or may be shaped by 
individual events such as outbreaks; or changes in human behaviour which affect the risk 
of exposure.156 
Most JEV infections are asymptomatic, with only 1:25 – 1:1000 resulting in symptomatic 
disease.157 Laboratory confirmation practices are variable and even severe JE cases may 
not be reported to public health authorities leading to highly uncertain disease burden 
estimates.55 Sero-epidemiological data can therefore provide useful information on the 
range and frequency of transmission which is more common in rural areas. A well-
documented challenge to this approach – in areas where multiple flaviviruses co-circulate 
or where vaccination is common – is cross-reactivity, particularly in IgG antibodies, 
between members of the flavivirus family.21,147,158 Neutralizing assays including the PRNT 
are more specific;159 for JEV, a PRNT titre ≥1:10 dilution by PRNT50 is considered 
protective but a more stringent threshold, PRNT90, may be preferred for epidemiological 




reactivity.160,161 To our knowledge, no previous study had used serological data to 
estimate the JEV infection rate.  
This chapter describes a series of studies which estimated FOI of dengue from 
seroprevalence studies in Indonesia and India; and from a global analysis which included 
7 Asian countries. Using related methods we also estimated the ages of median, 70% 
and 80% seroconversion; assessed variations in transmission intensity by participant age; 
and estimated the number of children infected. We also provided the first estimates of 
JEV FOI from urban areas of 4 endemic Asian countries and explored immunological 
interactions which can affect these measurements.  
Aims and objectives 
Aim: Estimate the infection rate of dengue and Japanese encephalitis in endemic 
countries 
Specific objectives:  
1. Use dengue seroprevalence data to estimate dengue FOI across sites in multiple 
Asian countries  
2. Estimate the age at which 50%, 70% or 80% of children had experienced their first 
dengue infection 
3. Make the first estimates of JE FOI from serological data in 4 Asian countries 
Methods 
Data sources 
Underlying data sources have been described in detail in previous sections and in original 
manuscripts. Briefly, we analysed data from clinical trials or epidemiological studies which 
measured dengue and/or JE serological status in healthy, asymptomatic children. All data 
and blood samples originated from baseline measurements of clinical trials before any 
vaccine or placebo were administered, or from dedicated cross-sectional seroprevalence 
surveys. Participants were enrolled directly by investigators who recruited patients under 
their care or following informational events at primary health care centres, schools or 




organization. Dengue or JEV exposure for each participant was ascertained either by 
PRNT50 with a lower limit of quantitation titre of 10 (reciprocal dilution)128 and/or IgG 
ELISA.139,162 As the youngest participant was aged 0.6 years we assumed declining 
maternal antibodies had no impact on our analyses.  
Statistical analyses common to all studies 
For each analysis, data were combined into a single database including participant exact 
age; serological status and information on geographical origins of participants at the 
national and/or sub-national levels. FOI was estimated using catalytic models in which 
seroprevalence is assumed to increase with age and seroconversion is irreversible by: 
𝑃𝑎 = 1 − 𝑒
−𝜆𝑎 
Pa is the seroprevalence at age a years, λ represents FOI, or the annual risk of 
seroconversion among initially seronegative individuals. The parameter λ can be 
estimated through a generalized linear model with complementary log-log link:153,163  
𝑙𝑛(− 𝑙𝑛(1 − 𝑝𝑎)) = 𝑙𝑛(𝜆) + 𝑙𝑛(𝑎) 
where the logarithm of each participant’s age is included as an offset with a coefficient 
constrained to 1 and the model constant is the log FOI. This model implicitly assumes 
that FOI is constant throughout the included age range and that transmission intensity is 
stable over time.   
FOI estimates were derived for each country/site considered in the analysis. Uncertainty 
was described through generation of exact binomial 95% CIs; inter cluster-level variance 
in countries including >1 site was accounted for by generating robust standard errors, 
assuming sites were independent clusters. This underlying method was followed for all 
studies; with the specificities described in table 3.1, and below. 
Bhavsar et al., (India) 
This study used data from a previously-described dengue seroprevalence study in 
children aged 5 – 10.139 Dengue FOI was estimated for the country as a whole and for 




assuming that their populations were exposed to a similar risk of infection because of 
their geographical proximity (within a few hundred meters). We additionally estimated the 
age at which seroprevalence equalled 50% and 70%. Model goodness of fit was 
assessed by the Hosmer-Lemeshow test with predicted probabilities grouped into 
deciles.164  
Based on Indian 2011 census data165 and estimated annual seroconversion rates, we 
then estimated the number of children aged <11 years experiencing a primary dengue 
infection in 2011, assuming constant FOI from 2002 to 2011, according to:  




Where, δa represents the total size of the Indian population aged a years; and 𝑝𝑎 is the 
proportion of the population seropositive by age a years. 
Nealon et al., 2019 (multi-country Japanese encephalitis) 
Data were from a phase 3 dengue vaccine trial (CYD14) in children aged 2 – 14 years 
old in Indonesia, Malaysia, the Philippines, Thailand and Vietnam.30 In an immunological 
subset of approximately 20% of participants, serum was collected after enrolment but 
before any study vaccine administration. Neutralizing antibody against JEV was 
measured by PRNT50.128 Individuals with a history of JEV vaccination were removed from 
the analysis to ensure serological status was a consequence of natural infection. 
Participants from Thailand were excluded because >95% of children were vaccinated 
leaving a sample too small for meaningful analysis (n=15). 
Because we observed that JEV seroprevalence varied according to DENV serostatus, 
neutralizing JEV titres achieving 90% plaque reduction (PRNT90) were subsequently 
calculated to explore the impact of increasing specificity of the assay by decreasing the 
background serum cross-reactivity from other flaviviruses.161 JEV seroprevalence was 
calculated according to 1) PRNT50 and 2) PRNT90; overall; and separately for DENV 
seropositive and seronegative populations. We considered JEV serostatus in the DENV-




therefore treated the resulting FOI estimate as a minimal estimate of annual infection risk. 
The study flow chart is in figure 5. 
Figure 5: Study flow chart from Nealon et al. (2019), describing the population included 
in JEV seroprevalence study.148 
 
 
Nealon et al., 2020 (dengue, seven countries) 
We analysed data from cross-sectional, Sanofi Pasteur dengue vaccine clinical trials or 
epidemiological studies which collected dengue serological data from healthy, 
asymptomatic, unvaccinated individuals in 13 countries collected over six years. While 
the original study included sites from Latin America only results from the seven Asian 
countries, which are aligned with the topic of this thesis, are described here. The analysis 
was restricted to participants aged 7 months to <19 years on the day of blood sampling; 
to dengue-endemic areas; and to participants with conclusive dengue serological results. 
(figure 6). A country-level analysis was followed by a site-level analysis, in which sites 
with <10 participants; and those which enrolled only participants aged <2 years, were 
excluded.  
To describe possible changes in FOI within large age strata, we also generated age-
varying FOI estimates for specific age groups using linear piecewise models. We fitted 




−ln (1 − 𝑃𝑎 ) = 𝜆1𝑎1 + 𝜆2𝑎2 
For each study site, we determined the optimal age-varying FOI model by sequentially 
varying the age breakpoint for each whole year of data with at least 2 adjacent data points 
(e.g., for countries with data starting in 3-year old children the first possible breakpoint 
was age 5) and identifying the model with the lowest value for Akaike’s information 
criterion (AIC). For each country, we determined whether constant or age-varying models 
fit the data better by ten-fold cross-validation, taking a random 10% of the sample, and 
selected the model (constant or age-varying) with lower root mean squared error (RMSE).  
Seroprevalence by age, per country, was estimated from the resulting models. Graphs of 
estimated constant and age-varying seroprevalence were developed for each country, 
overlaid with observed seroprevalence and their 95% CIs grouped by year. 
We estimated the age at which 50% and 80% (p = 0.5 or 0.8) of children seroconverted 
in each country and site from the optimal model, using the following formula in case of 
constant FOI or if the threshold was reached before the breakpoint: 




or if after the observed breakpoint for age-varying models, by: 
𝑎2 =  








Figure 6: Study flow chart, modified from Nealon et al. (2020), multi-country dengue FOI 
study166 
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Results 
Prayitno et al., (Indonesia) 
In Indonesia overall, we estimated that 13.1% of naïve children experience their first 
dengue infection, annually.140 There was no clear trend in changes in FOI with age but 
FOI seemed to be higher in the younger study participants.  
Bhavsar et al., (India) 
The analysis included data from 2,556 participants, between 301 and 649 children per 
site. The overall annual FOI for all sites combined was 11.9% (95% CI 8.8 – 16.2), varying 
across sites from 3.5% (2.8 – 4.4) in Kalyani to 21.2% (18.4 – 24.5) in Mumbai (table 3.2; 
figure 7). The ages by which 50% and 70% of children were first infected were lowest in 
Mumbai, 3.3 and 5.7 years respectively. In the study population overall, 70% of children 
were estimated to have been infected at least once by the age of 10.1 years and the 
median age of infection in all sites except Kalyani varied between 3.3 and 6.0 years. 
Model goodness of fit indicated differences between predicted and observed 
seroprevalence in Wardha (P = 0.03), Hyderabad (P = 0.01) and for India overall (P = 
0.01).  
In 2011, India had a population of ~260,000,000 children aged <11 years. We estimated 
that in 2011 17,013,527 (95% CI 14,518,438 – 19,218,733) children aged up to 10 years 





Table 3.2. Annual FOI, goodness-of-fit statistics; and the ages by which 50% and 70% of 
children seroconverted from multiple Indian cities. 95% CI in brackets167 
Site Annual FOI, 
% 
Goodness of fit 
Chi2 statistic; 
P- value 
Age of 50% 
seroconversion, 
years 





(2.8 - 4.4) 




(11.2 – 11.8) 
20.9; 0.01 6.0 (5.9 – 6.2) 10.4 (10.2 – 10.7) 
Delhi (2 sites) 
12.9  
(11.1 – 15.0) 
2.96; 0.94 5.4 (4.6 – 6.2) 9.3 (8.0 – 10.8) 
Bangalore 
13.2 ( 
11.5 - 15.3) 
10.2; 0.25 5.2 (4.5 – 6.0) 9.1 (7.9 – 10.5) 
Wardha 
15.4  
(13.4 - 17.7) 
16.9; 0.03 4.5 (3.9 – 5.2) 7.8 (6.8 – 9.0) 
Mumbai 
21.2  
(18.4 - 24.5) 
12.8; 0.12 3.3 (2.8 – 3.8) 5.7 (4.9 – 6.6) 
All sites combined 
11.9  
(8.8 - 16.2) 






Figure 7: Estimated seroprevalence (red lines), 95% confidence intervals (shaded areas) 
and observed seroprevalence (circles) from Indian sites in Bhavsar et al.167 
 
Nealon et al., 2019 (multi-country Japanese encephalitis) 
The mean age of study participants in each country was 8.2 years in Indonesia, 8.3 years 
in Malaysia, 8.2 years in Philippines and 7.6 years in Vietnam. By PRNT50, overall JEV 
seroprevalence was 46.1% in Indonesia, 22.4% in Malaysia, 45.7% in Philippines and 
47.5% in Vietnam. Seroprevalence increased with age, reaching >70% in the 13 – 14 
years old children in Indonesia, Philippines and Vietnam; and 40% in Malaysia (table 3.3). 
When stratified by DENV serostatus, JEV seroprevalence was 54.4% in Indonesia, 41.0% 
in Malaysia, 55.3% in Philippines and 59.4% in Vietnam in DENV seropositive individuals; 
and 8.1% in Indonesia, 5.8% in Malaysia, 10.8% in Philippines and 30.7% in Vietnam in 
DENV seronegative individuals. By JEV PRNT90, seroprevalence was considerably lower: 




FOI estimates based on seropositivity using the PRNT50 threshold revealed an annual 
infection rate within DENV positive participants of 9.1% (95% CI: 7.7; 10.7) in Indonesia, 
5.4% (95% CI: 4.1; 6.9) in Malaysia; 9.3% (95% CI: 8.2; 10.6) in Philippines, and 11.1% 
(95% CI: 8.8; 13.8) in Vietnam. In DENV seronegative participants FOI was considerably 
lower: 1.4% (95% CI: 0.5; 3.0) in Indonesia, 0.8% (95% CI: 0.4; 1.4) in Malaysia, 1.8% 
(95% CI: 1.0; 2.9) in Philippines and 5.2% (95% CI: 3.6; 2.3) in Vietnam. The goodness 
of fit statistics were respected for all models (Pearson test P-value >0.05; deviance test 
P-value >0.05) except for the DENV positive population in Vietnam. 
Table 3.3: Number of participants included by age (N) and Japanese encephalitis 
seroprevalence (%) by PRNT50 according to DENV serostatus in four Asian countries.148 
  Indonesia Malaysia Philippines Vietnam 
Dengue 
status 
Positive Negative Positive Negative Positive Negative Positive Negative 
Age N % N % N % N % N % N % N % N % 
2 13 23% 11 9% 1 0% 21 0% 21 19% 18 22% 3 100% 7 14% 
3 19 37% 10 0% 9 11% 12 0% 33 30% 24 8% 9 56% 11 46% 
4 18 56% 13 8% 12 42% 12 0% 33 30% 20 10% 14 43% 8 38% 
5 27 33% 6 0% 6 50% 25 8% 35 40% 17 6% 13 15% 22 9% 
6 14 21% 2 0% 8 75% 10 0% 41 51% 14 7% 12 33% 10 30% 
7 21 52% 2 50% 4 0% 9 11% 29 52% 6 0% 8 75% 4 25% 
8 14 43% 3 0% 9 22% 10 10% 20 55% 5 20% 11 72% 8 38% 
9 14 36% 3 0% 9 44% 9 11% 31 61% 4 25% 9 67% 6 50% 
10 23 52% 3 0% 8 25% 4 0% 21 67% 1 0% 13 54% 7 43% 
11 13 69% 2 50% 11 36% 8 0% 29 45% - - 12 75% 4 25% 
12 51 75% 6 17% 30 57% 20 5% 58 64% 12 0% 28 71% 13 39% 
13 34 74% 1 0% 24 42% 14 14% 68 75% 8 25% 6 100% 1 100% 
14 22 73% - - 8 38% 2 50% 51 80% 1 0% - - - - 
Total 283 54% 62 8% 139 41% 156 6% 470 55% 130 11% 138 59% 101 31% 
 
Nealon et al., 2020 (dengue, seven countries) 
After exclusions, our dataset included 9,096 participants in seven country-level analyses 




assumption of constant FOI, dengue FOI varied between countries from a low of 1.7% 
(95% CI: 1.4 – 2.2) in Singapore, increasing to 24.1% (21.8 – 26.5) in the Philippines 
(table 3.4). In most countries, constant and age-varying models predicted similar 
seroprevalence at most ages; constant models fit data better in four out of seven countries 
(figure 8). The highest FOI estimates occurred in very young Filipino children, with an 
annual seroconversion risk of 43% up to the age of two years. Estimated dengue 
seroprevalence increased with age in all scenarios, except for the age-varying Singapore 
model where estimated seroprevalence declined at age 4 years. At the site level, the age-
constant FOI was >10% per year at 23 of 31 sites and constant models fit observed data 
better at 25 of 31 sites.  
Table 3.4. Constant and age-varying FOI estimates for each of 7 Asian countries included 
in Nealon et al. (2020).166 
Country  





age ranges (yrs) 
Better fit* 
India 11.9 (8.7 - 16.2) 
10.7 (6.8 - 14.4) 
20 (10.7 - 29.4) 
5 – 6 
7 – 18 
Constant 
Indonesia 14.7 (12.8 - 16.9) 
15.1 (13.1 - 17.1) 
4.1 (-3.9 - 12.1) 
1 - 13 
14 – 18 
Constant 
Malaysia  8.6 (6.7 - 10.9) 
12.2 (11.2 - 13) 
4.6 (-0.2 - 9.5) 
2 - 3 
4 – 14 
Constant 
Philippines 24.1 (21.8 - 26.5) 
42.6 (35.4 - 49.7) 
13.5 (10.1 - 16.9) 
0 - 1 
2 – 14 
Age-varying 
Singapore  1.7 (1.4 - 2.2) 
6.6 (3.9 - 9.2) 
-0.8 (-2 - 0.3) 
2 - 3 
4 - 18 
Age-varying 
Thailand  14.8 (13.7 - 16.0) 
16.4 (14.9 - 17.8) 
8.7 (6.5 - 10.9) 
2 - 6 
7 - 14 
Age-varying 
Vietnam 11.4 (10.2 - 12.8) 
17.3 (16.4 - 18.1) 
5.4 (3.8 - 6.9) 
2 - 3 






According to the best-fitting model, the estimated age at which 50% of children had 
seroconverted was <10 years in six of the seven countries in our analysis; the youngest 
was in the Philippines (1.6 years; 1.4 – 3.1). In Singapore, a seroprevalence of 50% was 
not reached within the range of our observed data, by age 18. An 80% seroprevalence 
threshold was reached at the age of 8.7 years in the Philippines, at 11.0 years in 
Indonesia, 12.7 years in Thailand, 13.5 years in India, 14.1 years in Vietnam and 18.8 
years in Malaysia.  
Thirty-one sites were included in the site level analysis. We estimated 80% of children 
had been infected by age 18 years (e.g., within the range of our observed data) at 24 
(77%) sites and by age 9 years, at 8 (26%) sites (figure 9). The youngest estimated age 
at which 80% of children seroconverted was 5.3 years, observed in Southeast Sulawesi 
in Indonesia. At least 50% of children were estimated to have seroconverted by the age 
of 18 at 29 (94%) sites. Seroprevalence at age 9 years was also high at other sites, 
notably across Indonesia. Within countries, there was substantial heterogeneity between 






Figure 8: Observed seroprevalence in seven Asian countries by age (circles) and 95% 
CIs (spikes) and estimated seroprevalence assuming constant FOI (solid line) and 95% 







Figure 9: Age of 80% seroconversion by site, estimated from best-fitting constant (circles) 
or age-varying (diamonds) models. Bubble size corresponds to frequency weights. “>19” 
signifies estimates were outside the range of our data.166 
 
 
Conclusions and critical assessment 
We analysed data from over 9,000 children from 13 countries to describe dengue and 
JEV transmission intensity in endemic countries. Study participants were in age groups 
likely to seroconvert, providing the necessary variation in seroprevalence to estimate FOI. 
Serological status was confirmed with gold-standard diagnostics and consistent analyses 
were used to make comparisons across countries and sites. 
Across the age ranges sampled, children at most sites were at high risk of dengue 
infection, with FOI exceeding 7% in all countries except Singapore. Countries with higher 
levels of dengue transmission included the Philippines, Indonesia and Thailand, in which 
≥14% of seronegative children were infected each year. In these countries, intense 




While these data describe the force of primary – i.e., first – dengue infections, these 
transmission intensities would translate, at the population level, to a significant burden of 
secondary infections which are more likely to be symptomatic and severe. Malaysia and 
Singapore had lower transmission than other Asian countries, which could be an 
indication of improvements in dengue control measures. 
Age-varying models were developed to assess whether clear variation in infection risk 
was observed as children aged. Strong evidence for this variation was lacking; 
seroprevalence estimates from constant and age-varying models were broadly similar 
and differences in cross-validation errors from different models were small. However in 
age-varying models transmission intensity was more frequently (six out of seven 
countries) higher in younger children, perhaps indicating their increased exposure to 
infectious mosquito bites. In Singapore, FOI declined for a significant proportion of the 
study sample (children aged >3 years old), a finding which is biologically counter-intuitive. 
This is possibly a consequence of intensive and effective vector control activities and 
behaviour which minimizes exposure to infectious bites (e.g., use of air-conditioning) 
resulting in low seroprevalence throughout childhood. Singapore also tends to experience 
severe, cyclical epidemics, and a recent large outbreak could result in higher 
seroprevalence in younger than older children. For example there was a large outbreak 
in late 2005, approximately 4 years before study participants were bled and if young 
children were disproportionately infected, this could give the impression of declining 
FOI.168 These models assume constant FOI across included age groups, an assumption 
which was violated for Singapore, where more flexible modelling approaches 
incorporating more granular variations in epidemiology would be more appropriate.  
According to WHO guidelines, an overall population benefit of dengue vaccination with 
CYD-TDV dengue vaccine can be expected in very high transmission settings, as defined 
by seroprevalence of ≥80% in participants aged 9 years of age or above, noting that such 
areas are rare.31 Here, we estimated that 26% of sites met this criterion, one in India, six 
in Indonesia and at the only site included from the Philippines. These data represent 
transmission levels when blood samples were drawn, several years ago, but indicate 




Another objective of this analysis was to understand variability in endemicity and we 
identified substantial variability within the same country: for example, in Indonesia, the 
median age of first infection varied between sites from 2.3 to 10.1 years; and in Malaysia 
this varied from 6.9 to 12.5 years. We did not have data from multiple sites in all countries, 
but this implies site-specific seroprevalence assessments would be needed prior to 
dengue vaccine introduction without prior sero-testing. Subnational data would also be 
useful to prioritize areas where vaccination would be most efficient.31 However, few 
observed seroprevalence data points fell outside the confidence intervals of our estimated 
seroprevalence and statistical approaches such as this, accounting for uncertainty, could 
be considered complementary to empirical seroprevalence studies in endemic 
countries.169  
For JE, our study documented serological evidence of JEV circulation in urban and peri-
urban areas of Indonesia, Malaysia, Philippines and Vietnam, countries with differing 
epidemiology and JEV risk. The WHO vaccine-preventable disease monitoring system 
reports an annual average for these countries over recent years varying from 35.2 cases 
(Malaysia) to 310.6 cases (Vietnam).170 In contrast, we calculated minimal estimates that 
0.8% - 5.2% of children were infected annually and, even after correcting for a low 
proportion of symptomatic infections, these infection rates imply a substantial level of 
under-reporting of symptomatic cases. These urban regions were previously considered 
of low JEV risk and have no JEV vaccination programs in place; measures to improve 
disease awareness, increase use of confirmatory diagnostics and surveillance 
enhancements may be justified in response. 
To our knowledge, this was the first time JEV FOI has been estimated from serological 
data. JEV seroprevalence varied according to DENV status, likely a consequence of 
cross-reactive antibodies raised following DENV infections. Indeed, these sites were 
originally selected for inclusion in dengue clinical trials due to their high levels of dengue 
endemicity.67 We therefore estimated JEV FOI for individuals with no previous DENV 
exposure, resulting in minimal JEV exposure estimates and strong evidence for JEV 
circulation within these study populations, findings which should lead to consideration of 




estimated JEV FOI in DENV-exposed individuals was considerably higher and the true 
infection rate is likely somewhere in between.  
These analyses suffer from several limitations. Perhaps partly because of small numbers 
of dengue positive/negative study participants in each age group, JEV seroprevalence 
did not increase monotonically, and relatively small numbers of JEV positive subjects 
could have been influential on overall results. Phenomena including focal outbreaks, 
migration from rural areas or transmission during visits to those areas could have inflated 
seroprevalence in specific age groups and incorrectly implied ongoing local transmission 
in rural areas from which study participants were enrolled. JE vaccination rates were close 
to zero except in Vietnam, where a national JE vaccination programme exists in some 
parts of the country. Vaccinated individuals were excluded from our analysis and because 
humans are dead-end, incidental JE hosts, this vaccination coverage would not have 
provided indirect protection that would influence serostatus in the population as a whole.  
It is well-known that flavivirus genera share epitopes inducing cross-reactive antibodies 
leading to difficulty in differentially diagnosing flaviviral infections.21,147 More recent or 
secondary infections generate broader, heterotypic, cross-reactive responses and – 
because these sites were chosen due to their high level of DENV endemicity – we 
considered anti-DENV antibodies would be more likely to cross-react with JEV virus in 
the PRNT than the reverse. Our additional observation that JEV seroprevalence by 
PRNT50 in DENV naïve children was higher than corresponding rates derived from JEV 
PRNT90 implies that PRNT90 is overly specific, excluding true positive samples, for 
epidemiological studies such as this.  
These studies estimated FOI from increasing seroprevalence as a function of age, but 
during outbreaks or where transmission is irregular the entire population may be 
concurrently exposed irrespective of their age, violating assumptions of constant infection 
risk as individuals age.171 FOI estimates are dependent on the underlying data, so 
limitations in laboratory assays and recruitment biases described in the previous section 
are also applicable here, most importantly that participants were recruited for the 




representative and likely represent populations with higher-than-average dengue 
exposure. 
The models used for FOI estimation impose certain constraints; notably, the power of 
age-varying models to detect a meaningful breakpoint is partly dependent on the age 
range of the data which varies between countries. We used AIC, RMSE and also the 
Hosmer Lemeshow test to assess model fit and identified optimal (constant vs age-
varying) models for each country. These tests are somewhat subjective and, in many 
cases, both models fit the data well and we identified only weak evidence for age-varying 
effects.  
All four dengue serotypes circulate in most of these countries9 and we calculated only 
total, (or average), dengue FOI, assuming this is relatively stable over time, without more 
granular or serotype specific variation. From our samples, over 90% tested by PRNT50 
showed evidence of infection with >1 serotype (possibly due to cross-reaction rather than 
true infection), and calculation of meaningful serotype-specific FOI estimates was 
therefore not possible without making unreliable assumptions from PRNT titres. Because 
total FOI has been shown to approximate the sum of serotype-specific FOI155 we 
considered the approach was reasonable to represent long-term average dengue 
exposure rates, and more complex modelling activities would be needed to further 
understand serotype-specific transmission dynamics.  
Nonetheless, these data provide one of the largest flavivirus seroprevalence analyses 
performed. They present new information regarding flavivirus endemicity in different 
Asian countries, can be used to inform future studies, guide public health decision-making 
including the benefits/risks of vaccination and inform health economic analyses. 
Critical reflection  
My contribution to these studies was variable. For the Indonesian paper, they were 
confined to advising on the approach and providing critical comments and review of the 
first draft. But for the other three papers, I was the study lead and was responsible for 
identifying the research question, designing the analysis plan, generating the statistical 




performed by a co-author) and drafting the final manuscripts, with the exception of the 
Indian paper.167 For this analysis I also developed the statistical model to estimate the 
number of Indian infections. Throughout this process I received academic guidance for 
these papers from co-authors with expertise in epidemiology, serology and clinical 
research. Key learnings were of the importance of working with experts: there was a 
mistake in the FOI estimates reported in Prayitno et al.140 which required an corrigendum 
and without strong expert guidance it would not have been possible to publish some of 
these manuscripts, particularly Nealon et al.,166 where the analyses and interpretation for 






Chapter 5. Discussion and recommendations for future 
research 
In the preceding chapters I summarize a body of epidemiological research conducted with 
the overarching objective of informing policies around dengue vaccine introduction in 
Asia. It can be broadly divided into two sections. The first discusses symptomatic disease 
and related burden estimates, including from a case-control study conducted to prepare 
for dengue VE studies (chapters 1 and 2); and the second describes dengue endemicity 
and heterogeneity based on serological assessments, and includes applications to JEV, 
a closely-related flavivirus  (chapters 3 and 4).  
The first section identified a substantial burden of symptomatic disease: nearly 1/20 
children had suffered a dengue episode each year and eight percent were assessed as 
DHF, almost all hospitalized, representing an important public health burden of severe 
disease episodes in some of the most populous countries in the world. Systematic 
laboratory confirmation of febrile episodes gave rise to approximately 3.5-times more 
cases than clinical diagnosis alone, and the rates of disease captured using active 
surveillance were up to 30-times higher than from passive national surveillance reports. 
The hospitalized case-control study described in chapter 2 was a template for future VE 
studies but we identified limitations which could challenge their validity, most notably 
through challenges in recruitment of adequate numbers of control participants. In 
chapters 3 and 4, serological methods identified that children receive intense early 
dengue exposure with as many as 1/4 infected each year in the most endemic areas. 
However a site-level analysis revealed heterogeneity within countries which would 
prevent national-level dengue vaccine introduction aligned with WHO recommendations 
without prior serotesting. Site-specific seroprevalence assessments or subject level 
serotesting would be needed to ensure that appropriate populations were vaccinated. 
Applying similar methods to JEV, another flavivirus, we estimated 0.8% – 5.2% of children 
had been naturally infected annually in urban areas where transmission is thought to be 





Strengths and novelties 
Uniform surveillance and diagnostics 
Several of the underlying studies described in this thesis used data derived from placebo-
controlled clinical trials. As a consequence, very similar or identical protocols were applied 
in several countries concurrently using uniform case definitions and gold-standard 
laboratory confirmation which allowed us to combine data from multiple sites and 
countries into uniform databases of flavivirus data suitable for epidemiological analysis. 
These allowed us to conduct the published estimates of dengue according to different 
case definitions (VCD, cVCD, and CDD) providing a quantitative comparison of different 
case definitions and more complete understanding of the full spectrum of dengue disease 
according to clinical and laboratory criteria. The strict definition of fever ≥38°C as an 
inclusion criterion makes these estimates reproducible but would not capture episodes of 
milder febrile illness. This work has been cited by subsequent researchers, notably in 
Asian disease burden and health economic assessments of dengue interventions for 
which robust incidence rate estimates are needed.99,172–175  
Incorporation of sub-national data and local expertise 
When comparing active and passive surveillance, rather than comparing with national 
data our studies accessed age-stratified, sub-national surveillance data from provinces 
or districts in which study hospitals were located therefore improving the accuracy of 
under-reporting estimates. All studies included local experts as team members and 
authors, improving our ability to interpret data in the context of local healthcare practices, 
and enhancing their policy-relevance.  
Comparison of serological responses to multiple flaviviruses  
It is well-known that flavivirus genera share epitopes inducing cross-reactive antibodies 
which can confuse the interpretation of serological tests where >1 virus circulates.21,147 
The work in Nealon et al., 2019148 compared immunological profiles for JEV and dengue 
by both PRNT50 and PRNT90, providing the first quantitative understanding of the 
implications of these decisions for study design. For example, our observation that JEV 




derived from JEV PRNT90 implies that PRNT90 is overly specific, excluding specimens 
from some individuals who have experienced natural infection, in epidemiological studies 
such as this.  
Limitations 
Lack of national level generalizability, bias and sample size 
Study sites selected for clinical trials which generated some data were urban areas of 
known dengue endemicity, which likely experienced higher levels of transmission than 
elsewhere and their generalizability is therefore limited. This was also a limitation of our 
seroprevalence studies in India and Indonesia: in India, data were generated from 8 sites 
which were geographically diverse but were not representative of the Indian population 
or randomly sampled. In Indonesia, we applied a probability proportional to size sampling 
method to choose 30 urban sites across the country but, as in India, participants were 
enrolled through community meetings which could have resulted in study populations 
which do not fully represent the communities from which they were drawn. A more 
comprehensive Indian dengue serosurvey, published since, identified overall lower 
seroprevalence suggesting the peri-urban and urban sites included in our study may 
represent areas of heightened dengue transmission, enforcing the requirement of more 
local data to make local policy decisions.146  
Another limitation is that study protocols may not always reflect real-life treatment 
realities: for example in our surveillance study, dengue diagnosis as a proportion of VCD 
was lowest in Philippines, but investigators postulated that Filipino study staff may have 
applied case definitions in the protocol more strictly than at other sites, in the full 
knowledge that participants were dengue cases. We also cannot exclude the impact of 
ongoing studies in towns or hospitals on case reporting or other surveillance practices, 
potentially biasing results. Underlying surveillance studies were designed to assess the 
benefits of CYD-TDV and were not powered to measure incidence rates with precision. 
For example, in Nealon et al. 2016,67 we included only ~3,400 children across five 
countries, a sample size inadequate to generate precise estimates of the more severe, 
less frequent outcomes observed. This was a consequence of the opportunistic use of 




FOI modelling assuming a constant infection risk 
Our endemicity analyses were confined to exploring FOI and seroprevalence as a 
function of age, but because dengue is a cyclical, epidemic disease, calendar time is 
another, and perhaps more plausible, explanation for observed variation in FOI. For 
example, a detailed cohort study from a single city of Iquitos in Peru has identified time-
varying dengue FOI, characterized by cyclical introductions of different serotypes giving 
rise to outbreaks.171,176  
Policy value in context of other health priorities 
These dengue disease burden estimates were performed to inform prevention and 
control. But a general limitation of conducting dedicated burden assessments is the lack 
of comparative assessments of burden of other important diseases such as malaria, 
diarrhoeal diseases or bacterial pneumonia with which dengue is a competing healthcare 
priority in endemic areas.177 Applying enhanced surveillance with sensitive diagnostics 
and detailed modelling approaches can provide granular and impressive estimates of 
dengue infection and disease risk. But without equivalent initiatives for other health 
priorities and harmonization with other development and environmental goals these data 
cannot easily inform local prioritization activities and therefore lack policy relevance. A 
solution could be to conduct studies comparing disease burdens of >1 pathogen using 
similar methods, rather than focussing on individual diseases which are well-funded or 
fashionable.178 
Sources of uncertainty  
The studies described in this thesis are subject to variability/random error and to address 
this we calculated confidence intervals based on standard distributions for all studies, 
including robust errors adjusted for clustering where appropriate. This approach is 
inherently narrow, ignoring systematic error/bias which cause uncertainty in the study 
results; an incomplete consideration of this uncertainty over-estimates confidence in the 
findings and therefore diminishes the value of the study to support policy.179 As discussed 
previously, important biases from these studies include that data were derived primarily 
from geographical sites with historically high dengue transmission and are therefore not 




treatment and diagnostic practices vary from routine settings; and that study participants 
may differ systematically from the overall population in unknown ways (because, for 
example, of their willingness to participate in clinical studies). Quantifying this systematic 
bias is complex; was not included in our analysis outside of the bootstrapping in Wahyono 
et al.,68 and represents a major limitation when extrapolating these data outside of the 
study setting. 
Global and regional modelled burden estimates have used various methods to 
incorporate uncertainty. Bhatt et al. expended considerable effort to derive the 
relationship between incidence and environmental conditions through an ensemble of 
hundreds of boosted regression tree models and incorporated additional uncertainty in 
the relationship between incidence and probability of occurrence using a Bayesian 
hierarchical model.3 Stanaway et al. used a Bayesian posterior simulation, resampling 
incidence rate estimates drawing input data from plausible distributions of key predictor 
variables.80 Similarly, O’Reilly et al. used a combination of bootstrapping and Bayesian 
resampling methods.99  
This level of modelling complexity was beyond the scope of our work, but even relatively 
simple sensitivity analyses or resampling methods which can relatively easily 
implemented in statistical software would have incorporated some uncertainty and 
improved the quality of the resulting estimates.180 For example in Nealon et al., 2016,67 
we assumed dengue incidence from the surveillance system were known data without 
variability but we could have incorporated data from multiple years and employed a 
resampling technique such as bootstrapping to estimate a sampling distribution whose 
variability would have been more representative of historical transmission. These 
uncertainty estimates may have been even more informative than the point estimates 
presented. We intentionally collected local surveillance data for comparison but should 
also have conducted a qualitative and quantitative assessment of whether the conduct of 
a clinical trial nearby changed those surveillance practices. And a relatively simple 
description of the characteristics (in terms of profession, socio-economic status or 
demography) of study participants as compared to the underlying population may have 




Our seroprevalence assessments assumed diagnostic performance was perfect and we 
did not attempt to estimate seroprevalence for populations outside of our sample but a 
recent study – using SARS-CoV-2 seroprevalence data – shows how multiple sources of 
uncertainty can be incorporated into serosurveys. Larremore et al., adopted a Bayesian 
framework to produce a posterior distribution of seroprevalence that incorporates 
uncertainty associated with a finite sample size; and specified a hierarchical model 
describing sub-populations within the sample.181 The distribution of subpopulation 
prevalences was then sampled using a Markov chain Monte Carlo process and combined 
in a demographically weighted average to represent the uncertainty overall. A similar 
project for dengue seroprevalence would represent interesting future work to describe 
sources and consequences of uncertainty including stemming from heterogeneity in 
transmission and age of first infection. 
Comparisons with other dengue burden estimates 
Disease burden estimates and under-reporting 
Nealon et al. 201667 estimated multiplication factors which, when combined with national 
surveillance reports, are analogous to dengue burden estimates. These factors varied 
between countries from 5.5 – 31.7 which allow comparison with estimates performed 
using different data sources, populations and methods. Undurraga et al. estimated under-
reporting of 7.6 across southeast Asian countries with some, but not all, country-specific 
point estimates falling within the 95% confidence intervals of our estimates.25 Their 
comparison was based on published literature of variable quality, expert opinion and 
regression-based extrapolation to neighbouring countries which involves relatively 
untested  assumptions. Toan et al. found national-level under-reporting factors of 11 – 
126 depending on country and year.81 Their literature review included published studies 
of variable quality and methods and compared with passive surveillance data from WHO 
websites which may themselves have suffered from under-reporting, inflating under-
estimation estimates. Global dengue burden modelling studies estimated national 
burdens from which Indonesian EFs of 57 and 106, respectively, can be derived.3,80 As 
described in chapter 1, the magnitude of these under-reporting differences from 




estimated Indonesian dengue burden 10X higher than our estimates implying only 12% 
of hospitalized dengue cases are reported in national surveillance statistics. They 
speculate spatial reporting bias may contribute and describe future work to account for 
the sensitivity and biases in the underlying data populating their model.99  
Case definitions and their impact on burden estimates  
Variability in case definitions is an important determinant of dengue disease burden 
estimates and their interpretation which is often obscured by binary definitions of 
“symptomatic” dengue. But the precise case definition which triggers diagnostic testing in 
the cohort studies which underpin most burden estimates are different, including: school 
absence and history of fever or measured oral temperature ≥38°C;124 febrile illness 
detected after ≥2 days’ school absence;182 [in our study] temperature ≥38°C on ≥2 
consecutive days following self-reporting by parents;30 or fever following self-reporting at 
participating healthcare facilities.137 The definitions used for passive surveillance and by 
various research groups, highlighting their variation, is provided in table 5.1. Symptomatic 
dengue incidence is defined as the rate of test positivity and can be expressed as the 
proportion of infections which are symptomatic, by dividing this number by the number of 
study participants seroconverting over the study duration. This proportion is inversely 
associated with severity and has been estimated at ~30 – 50% for primary infections and 
~40 – 80% for second infections.65 However a labour-intensive Cambodian cluster 
investigation study, which recruited study participants prior to development of symptoms, 
showed that in fact >90% of dengue infected-individuals display some level of 
symptoms,97 demonstrating the need to clearly understand underlying case definitions 
when interpreting resulting burden estimates. One solution would be to adopt uniform 
protocols when conducting dengue cohort studies, but this is complicated by different 
research study objectives, diagnostic practices, local clinical and hospitalization practices 
and resource availability. The variability of case definitions used in modelling studies is 
discussed in chapter 1 and, similarly, greater uniformity in these definitions would aid in 
the interpretation of these data. 
Table 5.1. Dengue case definitions as recommended by WHO (in 1997 and 2009 




Case definition Fever  Other criteria 
WHO 1997, ‘probable 
dengue fever’85 
None 
Two or more of: headache; retro-orbital pain; 
myalgia; arthralgia; rash; haemorrhagic 
manifestations; leukopenia, AND 
Supportive serology or occurrence at same 
time/place as other dengue cases 
WHO 2009, ‘probable 
dengue’6 
Fever 
Two or more of: Nausea/vomiting; rash; aches 
and pains; tourniquet test positive; 
leucopaenia; any ‘warning sign’ 
Kamphaeng Phet 
cohort, Thailand124 
History of fever or 
measured 




Febrile illness  ≥2 days’ school absence  
CYD14 dengue 
vaccine trial30 
≥38°C on ≥2 
consecutive days 








Fever Self-reporting at participating healthcare facility  
 
Implications for dengue vaccine introduction 
WHO recommends that an overall population benefit of dengue vaccination with CYD-
TDV dengue vaccine can be expected in very high transmission settings, as defined by 
seroprevalence of ≥80% in participants aged 9 years.31 We found this condition, which 
corresponds to a constant FOI of ~18%, had been satisfied in approximately 30% of sites, 
suggesting that many endemic areas could benefit from dengue vaccination. But these 
sites are distributed throughout large, heterogeneous countries which also contain 
pockets of lower endemicity which would not be candidates for vaccine use. Local 
seroprevalence assessments would therefore be needed prior to mass dengue vaccine 
introduction to identify those areas where vaccination would be most efficient and WHO 
has published a guideline to design and conduct these studies.169 The recommended 




knowledge no country has yet initiated a vaccination campaign with CYD-TDV after 
conducting a dedicated sub-national serosurvey for this purpose.  
Countries wishing to conduct mass vaccination would need to develop optimal 
programmes reflective of local epidemiolocal data in a manner which would be perceived 
as ethical and acceptable to politicians and vaccine recipients. This is not straightforward: 
opinion has been divided on the ethics of vaccinating populations who would receive 
considerable health benefits at the expense of rarer, individual-level increased risks of 
severe disease in small numbers of seronegative vaccine recipients.183,184 These debates 
focus on thresholds recommended by WHO but a well-regarded modelling analysis 
concluded that individual-level harm could be averted at lower levels of endemicity.185 
Ferguson et al. examined the impact of vaccination at different ages and seroprevalence, 
concluding that population-level benefits would arise when vaccinating an age group with 
seroprevalence exceeding ~35% and that even individual-level risks could be averted, 
thanks to indirect effects conferred on the overall population, by vaccinating where 
seroprevalence is over ~70% in 9-year olds.185 The Philippines is the only Asian country 
which decided to introduce dengue vaccination in a public programme, in 2016. This 
campaign was halted following safety concerns and resulted in declining vaccine 
confidence186 despite our and other results indicating suitability for vaccine 
introduction.74,187 Independent researchers have since concluded that the programme will 
have resulted in significantly more benefits than harm.188 
An implication of our FOI estimates, whereby >8% of children in every country except 
Singapore were infected with dengue annually, is that a very high proportion of adults in 
endemic countries will have been infected with dengue more than once. This was 
confirmed by serological surveys providing evidence for multiple previous infections in 
~50% of Indian children aged 5 – 10 years; and >60% of Indonesian children aged >15 
years. These immunological profiles are important for vaccine policymaking because the 
most efficient deployment of CYD-TDV would likely to be in individuals previously infected 
only once or twice.65,189 
CYD-TDV is currently the only licensed dengue vaccine but others are in clinical 




serostatus. The Takeda vaccine TAK-003 has reported phase 3 trial results which show 
efficacy of 74.8% (95% CI 68.6 – 79.8) in baseline seropositive and 67% (53.6 – 76.5) in 
baseline seronegative recipients after 24 months’ follow up.190 Depending on longer-term 
clinical results, different epidemiological criteria may be needed to guide vaccine 
introduction.  
Proposals for future studies and initiatives 
Improving understanding of the contribution of age and time  
The serological analyses described within this thesis were confined to exploring FOI and 
seroprevalence as a function of age, but because dengue is a cyclical, epidemic disease, 
calendar time is another explanation for observed variation in FOI. Additional work should 
examine the impact of time – and particularly outbreaks – on population-level 
seroprevalence and multiple infections, to identify populations who would benefit most 
from vaccination. Such an analysis would be possible using longitudinal serological 
survey data. An improved understanding of monotypic vs multitypic historical exposure 
would also allow better targeting of dengue vaccine to populations in whom benefits would 
be greatest. This could be possible using cross-sectional serological titre measurements 
from PRNT or IgG ELISA to classify individuals according to their likely infection history191 
and could be particularly interesting using our dataset which includes data from >30 sites 
across seven, diverse countries. 
Risk communication  
CYD-TDV displays long-term efficacy for high-risk individuals and could prevent a 
substantial burden of paediatric disease. However policymakers, media and the public 
are unfamiliar with nuanced scientific positions and complex data which inform them. 
Many inputs of benefit/risk assessment based on seroepidemiology are highly technical 
and, in the context of vaccine hesitancy and alarm in the media, improvements are 
required in the communication of accurate, impartial and understandable information to 
politicians and the general public. Risk mitigation and communication, to ensure 
individuals are aware of benefits and risks, remains an important topic of research, 




Bias assessment for VE studies  
We conducted a study to identify potential biases which could present in a dengue VE 
study but, lacking information on patterns of vaccine use, failed to address several 
potential biases, particularly around control selection. These are complex topics which – 
even for vaccines in routine use for many years such as against influenza – remain topics 
of research.192 Important, interrelated biases which could be relevant for dengue VE 
studies include misclassification of outcome due to suboptimal diagnostic performance; 
potential vaccine-modified disease severity; differential healthcare seeking in vaccine 
recipients who perceive themselves at risk; and the effects of serostatus on disease 
severity and likelihood to be vaccinated. Stratified analyses of seronegative and 
seropositive vaccine recipients would seem justified but challenging in practice because 
information on prior dengue infection is typically unavailable, and affected by vaccination 
status. A theoretical causal assessment of potential biases in dengue VE studies, as has 
been recently conducted for COVID-19,193 would be a valuable addition to the literature. 
Vaccination in combination with other interventions  
Another potential tool for dengue control involves the controlled release of mosquitoes 
transfected with Wolbachia bacteria which persists in wild-type Aedes mosquitoes and 
confers resistance to dengue infection and, therefore, transmission. Promising field trials 
in Yogyakarta, Indonesia, have recently demonstrated 73% reductions in dengue 
incidence in treated areas which, if expanded and replicated elsewhere could 
fundamentally change dengue epidemiology.194 Other promising vector control 
interventions are in development195 and dengue vaccine introduction would need to 
consider their impacts. For example, reduced transmission mediated by Wolbachia 
introduction could lower the proportion of seropositive individuals at a given age, thereby 
altering the benefit-risk profile of vaccine introduction. Recent studies have attempted to 
dissect the contribution of each strategy, much uncertainty currently exists, and this will 






Dengue surveillance  
Important differences in dengue surveillance systems include a) whether reporting of 
confirmed and/or suspected cases using various definitions is mandatory; b) the use of 
electronic vs paper systems; 3) the level of age group stratification reported; 4) the use 
of laboratory confirmation and serotype surveillance.23 (Surveillance systems of five Asian 
countries also reviewed in supplementary material of Nealon et al 2016.67). These 
differences give rise to reporting frequencies which are not descriptive of – but can easily 
be confused with – disease burden. This was illustrated in this thesis with an example 
from India, a country with FOI of ~12% per year, similar to other highly endemic countries. 
However India reports approximately 100-fold fewer cases than other endemic countries, 
a difference which must be ascribed to surveillance differences.145 We also observed 
symptomatic disease episodes which did not satisfy strict case definitions, for example 
from the Philippines, thereby underestimating the frequency even of recognized, 
symptomatic dengue cases. 
Recommendations to improve and standardize dengue surveillance include:  
• Increase laboratory confirmation of undifferentiated febrile episodes to identify 
milder dengue cases and increase reporting of outpatient cases. Because it would 
not be feasible to confirm all episodes, a sentinel network could be employed for 
this purpose to estimate a positivity rate which could inform the broader disease 
burden (as is currently done for influenza in many countries). 
• Mandatory reporting of confirmed dengue or suspected cases satisfying case 
definitions including those which are relatively mild (e.g., outpatient cases). This 
change would be accompanied by an increased number of notifications which may 
become burdensome for healthcare providers and it may be necessary to simplify 
reporting procedures, ideally using electronic tools. 
• Reporting using uniform age categories which provide sufficient granularity to 
detect a changing age distribution of cases in children, indicative of changing 





Future VE studies 
Several operational and theoretical problems with the conduct of dengue VE studies were 
identified in this thesis. We identified differences between cases and controls indicating 
that controls may not represent the exposure time at risk of cases; found it difficult to 
enroll adequate numbers of control participants; and possibly observed recall bias in their 
responses to questionnaires. Recommendations for a future VE study: 
• It will be necessary to validate important exposures from reliable records rather 
than relying on self-reported history. This would be essential for dengue 
vaccination status but also applies to other potentially confounding variables (egg, 
proximity to dengue cases/outbreaks). 
• The superiority of a case control vs TND study has not been demonstrated by the 
work in this thesis and future VE studies should enroll both types of controls to 
further assess important biases and their implication on VE. 
o For TND studies, enrolling from secondary or regional hospitals (rather than 
tertiary centres of excellence) may increase the number of participants who 
have not yet received confirmatory diagnostics and therefore increase the 
proportion of test-negative controls, improving study feasibility. This would 
require a greater number of study sites to enroll the same number of 
participants, which could increase costs and complexity. TND controls 
should be matched on age, sex and geography (e.g., district) to improve 
their representativeness of the exposure time at risk of cases. 
o TND studies for dengue remain untested and a full bias assessment, as has 
been recently conducted for COVID-19,198 should be conducted, including 
assessment of the impact of spatiotemporal and laboratory practices which 
are unique to dengue.  
o For CC studies, enrolling community controls (e.g., neighbours) should be 
attempted to increase the number of eligible participants and also improve 
their comparability in terms of exposure risk. Controls should be matched 




it would be necessary for study teams to physically travel to identify controls 
participants from their residences. 
• VE study designs to identify and quantify vaccine-associated enhanced disease, 
expressed as a negative VE, are also needed. These are challenging because the 
outcome (hospitalized/severe dengue) would occur several years after the 
exposure (vaccination) and the risk is modified by baseline serostatus which is 
typically unknown. The most promising study design would be a large, prospective 
observational cohort, with blood samples from participants stored and, for 
economy, tested only if participants developed a symptomatic episode. For severe 
dengue which is rare, a cohort would be very large and a case control study 
measuring the frequency of vaccination in severe vs mild cases would estimate 
the odds of vaccination in severe vs non-severe dengue which could act as an 
indicator of harm, but it would not be possible to control for baseline serostatus 
with this design. 
• Any future dengue VE studies should be conducted for the long term (e.g., 10 
years) to account for all vaccine mediated benefits and harm and minimize the 
chance of conducting studies during particular windows of enhanced risk, whose 






Chapter 6: Conclusions 
At the onset of the body of work described in this thesis, it was anticipated that decisions 
around dengue vaccine introduction would be taken in light of vaccine efficacy and safety, 
age-stratified disease burden and related health economic considerations. These topics 
form the first chapters of this thesis. The availability of additional data on vaccine 
performance changed this decision-making framework when endemicity, indicated by 
seroprevalence, became a criterion for safe and effective vaccine use. Despite those 
thresholds having been reached in several countries, as described in the second part of 
this thesis, CYD-TDV remains in very limited use globally. Irrespective of public health 
benefits, it is likely that the theoretical risk of vaccine-mediated harm will limit any future 
CYD-TDV mass vaccination programmes to those that follow individual-level verification 
of infection history, either following serological testing or a laboratory-confirmed dengue 
episode. These approaches seem feasible: commercial dengue serological tests are 
highly specific and can therefore be used to avoid inappropriately vaccinating 
seronegative individuals.199 A recent consultation described the ideal characteristics of 
point of care tests for pre-vaccination screening and programmatic guidance on using 
them, which would potentially allow wider vaccine uptake.189 As post-licensure data 
accumulate on the safe and efficient use of this and other vaccines it is hoped that the 
impact of this highly endemic disease will begin to be blunted. The methods described in 
this thesis can be used to monitor the changing epidemiology of dengue and the real-life 
performance of interventions aimed at preventing transmission and symptomatic 
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Dengue incidence has increased globally, but empirical burden estimates are scarce. Pro-
spective methods are best-able to capture all severities of disease. CYD14 was an
observer-blinded dengue vaccine study conducted in children 2–14 years of age in Indone-
sia, Malaysia, Thailand, the Philippines, and Vietnam. The control group received no vac-
cine and resembled a prospective, observational study. We calculated the rates of dengue
according to different laboratory or clinical criteria to make inferences about dengue burden,
and compared with rates reported in the passive surveillance systems to calculate expan-
sion factors which describe under-reporting. Over 6,933 person-years of observation in the
control group there were 319 virologically confirmed dengue cases, a crude attack rate of
4.6%/year. Of these, 92 cases (28.8%) were clinically diagnosed as dengue fever or den-
gue hemorrhagic fever by investigators and 227 were not, indicating that most symptomatic
disease fails to satisfy existing case definitions. When examining different case definitions,
there was an inverse relationship between clinical severity and observed incidence rates.
CYD14’s active surveillance system captured a greater proportion of symptomatic dengue
than national passive surveillance systems, giving rise to expansion factors ranging from
0.5 to 31.7. This analysis showed substantial, unpredictable and variable under-reporting of
symptomatic dengue, even within a controlled clinical trial environment, and emphasizes
that burden estimates are highly sensitive to case definitions. These data will assist in gen-
erating disease burden estimates and have important policy implications when considering
the introduction and health economics of dengue prevention and control interventions.
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Author Summary
Dengue is a mosquito-borne, viral febrile disease transmitted between humans in most of
the tropical and sub-tropical world. In recent years, an increasing number of cases has
been widely reported. However, understanding the full disease burden remains a topic of
public health research. One reason for under-reporting is that severe episodes are more
likely to be captured in routine surveillance statistics, and mild episodes unreported/
unrecognized. We re-analyzed data from the control arm of a dengue vaccine clinical trial
in five Asian countries. The trial captured dengue incidence rates following active surveil-
lance and virological confirmation, and we compared those with incidence rates from the
passive surveillance system. As expected, the active surveillance system captured many
more cases of symptomatic dengue than routine systems. Of virologically confirmed den-
gue in the clinical trial, only ~29% were diagnosed by investigators as dengue, indicating
there is a significant disease burden excluded from existing case definitions and diagnostic
practices. The analysis confirmed that dengue is under-reported, by different magnitudes,
in these Asian countries. Case definition is an important determinant of burden. These
findings are important when considering the health economics and public health impacts
of new prevention and control tools.
Introduction
Dengue is a viral disease transmitted between humans by Aedesmosquitoes throughout the
tropical and subtropical world. Infection may be asymptomatic, or can result in a spectrum of
clinical disease including self-limiting fever with manifestations of varying severity (classical
dengue fever; DF) progressing to life-threatening dengue hemorrhagic fever (DHF) and dengue
shock syndrome (DSS). [1] While this classification remains in clinical use in some countries, a
new system was proposed by the World Health Organization (WHO) in 2009 primarily to
improve triage and clinical management, and to capture warning signs of potentially severe
dengue episodes. [1,2] Disease prevention efforts with mosquito control have been largely
unsuccessful and recent decades have witnessed increased disease frequencies and expanded
ranges of transmission. [3,4] Dengue is now endemic in over 120 countries worldwide, with
almost half of the global population at risk. [3,5]
Approximately 75% of this at-risk population resides within the Asia Pacific region, where
the primary vectors (Aedes aegypti and Ae. albopictus) and dengue virus have become widely
dispersed over recent decades following a number of social, environmental, and demographic
changes. [6,7] Multiple dengue virus serotypes co-circulate and the disease constitutes a leading
cause of hospitalization and death in some countries. [8] In the midst of this expansion, and
possibly due to it, reliable dengue disease burden estimates are uncommon. [3,9] Passive
national dengue surveillance systems are designed to detect outbreak activity rather than
describe burden. [10] More reliable estimates are required to guide disease control programs,
allow rational allocation of resources, and assess the impact of new interventions such as den-
gue vaccination. Accordingly, estimating the true disease burden constitutes one of the WHO’s
three objectives in the 2012 Global Strategy for Dengue Prevention and Control 2012–2020. [3]
In most scenarios, national surveillance systems underestimate disease burden due to the
non-specific clinical presentation of dengue; unavailability and limitations of confirmatory
diagnostic tests; and health system issues that result in incomplete reporting. [11] Under-esti-
mation is typically most severe in the milder manifestations of illness, and is a function both of
under-ascertainment and under-reporting. [12] In recent years, several methods have been
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used to improve the accuracy of historical global disease burden estimates of approximately
100 million infections/year. [3,13] These include empirical methods where overlapping data
sources enable estimation of cases missed (capture-recapture studies); expert consensus-based
approaches; statistical and/or cartographic methods incorporating dengue occurrence data or
their covariates; regression methods to estimate unknown variables; and derivations from sero-
prevalence data. [9,14–16] Notably, a 2013 study by Bhatt et al. used a cartographic modeling
approach combining demographic and epidemiological data, adjusted for clinical severity and
determinants of dengue incidence, to estimate a global burden of 390 million (95% credible
interval: 284–528 million) infections in 2010, of which 96 million (67–136 million) were symp-
tomatic. [9] It has been estimated that 70% of cases and>50% of the economic burden of den-
gue are in Asia. [9,17]
Prospective cohort studies utilizing active surveillance can yield more accurate estimates of
symptomatic disease than passive surveillance systems. [18] Resulting incidence rates (IRs),
when compared with data from routine surveillance systems, can describe the extent of under-
estimation, expressed as multiplication or expansion factors (EFs). [12,19] In Cambodia, Thai-
land, and the Philippines, individual studies using these methods calculated EFs for dengue of
between 7.2 and 9.1. [20,21] A review using data from all WHO regions found dengue EFs in
Asia of up to 126, with significant variation among countries and over time resulting from dif-
ferent underlying epidemiology, surveillance practices, and comparative study design. [19]
Dengue vaccine clinical trials are conducted with a high degree of operational integrity and
produce data closely resembling those from active epidemiological studies. Subjects allocated
to the control group do not receive dengue vaccine, so incidence data from these individuals
can be interpreted as an observational dengue cohort. [22] CYD14 was an observer-blinded
dengue vaccine study conducted in 2011–2013 in 10,275 children aged 2–14 years in Indonesia,
Malaysia, Thailand, the Philippines, and Vietnam. [23] Each of these countries conducts pas-
sive routine dengue surveillance, sometimes using different case definitions and different
reporting, laboratory, and diagnostic practices. [10,11] (described in S1 File).
Dengue epidemiological data from CYD14 and its Latin American sister, CYD15, were
recently described by L’Azou et al., allowing comparison across countries of data collected
using standardized, active methods. [24] Here, we exploit the comprehensive dataset to further
explore dengue incidence in the CYD14 control group according to different clinical endpoints
(in addition to the primary clinical endpoint of the efficacy trial) to examine the relationship
between burden and severity in five Asian countries. We also made comparisons with national
surveillance reports to estimate EFs for symptomatic dengue of different clinical severities,
from which broader burden estimates can be inferred.
Materials and Methods
Ethics statement
This was a secondary analysis using records from a vaccine clinical trial. The original clinical
trial which generated the data (ClinicalTrials.gov number NCT01373281) underwent ethics
committee approval of the protocol, amendments, consent, and assent forms. [23] Parents or
legal guardians provided informed consent before participation, and written assent was
obtained from older children, in compliance with the regulations of each country. All data
were analyzed anonymously.
CYD14 study design and data
CYD14 (CT.gov identifier NCT01373281) was an observer-masked, randomized, controlled,
multicenter, phase 3 dengue vaccine trial in Indonesia (3 study centers), Malaysia (2 study
Dengue Disease in Asia: Evidence from a Dengue Vaccine Trial
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centers), the Philippines (2 study centers), Thailand (2 study centers), and Vietnam (2 study
centers) and has been described previously. [23] There was ethics committee approval of the
protocol, amendments, consent, and assent forms. Parents or legal guardians provided
informed consent before participation, and written assent was obtained from older children, in
compliance with the regulations of each country. Briefly, children aged 2–14 years were ran-
domly assigned to receive three injections of a recombinant, live-attenuated, tetravalent dengue
vaccine (CYD-TDV), or placebo, at 0, 6, and 12 months. Participants were followed up actively
for a total of 25 months and episodes of fever 38°C on 2 consecutive days were recorded
and clinically diagnosed as DF or DHF based on 1997 WHO guidelines (Fig 1). Concurrent
Fig 1. CYD14 study flow chart and source of each case definition.Control arm subjects were actively followed for 25 months to detect
episodes of fever38°C for 2 consecutive days. Febrile episodes were recorded and clinically diagnosed as dengue based on 1997WHO
guidelines, or an alternative etiology. Irrespective of clinical diagnosis, serum samples were taken for virological confirmation of dengue by
detection of NS1 antigen by immunoassay and viral RNA by RT-PCR. A positive result for either laboratory test was considered confirmatory of
dengue. Clinically diagnosed dengue (CDD): all episodes that were clinically diagnosed as dengue, irrespective of virological confirmation. VCD:
all virologically confirmed dengue episodes, irrespective of clinical diagnosis. cVCD: all VCD episodes that were also clinically diagnosed as
dengue. UF-VCD: all VCD episodes that were not clinically diagnosed as dengue.
doi:10.1371/journal.pntd.0004918.g001
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with and irrespective of clinical diagnosis, serum samples were taken for virological confirma-
tion of dengue by detection of NS1 antigen by ELISA and dengue viral RNA by RT-PCR. A
positive result for either laboratory test was considered virological confirmation of acute den-
gue infection. This allowed febrile individuals to be grouped into four case definitions accord-
ing to their clinical diagnosis and laboratory results: 1) clinically diagnosed dengue (CDD) was
diagnosed by the investigator as dengue, irrespective of the laboratory result; 2) virologically
confirmed dengue (VCD) was a dengue virological laboratory confirmation, irrespective of the
clinical diagnosis; 3) clinical VCD (cVCD) was clinically diagnosed by the investigator as den-
gue and accompanied by laboratory confirmation of dengue infection; 4) undifferentiated fever
VCD (UF-VCD) was laboratory confirmation of dengue infection but was not diagnosed as
dengue by the investigator. Detailed case report forms were completed for each febrile episode,
including whether subjects required hospitalization. This manuscript describes results of a sec-
ondary analysis of anonymous data from this vaccine clinical trial.
National dengue surveillance, population data and incidence rates
Sub-national passive dengue surveillance data from districts, provinces, or cities (hereafter
referred to as “geographical units”) encompassing each clinical trial center were retrieved from
official government surveillance websites for Thailand [25] and Jakarta, Indonesia, [26] or
from personal communications with trial investigators, or sub-national health authorities in
Malaysia [27], Indonesia, the Philippines, and Vietnam [28]. Dengue cases of any severity were
pooled for the period of time during which CYD14 was active in that country.
Age-specific population data for sites were retrieved from census or other official records
for each geographical unit. [29–33] Populations at the mid-point of the study were estimated
by applying national-level population growth factors. Where surveillance or census data lacked
age-stratifications (Vietnam and Indonesia for census; Malaysia and Thailand for monthly age-
specific surveillance data), we assumed age-distributions of populations/cases were propor-
tional to those at the national level. Average annual IRs were calculated for each country by
pooling data from all geographical areas participating in the study, expressed as cases/100,000
population/year, as:





Where Nc is the number of cases reported to the surveillance system over the study observation
period; Tm is the duration of the study in each country, in months; and Populationji is the aver-
age population size over the study period.
Calculating CYD14 incidence densities
Site- and age-weighted incidence densities (IDs) were calculated by direct standardization for
each country to correct for the fact that the age and geographic distributions of study popula-
tions were different from those in the geographic units from which they were drawn. [34]
Study populations were divided into three age groups according to their age when they contrib-
uted time to the study:< 5 years; 5 −< 10 years; and> 10 years (all were aged<15 years at
enrollment). Crude age-specific IRs were calculated for each age group and each center by
dividing the number of cases satisfying each case definition by the number of person-years (p/
y) of observation. These crude IRs were to match the demographics from CYD14 with those of
each geographical area, resulting in age- and site-adjusted IDs aligned with the census popula-
tions at the country level. [34] Results were presented as cases/100,000 p/y. Standardized 95%
Dengue Disease in Asia: Evidence from a Dengue Vaccine Trial
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confidence intervals (CIs) were calculated based on the gamma distribution using SAS 9.4
(SAS Institute, Cary, NC).[35]
Expansion factors and case definitions
Expansion factors were calculated by dividing the adjusted ID captured during CYD14 for each
case definition by the IRs reported by the national passive surveillance systems at each geo-
graphical unit. For calculating 95% CIs, IRs from surveillance systems were considered known
data without variability. [34]
Descriptive exploratory statistical analysis was performed on the ability of each case defini-
tion to identify symptomatic dengue cases; the proportion hospitalized; and the duration of
clinical symptoms, fever, and hospitalization, for each. Using VCD as the gold standard diag-
nosis of dengue following a febrile episode, positive predictive value, negative predictive value,
sensitivity, and specificity were calculated for clinical diagnosis of dengue disease with their
95% CIs according to the efficient-score method [36]. Data used for the analyses described
above are provided in S1 and S2 Tables.
Results
VCD and CDD in the CYD14 cohorts
Between June and December, 2011, 3,424 children were enrolled in the control arm of the
CYD14 study (Table 1). The demographics of the subjects have been reported elsewhere. [23]
The period of observation was 6,933 p/y, during which there were 3,099 febrile episodes tested
for dengue, of which 319 (10.3%) were VCD. This proportion in each country varied between
6.3% (Malaysia) and 12.3% (Indonesia). The overall crude annual VCD attack rate was 4.6%,
varying from 2.2% (Malaysia) to 6.6% (Philippines). A total of 108 cases satisfied the CDD defi-
nition and 227 satisfied the UF-VCD definition (underlying data in S1 Table).
Of the 319 VCD cases, 25 (7.8%) were clinically diagnosed as DHF and 67 (21.0%) as DF,
giving a total of 92 (28.8%) cases of cVCD. This proportion of VCD correctly diagnosed varied
widely among the countries, from 10.3% (Philippines) to 74.5% (Thailand). In addition to the
25 clinical diagnoses of DHF in the VCD group, there were an additional 4 DHF diagnoses
which were not virologically confirmed. Only one DHF diagnosis was in a subject aged<5.




























Indonesia 623 357 1232 44 (12.3) 26 (7.3) 33 (9.2) 18 (5.0) 59.1 3.6
Malaysia 465 332 937 21 (6.3) 9 (2.7) 11 (3.3) 12 (3.6) 42.9 2.2
Philippines 1166 1420 2370 156 (11.0) 16 (1.1) 19 (1.3) 140 (9.9) 10.3 6.6
Thailand 392 388 792 47 (12.1) 35 (9.0) 36 (9.3) 12 (3.1) 74.5 5.9
Vietnam 778 602 1602 51 (8.5) 6 (1.0) 9 (1.5) 45 (7.5) 11.8 3.2
Totals 3,424 3,099 6,933 319 (10.3) 92 (30) 108 (3.5) 227 (7.3) 28.8 4.6
n, number of subjects or events; VCD, virologically confirmed dengue. cVCD, clinically diagnosed and virologically confirmed dengue; CDD, clinically
diagnosed dengue; UF-VCD, virologically confirmed dengue not diagnosed as dengue. Crude attack rates are VCD cases/person-years followed.
1Total episodes that were clinically diagnosed dengue (CDD).
2VCD episodes accompanied by a clinical diagnosis other than dengue.
3cVCD/VCD (i.e. sensitivity).
doi:10.1371/journal.pntd.0004918.t001
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Incidence of dengue in the cohorts compared to national routine
surveillance estimates
There was significant heterogeneity in average IRs observed between countries over the dura-
tion of the clinical trial. The IRs for all dengue cases (per 100,000 p/y) reported to national rou-
tine surveillance systems for the study locations during the study period varied by country
from: 64.7 (Malaysia); 263 (Indonesia); 497 (Thailand); 509 (Vietnam); and 954 (Philippines)
(Table 2). Adjusted dengue IDs (per 100,000 p/y) in the CYD14 study were considerably higher
than the rates captured by the national systems and varied according to the case definition
used. IDs were highest for VCD (range: 2,048 [Malaysia] to 10,960 [Philippines]), and were fol-
lowed by the IDs for UF-VCD (range: 1,192 [Indonesia] to 10,290 [Philippines]), CDD (range:
701 [Philippines] to 4,383 [Thailand]), and finally cVCD (range: 261 [Vietnam] to 4,262 [Thai-
land]). Surveillance data and corresponding incidence rates provided in S2 Table.
Expansion factors
EFs varied according to case definitions. They were 5.5−31.7 for VCD, 0.5−10.4 for cVCD, and
0.7−12.0 for CDD (Table 3). These factors varied widely but tended to be lowest in Vietnam
and highest in Malaysia. The incidence rates of dengue reported to the routine surveillance sys-
tem appeared to be important determinants of EF: the highest EF (31.7) was observed in
Malaysia (with the lowest reported IR) and the Philippines (with low EFs) reported the highest
IRs in passive surveillance.
Table 2. Dengue incidence rates [and 95%CIs] from routine surveillance systems and adjusted incidence densities of disease according to differ-
ent case definitions from the CYD14 study.
Country Average IR from routine surveillance system CYD14
VCD, adjusted ID cVCD, adjusted ID CDD, adjusted ID UF-VCD, adjusted ID
Indonesia 262.9 3,017 [1,951–4,542] 1825 [996, 3,153] 2,479 [1,483, 3,963] 1,192 [602, 2,269]
Malaysia 64.7 2,048 [1,099, 3,720] 671 [288, 1,851] 777 [367, 1,961] 1,377 [567, 2,993]
Philippines 954.4 10,960 [8,673, 13,620] 677 [262, 1,439] 701 [281, 1,461] 10,290 [8,055, 12,890]
Thailand 496.7 5,938 [4,273, 8,059] 4,262 [2,914, 6,055] 4,383 [3,015, 6,194] 1,676 [808, 3,065]
Vietnam 509.2 2,784 [1,813, 4,238] 261 [94, 1,083] 840 [156, 2,371] 2,523 [1,580, 3,964]
Incidence rates and densities are in cases/100,000 person-years. Incidence rates for routine surveillance calculated from total number of cases over the
period of study and study mid-point populations. IR, incidence rate; VCD, virologically confirmed dengue; ID, incidence density; CI, confidence interval;
cVCD, clinically diagnosed and virologically confirmed dengue; CDD, clinically diagnosed dengue; UF-VCD, virologically confirmed dengue not diagnosed
as dengue.
doi:10.1371/journal.pntd.0004918.t002
Table 3. Expansion factors for VCD, cVCD, and CDD over the active phase of the CYD14 study.
Country VCD [95% CI] cVCD [95% CI] CDD [95% CI]
Indonesia 11.5 [7.4, 17.3] 6.9 [3.8, 12.0] 9.4 [5.6, 15.1]
Malaysia 31.7 [17.0, 57.5] 10.4 [4.5, 28.6] 12.0 [5.7, 30.3]
Philippines 11.5 [9.1, 14.3] 0.7 [0.3, 1.5] 0.7 [0.3, 1.5]
Thailand 12.0 [8.6, 16.2] 8.6 [5.9, 12.2] 8.8 [6.1, 12.5]
Vietnam 5.5 [3.6, 8.3] 0.5 [0.2, 2.1] 1.7 [0.3, 4.7]
CI, confidence interval; VCD, virologically confirmed dengue CDD, cVCD, clinically diagnosed and
virologically confirmed dengue; CDD, clinically diagnosed dengue.
doi:10.1371/journal.pntd.0004918.t003
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Hospitalization and symptoms
Overall, 126 (4.1%) of the acute febrile episodes in the cohort were hospitalized (Table 4). For
the individual countries, this proportion varied between 1.2% (Vietnam) and 8.8% (Thailand).
Hospitalization rates varied according to local standard of care (i.e., laboratory and clinical
diagnosis): 61 (19.1%) of the 319 VCD episodes; 62 (57.4%) of the 108 CDD cases; and 24
(96.0%) of the 25 VCD cases diagnosed as DHF, were hospitalized. These proportions varied
between countries. Clinical dengue diagnosis appeared to be an important determinant of hos-
pitalization. The median duration of clinical symptoms was 5.0 days [min; max: 2.0; 38.0] for
cases of UF-VCD; 6.0 [20; 380] for VCD and 8.0 [2.0; 31.0] for CDD. Median durations of
fever were 3.0 [2.0; 11.0], 30 [20; 110] and 4.0 [2.0; 9.0)] and hospitalization 4.0 [3.0; 6.0]; 50
[20; 90] and 5.0 [2.0; 9.0)], respectively.
Positive and negative predictive values, sensitivity, and specificity of
clinical diagnosis
The positive predictive value (PPV) of clinical diagnosis, using VCD as the gold standard, was
85.2% (95% CI 77.1−91.3) and the negative predictive value (NPV) was 92.4% (91.4−93.3). The
sensitivity of clinical diagnosis was 28.8% (95% CI 23.9−34.2) and the specificity was 99.4%
(99.1−99.7).
Discussion
We used the control arm of a large, phase 3 efficacy dengue vaccine trial to describe the symp-
tomatic and virologically-confirmed dengue burden in five Asian countries. This permitted
comparison of clinical vs. laboratory dengue diagnosis for different classifications of symptom-
atic dengue identified through active surveillance. Importantly, data were consistently collected
according to standardized case definitions and with high-quality virological confirmation,
allowing IDs to be measured for different clinical outcomes and in different countries, within a
single study. Rates observed in study participants were adjusted to match the populations from
which they were sampled.
Discrepancies between dengue clinical and laboratory diagnosis typically find case defini-
tions which are sensitive but lack specificity, particularly in episodes of mild disease. [37–39]
Our results showed that virological confirmation was the most sensitive means of identifying
dengue disease, capturing approximately 3.5 times more episodes than clinical diagnosis alone,
even in this acutely febrile patient population. Clinical diagnosis alone captured only 28.8% of
Table 4. Number of episodes and hospitalizations in CYD14 study control subjects experiencing acute fever, VCD, CDD, or VCD clinically diag-
nosed DHF.
Country Febrile episodes VCD CDD VCD clinically diagnosed DHF
n Number of episodes
hospitalized (%)
n Number of episodes
hospitalized (%)
n Number of episodes
hospitalized (%)
n Number of episodes
hospitalized (%)
Indonesia 357 30 (8.4) 44 20 (45.5) 33 21 (63.6) 10 11 (100.0)
Malaysia 332 20 (6.0) 21 8 (38.1) 11 7 (63.6) 1 1 (100.0)
Philippines 1420 35 (2.5) 156 17 (10.9) 19 17 (89.5) 9 10 (100.0)
Thailand 388 34 (8.8) 47 13 (27.7) 36 13 (36.1) 2 2 (100.0)
Vietnam 602 7 (1.2) 51 3 (5.9) 9 4 (44.4) 3 3 (60.0)
Total 3,099 126 (4.1) 319 61 (19.1) 108 62 (57.4) 25 24 (96.0)
n, number of subjects or events; VCD, virologically confirmed dengue, CDD, clinically diagnosed dengue; DHF, dengue haemorrhagic fever.
doi:10.1371/journal.pntd.0004918.t004
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symptomatic cases. Because most passive disease surveillance systems in Asia rely almost
entirely on clinical diagnosis, [10,40] it is reasonable to believe a substantial proportion of
symptomatic dengue disease is unrecognized and therefore unreported.
The proportion of VCD clinically diagnosed by investigators as dengue varied substantially
between countries (range: 10.3%−74.5%), likely resulting from the multifactorial impacts of
local clinical guidelines and case definitions that affect diagnostic practices, and variable clini-
cal presentations. Disease severity and clinical manifestation may be affected by factors includ-
ing circulating viral genotypes; the order and duration between sequential, heterotypic
infections; year/season; and subject age [41–43]. Notably, VCD cases appeared to be younger
in the Philippines–where dengue was least-frequently diagnosed–than other countries.
Estimates of dengue burden are, in large part, a function of case definition. [9] The active
surveillance methods here allowed calculation of IRs according to different case definitions
(VCD, cVCD, and CDD) and thus determine EFs for each. The higher rates of VCD captured
gave rise to EFs ranging from 5.5 to 31.7, with lower EFs for more specific case definitions of
cVCD and CDD. These figures are notable for their variability and emphasize that study and
surveillance system methodology and geography are important determinants of under-report-
ing estimates, as reported elsewhere. [15,19] However, the finding that dengue is under-
reported by factors of>30 in some countries and contexts is consistent between these studies.
Notable exceptions are the expansion factors<1, observed in Philippines and Vietnam against
specific, clinically-diagnosed case definitions (cVCD and CDD): passive surveillance had cap-
tured a higher proportion of cases than the active system. There are two likely possibilities: 1)
the passive surveillance reported false-positive cases (ie, episodes of febrile, non-dengue dis-
ease, thereby increasing the denominator) or, more likely, 2) the active system excluded febrile
cases which failed to satisfy case definitions (thereby reducing the numerator). Both scenarios
emphasize the heterogeneity of dengue case definitions, surveillance systems and clinical prac-
tices, which challenge the generation of consistent burden estimates. Additional complexity
has been observed during outbreaks from both over- and under-reporting due to differing lev-
els of disease awareness and/or reporting practices. [44]
A similar analysis was conducted in slightly older Latin American children, focusing on
VCD cases and comparing with dengue reported at different levels of the surveillance system
(country; state; local). [45] It found lower rates of VCD (from 2,500 cases/100,000 p/y in
Mexico to 3,500 in Brazil), and corresponding EFs which varied widely, from 3.5–45.5
(depending on country and comparator), emphasizing that EFs are a complex outcome of local
epidemiology, disease awareness, health system characteristics and other factors. [19] Addi-
tional analyses of under-reporting according to indicators of socio-demography or dengue
awareness, for example, may be illuminating.
Hospitalization was based on local routine practice and rates were shown to be substantial:
over 4% of fevers, and over 50% of dengue diagnoses were hospitalized. A clinical diagnosis–
rather than virological confirmation–seemed to determine the decision to hospitalize, demon-
strated by the successively decreasing incidence and increasing hospitalization rate of episodes
of fever; VCD; CDD; and DHF. Interestingly, four cases of clinically diagnosed DHF (13.8% of
the total) could not be virologically confirmed, highlighting a possible over-attribution in
endemic areas, of consequence for prospective epidemiological or vaccine effectiveness studies
using clinical endpoints. Interpretations of the interplay between severity, case definitions and
hospitalization are particularly important from a health economics perspective when we con-
sider that a single hospitalization has been reported to cost between USD 289 (Philippines) and
USD 863 (Malaysia). [21,46]
The case definition applied in CYD14 (fever 38°C on 2 consecutive days) intentionally
captured a broad spectrum of disease, enabling calculation of vaccine efficacy against dengue
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of any severity. However, a considerable proportion of VCD episodes (7.8%) were assessed as
DHF by the investigators, and while empirically-derived global burden estimates of severe den-
gue/DHF are not available, [47] our data suggest that in Southeast Asia, the burden is substan-
tial. Extrapolations using appropriate baselines and harmonized case definitions associated
with clinical severity could theoretically be used to generate estimates of severe disease, and
may be a topic of further research.
Most clinical diagnoses of dengue were virologically confirmed, resulting in a PPV of 85.2%.
However the sensitivity was 28.8%, reflecting the significant proportion of VCD which was not
clinically diagnosed as dengue. This is likely because local DF or DHF reporting case defini-
tions had not been satisfied, even when investigators suspected dengue as the underlying aetiol-
ogy, and is a finding which should contribute to the understanding of the clinical and
economic burden of mild dengue disease. Using VCD as a denominator, the complement to
clinical diagnoses were termed undifferentiated fever VCD in our study, and represent symp-
tomatic, febrile, virologically confirmed cases which were not diagnosed. Policymakers some-
times consider milder manifestations of disease unimportant, but a recent Cambodian study
found mild dengue cases are significantly more infectious than those with symptoms. [48]
Mild cases may thus contribute significantly to transmission and constitute an important viral
reservoir. Additional studies will be required to understand the impacts on population-level
immunity and transmission dynamics.
A clinical diagnostic exclusion of dengue following a febrile episode was correct in>90% of
instances (NPV: 92.4%) and the specificity of clinical diagnosis was 99.4% in these epidemio-
logical settings where>10% of acute fevers were caused by dengue virus infection. The accu-
racy of diagnosis was much improved when considering only hospitalized episodes, indicating
that surveillance reports and burden estimates of more severe disease are likely more reliable
than those of mild cases. However this leaves a considerable burden of mild disease which is
unaccounted for. We are not aware of health economic or healthcare utilization studies exam-
ining the impact of these mild episodes but their frequency implies a significant source of bur-
den. Additional analyses could consider aggregating costs (including indirect costs), disability-
adjusted life years or other measures to quantify impacts.
The study has limitations. The ID of cVCD was low in some settings, with only six episodes
in Malaysia and nine in Vietnam. This is an unavoidable consequence of examining infrequent
disease outcomes using prospective methods. Our approach annualized incidence, which may
have introduced some bias, but our comparison with local surveillance data and overlapping
timeframes will limit geographical/temporal distortions. As this was a vaccine trial, sites were
chosen for their historically high reported dengue burdens, so results from lower-endemic
areas may differ. [38] For this reason, incidence rates and other findings could not be combined
between countries. However, the socio-environmental determinants of dengue incidence are
poorly understood and in many Asian countries burdens are unpredictable throughout urban
endemic areas. Where age-stratified incidence data were unavailable, adjustments were made
which introduced slight inaccuracies to the data. More substantial variability was caused by the
differences in national surveillance systems, with more sensitive surveillance giving rise to
lower EFs. This is an inherent study bias but also an interesting result; the use of a stable
denominator in expansion factor calculations provides an insight into surveillance system
specificities.
WHO 1997 classifications were applied, as assessed by investigators, because at study initia-
tion 2009 guidelines were not in routine use at all sites. Cases were also classified according to a
more inclusive definition of severe dengue, integrating criteria from the WHO 1997 and 2009
and South East Asia Regional Office 2011 guidelines, and applied by the study Independent
Data Monitoring Committee (IDMC). [49] Of the 25 VCD cases clinically diagnosed as DHF,
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20 met these IDMC criteria indicating, in this clinical trial environment at least, a level of con-
cordance between the two.
This analysis was performed to inform policy making and strengthen evidence for public
health decisions, including financing for dengue control efforts such as vaccination. It adds to
available evidence indicating that passive surveillance systems greatly underestimate dengue
burden and emphasizes that burden estimates are highly sensitive to case definitions. The con-
trol arms of vaccine clinical trials can provide valuable data to estimate disease burdens.
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SUMMARY
Routine, passive surveillance systems tend to underestimate the burden of communicable diseases
such as dengue. When empirical methods are unavailable, complimentary opinion-based or
extrapolative methods have been employed. Here, an expert Delphi panel estimated the proportion
of dengue captured by the Indonesian surveillance system, and associated health system parameters.
Following presentation of medical and epidemiological data and subsequent discussions, the panel
made iterative estimates from which expansion factors (EF), the ratio of total:reported cases, were
calculated. Panelists estimated that of all symptomatic Indonesian dengue episodes, 57·8% (95%
confidence interval (CI) 46·6–59·8) enter healthcare facilities to seek treatment; 39·3% (95%
CI 32·8–42·0) are diagnosed as dengue; and 20·3% (95% CI 16·1–24·3) are subsequently reported in
the surveillance system. They estimated most hospitalizations occur in the public sector, while ∼55%
of ambulatory episodes are seen privately. These estimates gave an overall EF of 5·00; hospitalized
EF of 1·66; and ambulatory EF of 34·01 which, when combined with passive surveillance data,
equates to an annual average (2006–2015) of 612 005 dengue cases, and 183 297 hospitalizations.
These estimates are lower than those published elsewhere, perhaps due to case definitions, local
clinical perceptions and treatment-seeking behavior. These findings complement global burden
estimates, support health economic analyses, and can be used to inform decision-making.
Key words: Epidemiology, Delphi, dengue, Indonesia, under-reporting.
Dengue is a systemic viral disease, transmitted to
humans by the bite of infected Aedes spp. mosquitoes
throughout the tropical and subtropical world. It
results in substantial disease burden, health service dis-
ruption and costs [1]. Historically, the World Health
Organization (WHO) estimated 50–100 million global
infections per year including 500 000 dengue hemor-
rhagic fever (DHF) cases and 20 000 deaths but more
recent modeling studies have found approximately
four billion people in over 120 countries at risk, with
50–100 million annual symptomatic cases, mostly
occurring in the Asia–Pacific region [2,3].
Indonesia has over 900 permanently inhabited
islands extending over 5000 km from east to west.
Since the first dengue reports in Jakarta and Surabaya
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in 1968, the disease has been expanding in incidence and
geography, and is likely hyperendemic (i.e. multiple
co-circulating serotypes) nationwide [4,5]. Notification
of DHF is mandatory and Indonesia typically reports
the highest number of cases in the WHO Southeast
Asia Region [1]. Between 2001 and 2011, there was a
reported average of 94 564 cases and between 472 and
1446 deaths per year [6]. The surveillance system uses
WHO 1997 case definitions, whether clinically or
laboratory diagnosed, but likely captures only a pro-
portion of symptomatic disease due to inconsistent
health-seeking behavior, non-specific symptoms, lim-
ited use of imperfect diagnostics and health systems
issues. Between provinces, significant variation exists
in reported incidence rates which may be a function of
disease dynamics, surveillance and reporting practices,
or both. Under-reporting is thus a complex product
of geographical, clinical, epidemiological, laboratory,
and health system factors. It may be that the introduc-
tion of point-of-care dengue rapid diagnostic tests has
increased the reporting rate but data documenting this
effect are currently lacking, and the full disease burden
is unknown.
Estimating the public health and economic burdens
of dengue are elements of the WHO Global Strategy
for Dengue Prevention and Control, 2012–2020, and
are priorities of many ministries of health to support
disease control planning, allocation of resources and
assessment of the value of novel prevention measures,
including vaccination. Accordingly, a range of empir-
ical or extrapolative methods have been employed to
make more complete disease burden estimates in
Indonesia and other countries [7]. However reliable
data to make empirical assessments, particularly
robust epidemiological data from active surveillance
projects, are often lacking. A Delphi panel is a struc-
tured communication process which aims to achieve a
convergence of opinion on a specific real-world issue.
Experts make iterative estimates to answer a pre-
defined research question, under the assumption that
the range of answers will narrow as the process pro-
gresses. A group discussion makes each participant
aware of the range of opinions and their rationale,
information which is used to refine subsequent esti-
mates, typically leading to confluence of opinion
based on the expertise of the panel. The process is
stopped upon reaching predefined criteria [8]. In
combination with statistical methods, this approach
has been used to calculate an overall adjustment
factor for dengue under-reporting in the Philippines,
Malaysia, and India, and it can be used to derive
health system parameters which are otherwise unavail-
able [9,10].
A Delphi panel meeting was convened in Jakarta
on 8 December 2015 comprising 14 experts, including
infectious disease physicians and pediatricians,
national specialists in dengue treatment guidelines
and epidemiology, healthcare system managers, sur-
veillance officers, academics, and laboratory workers,
from different geographical areas across Indonesia,
invited based on the advice of national-level dengue
experts (full list of panelists provided in acknowledg-
ments). The panel was expected to estimate the propor-
tion of symptomatic dengue cases captured in the
surveillance system and thus enable calculation of
national-level dengue burden estimates. The panel also
estimated the percentage of hospitalized and ambulatory
dengue cases treated in private and public institutions.
A range of epidemiological and clinical data
documenting current knowledge and gaps related to
dengue in Indonesia was first presented to the panel,
to align on recent study results and their methods.
With the explanations that: (a) ‘dengue case’ refers
to any patient whose symptoms are the result of infec-
tion with a dengue virus, including mild cases (e.g.
fever >38°C for51 day) and thosewhich present atyp-
ically; (b) ‘dengue diagnosis’ refers to adengue casewith
a dengue diagnosis from a physician according to local
practices (clinical and/or laboratory confirmation); (c)
‘healthcare facility’ refers to a licensed clinic, hospital,
or other health provider (e.g. subdistrict-level primary
healthcare center); and (d) ‘hospitalized dengue case’
is any dengue case spending at least one night in a
healthcare facility; panelists were asked five questions,
each of which was to be considered from the national
perspective:
Q1: What percentage of dengue cases enters a
healthcare facility to seek treatment?
Q2: Of all dengue cases entering a healthcare facil-
ity, what proportion is diagnosed as dengue?
Q3: Of dengue cases diagnosed in a healthcare facil-
ity what proportion is then reported in the routine
Indonesian dengue surveillance system statistics?
Q4: Of dengue cases entering an Indonesian health-
care facility, what proportion is hospitalized for any
duration?
Q5: Among all dengue cases entering healthcare
facilities, what proportion is seen in the public sector
if: (a) hospitalized; (b) outpatient (i.e. ambulatory).
Anonymous responses were collected by a moder-
ator who aggregated the data, presented them to the
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group and facilitated a discussion. Participants were
then invited to re-cast their votes in light of the previ-
ous results and discussions. The process was termi-
nated after three rounds of voting (two rounds of
discussion). Medians of final round votes were used
for analysis, and a bootstrapping resampling method
(200 samples; SAS software) employed to provide vari-
ability based on the theoretical non-parametric distri-
bution of observed values, enabling estimation of
medians and their 95% confidence intervals (CIs) [11].
These medians were used to calculate the total number
of symptomatic dengue cases occurring in Indonesia via
generation of an overall expansion factor (EFO):
EFO = Total casesReported cases .
By proportionally adjusting a theoretical 100% of
symptomatic cases according to the responses to the
questions above, this can be logically calculated
according to the formula:
EFO = 1Q1∗Q2∗Q3 .
The total number of cases can be estimated as:
Total dengue = EFO∗Reported dengue cases.
Cases could be further stratified into hospitalized
and ambulatory dengue, which are likely under-
reported in different magnitudes and incur different
public health consequences and costs:
Hospitalized dengue = EFO∗Q1∗Q4
and
Ambulatory dengue = EFO∗1− (Q1∗Q4).
Specific EFs for hospitalized/ambulatory dengue
EFH and EFA are often reported [7,9]. While they
do not affect final burden estimates here, they may
have value for policy-makers and can be calculated
assuming the proportionof hospitalized andambulatory





EFA = 1− (Q1
∗Q4)∗EFO
Pa
where Ph and Pa are the proportion of reported cases
which is hospitalized/ambulatory (Ph = 100−Pa).
Based on local experience that most reported cases
are hospitalized, we made a base-case assumption of
Ph = 90%, with uncertainty assessed by applying rates
from 80% to 99% in sensitivity analysis.
Proportions of cases seen in public/private facilities
were similarly adjusted using the responses to question
5. National-level estimates were calculated by multi-
plying these EFs by the number of reported dengue
cases in Indonesia, from 2006 to 2015 [12].
One participant departed after the first voting
round leaving 13 voting participants at the meeting.
At the third vote, four questions were unanswered
leaving a total of 74 responses in the analysis. There
was significant confluence of opinion by the third
round with more than half (45/74) of votes agreeing
on the response to each question. Voting summaries
from the final round, and median estimates from boot-
strapping resampling and their 95% CIs are provided
in Table 1. Panelists estimated that, of all symptom-
atic dengue episodes, 57·8% (95% CI 46·6–59·8)
enter healthcare facilities to seek treatment; 39·3%
(95% CI 32·8–42·0) is diagnosed as dengue; and
20·3% (95% CI 16·1–24·3) is subsequently reported.
In all, 31·5% (95% CI 24·4–35·5) of cases are hospita-
lized. Of all cases entering the healthcare system,
20·0% (95% CI 14·5–24·2) are hospitalized in the pub-
lic sector (with a public/private split in hospitalized
cases of 64%/36%) and 12·0% (95% CI 9·8–14·1) are
outpatients in the public sector (public/private split
in ambulatory cases: 45%/55%).
These estimates gave rise to an EFO of 5·00 (95% CI
4·11–6·21); EFH of 1·66 (95% CI 1·51–1·86), and EFA
of 34·01 (95% CI 27·85–44·72) and, when combined
with passive surveillance data, a 2006–2015 annual aver-
age of 612 005 symptomatic cases (Fig. 1). This varied
from a low of 328 704 in 2011, to a high of 790 770
in 2007. This equates to a total from 2006 to 2015 of
3 537 238 (95% CI 2 854 797–3 657 332) cases entering
health facilities; 2 476 067 (95% CI 1 986 082–2 577 322)
dengue diagnoses and 1 832 969 (95% CI 1 665 785–2
052 687) hospitalizations, 1 164 543 of which are seen
in the public sector. Varying the hospitalization rate
from 80% to 99% led to EFH ranges of 1·51–1·87 and
EFA from 17·01 to 340·13. As these rates are compo-
nents of burden calculations they make no difference
to final estimates here, but this variability emphasizes
the importance of consistent assumptions and accurate
methodological reporting.
These findings support previous reports that dengue
is significantly under-reported in Indonesia, and pro-
vide granularity which was previously lacking, for
example the finding that approximately 1/3 of all
symptomatic cases is hospitalized for some duration.
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However, the magnitude of under-reporting is rela-
tively modest in comparison with other studies: a
regional analysis extrapolating from neighboring
countries found an overall EF of 7·6 [7] and an ana-
lysis of published data found national under-reporting
in Indonesia from 36- to 126-fold [13]. More recently,
two prospective comparisons between active and pas-
sive surveillance systems have been published: a
factory-based dengue cohort in West Java identified a
dengue incidence rate of 17·3 cases/1000 person-years,
43-fold higher than rates recorded in the passive sur-
veillance system; [14] and a comparative reanalysis of
placebo arm data from a dengue vaccine clinical trial
in Jakarta, Bandung, and Bali identified an overall
EF of 11·5 [15]. Finally, two influential global dengue
burden studies using complementary approaches
based on dengue occurrence data, incidence rates
from published cohorts, or vital registration and verbal
autopsy estimated national burdens from which
Indonesian EFs of 57 and 106, respectively, can be














1. What percentage of dengue cases enter a healthcare facility to
seek treatment?
13 57 60 60 57·8 (46·6–59·8)
2. Of all dengue cases who enter a healthcare facility, what
proportion is diagnosed as dengue?
13 70 70 70 70·0 (69·6–70·5)
3. Of dengue cases diagnosed in a healthcare facility what
proportion is then reported in the routine Indonesian dengue
surveillance system statistics?
12 54 60 60 56·7 (50·7–59·9)
4. Of dengue cases who enter an Indonesian healthcare facility,
what proportion is hospitalized for any duration?
12 56 60 60 59·0 (55·0–60·1)
5 (a). Among all dengue cases who enter healthcare facilities,
what proportion is seen in the public sector if hospitalized?
12 68 70 70 68·6 (65·6–70·0)
5 (b). Among all dengue cases who enter healthcare facilities,
what proportion is seen in the public sector if outpatient?
12 53 60 52·5 50·9 (50·8–51·0)
Fig. 1. Estimated annual number of dengue cases and hospitalizations in Indonesia following adjustment of surveillance
reports with EFs, and their 95% confidence intervals (CIs), 2006–2015.
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derived [2,3]. These recent studies are consistent in
finding that dengue is significantly under-reported in
Indonesia at magnitudes in significant excess of these
Delphi panel estimates.
Dengue causes a spectrum of clinical disease and
incidence rates are determined by the surveillance sys-
tem and case definitions applied to describe symptom-
atic episodes. The experts participating in this Delphi
panel, who are mostly familiar with dengue episodes
requiring medical intervention, may be familiar with
more severe and less frequent presentations of
dengue than considered in other analyses, a possible
explanation for these conservative projections [2].
Supporting this hypothesis, our estimates are similar
to those from a 2013 paper (which found 792 829
annual cases), conducted before contemporary esti-
mates were available [7]. Additionally, only dengue
cases meeting a DHF case definition are notifiable in
Indonesia, a probable reason why the nationally
reported incidence rates are lower than those fromneigh-
boring countries [data not shown]. A recent analysis
clearly described a relationship between clinical severity
and under-reporting, it therefore remains important for
policy-makers to understand methodological study
aspects, case definitions, and their implications [15].
Simple comparisons between countries are rarely jus-
tified. Some of these observations are limitations of an
expert-based approach and are reflective of local expert
opinion. However, such a method enables exploration
of experimentally challenging research topics in complex
countries, understanding of expert views and their
rationale, and projection of local experience and data
to inform decision-making at the national level.
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S U M M A R Y
Background: Dengue surveillance data in India are limited and probably substantially underestimate the
burden of disease. A community-based study was undertaken to assess the prevalence of dengue-
specific immunoglobulin G (IgG) antibodies in children across India and to examine historical dengue
exposure rates. Potential associations between socio-economic factors and dengue seroprevalence were
also assessed (registered at ctri.nic.in: CTRI/2011/12/002243).
Methods: A convenience sample of 2609 healthy children aged 5–10 years was enrolled; these children
were registered at or were living in the vicinity of eight centres located at six geographically distinct sites
across India. Blood samples were drawn to test for the presence of dengue IgG antibodies using ELISA.
Serotype-specific neutralizing antibody titres were measured in dengue IgG-positive children using
dengue plaque reduction neutralization tests. Socio-demographic and household information was
collected using a questionnaire.
Results: Overall, 2558/2609 children had viable samples with laboratory results for dengue IgG. Dengue
IgG seroprevalence across all sites was 59.6% (95% confidence interval 57.7–61.5%): the lowest (23.2%)
was in Kalyani, West Bengal, and the highest (80.1%) was in Mumbai. Seroprevalence increased with age.
Multivariate analysis suggested associations with household water storage/supply and type of housing.
Half of the subjects with positive IgG results presented a multitypic profile, indicating previous exposure
to more than one serotype.
Conclusions: The overall dengue seroprevalence suggests that dengue endemicity in India is comparable
to that in highly endemic countries of Southeast Asia. Additional prospective studies are required to fully
quantify the disease burden, in order to support evidence-based policies for dengue prevention and
control in India.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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1. Introduction
Dengue is caused by a mosquito-borne flavivirus that is
endemic in tropical and subtropical countries, including India.1
Sporadic outbreaks have been reported in India for over 200 years.
The scale and severity of two major epidemics in the 1990s
prompted the implementation of a number of strategies to aid the
control and surveillance of dengue. In particular, a passive
surveillance programme and publication of guidelines for dengue
prevention and control was launched as an initiative of the
National Vector Borne Disease Control Programme,2 in collabora-
tion with the existing Integrated Disease Surveillance Programme.
Due to non-specific and often mild symptoms, dengue is
significantly under-reported in nearly all countries. This is
exacerbated in India, where dengue surveillance data are collected
from only approximately 500 sentinel hospitals.3 Studies using
global or extrapolated data have quantified this under-reporting,
and suggest that the dengue disease burden in India is likely to be
the highest in the world.3,4
Dengue has spread from urban to rural areas of India in recent
decades.2,5 All four virus serotypes – DENV-1 to DENV-4 – have
been documented in India, without a clear geographical distribu-
tion. Areas where serotypes co-circulate are increasing in number
and scale.2 Specifically, DENV-1, DENV-2, and DENV-4 were
isolated during an outbreak of dengue fever in Vellore in
1963 and all four serotypes were isolated during another outbreak
in the same city in 1968.2 DENV-2 was the predominant serotype
from the early 1970s to 2000, responsible for large epidemics in
1993 and 1996. DENV-3 was the predominant serotype in a
2003 outbreak and co-circulated with DENV-1 in 2006 in Dehli.2
Delhi became hyperendemic for dengue, with all four serotypes
isolated in 2003 and 2006.2 No study to date has taken a nationally
representative view of serotype distribution.
Cross-sectional, population-based, age-stratified seropreva-
lence data describe historical disease transmission intensity.6,7 A
seroprevalence study was undertaken to describe the prevalence of
dengue-specific immunoglobulin G (IgG) antibodies and the
infecting serotype profiles of positive samples, in children from
eight sites across India.
2. Methods
2.1. Study design and centres
This was a community-based, descriptive, cross-sectional
seroprevalence study and was conducted between January
2011 and October 2012 in healthy children (registered at
ctri.nic.in: CTRI/2011/12/002243). A convenience sample of eight
private or government medical colleges at six geographically
distinct locations was selected (1) to provide a wide geographical
distribution across India, (2) to represent rural and peri-urban
areas, and (3) based on the recognized ability of the site to conduct
epidemiological research. Overall, two sites were selected in New
Delhi and Hyderabad, and one site each in Kalyani, Wardha,
Mumbai, and Bangalore.
This study was conducted in accordance with the latest revision
of the Declaration of Helsinki (Seoul, Korea, October 2008),
guidelines for Good Epidemiological Practice,8 and local regulatory
requirements. The study protocol was approved by ethics
committees at the study centres and by the Health Ministry
Steering Committee (HMSC) of the Government of India.
2.2. Participants
Children, 5–10 years old, who were resident at the study sites,
were eligible. This is an age at which blood sample collection is
relatively straightforward. Furthermore, seroconversion, and thus
the demonstration of age-specific variation in seroprevalence, was
considered likely in this age group. Parents or legal guardians were
invited to enrol children during routine household visits by
community health workers. Written informed consent was
obtained from the parents or legal guardians, and children aged
8–10 years also signed an assent form. Enrolment at the two sites
in Hyderabad was school-based; parent–teacher meetings were
held at randomly selected schools to explain the purpose of the
study, and all eligible children at those schools were invited to
participate. Permission was obtained from the District Education
Officer to perform study visits, complete questionnaires, and
collect blood samples from study participants on the premises of
each school.
Assuming a dengue seroprevalence of 30%, a sample size of
323 participants at each site was calculated to ensure a precision of
5% for the two-sided 95% confidence interval (CI) around the
seroprevalence point estimate.
2.3. Data and sample collection
Socio-demographic data (participant’s demographic character-
istics, household occupancy, water supply/storage, self-reported
history of dengue or Japanese encephalitis (JE) virus infection, and
education levels attained by the parents/guardians) were collected
using a questionnaire. The questionnaire was administered by the
health worker through interviews with the participant’s parents or
legal guardians during the first visit. Participants were asked to
report to the affiliated centre for blood sample collection (5 ml) by
a trained laboratory technician. The participant’s height and
weight were recorded using standard methods. Significant medical
history, current or previous medical conditions, concomitant
medication, recent vaccinations, and reasons for refusal of blood
sampling, where relevant, were recorded.
Blood samples were left at room temperature for 1–2 h before
centrifugation. Each serum sample was divided into aliquots and
stored in 3-ml cryotubes: 0.5 ml for dengue IgG antibody
assessment, 1 ml for dengue plaque reduction neutralization tests
(PRNT), and 0.5 ml for JE IgG antibody detection. Serum samples
were kept frozen at 20 8C or below until analysis.
2.4. Assays
Samples were sent to the Microbiology Department of the
Maulana Azad Medical College (New Delhi) for analysis. Dengue
IgG antibody levels were assessed using commercially available
ELISA kits. The EL1500G kit (Focus Diagnostics, California, USA)
was used for samples from the first two sites (New Delhi);
however, due to supply issues, the E-DEN 10G kit (Panbio
Diagnostics, Brisbane, Australia) was used for the other sites. A
sensitivity analysis of the two dengue IgG-specific ELISA kits
performed on 30 samples confirmed 100% concordance; data from
all centres were thus pooled. JE IgG antibody testing by indirect
ELISA was also performed using commercially available kits
(InBios, Washington, USA). Dengue IgG-positive samples were
sent to the Centre for Vaccine Development (Mahidol University,
Thailand) for measurement of dengue serotype-specific neutraliz-
ing antibody titres using PRNT based on 50% or greater reduction in
plaque counts (PRNT50).
9
Seropositivity for dengue and JE were defined according to the
manufacturer’s instructions. Seroprevalence was the percentage of
seropositive participants.
For the interpretation of PRNT50 titres, participants were
classified as follows: ‘naı̈ve’, if antibody titres were <10 (1/dil)
for the four serotypes; ‘monotypic’, if antibody titres were 10
(1/dil) for only one serotype or if titres were 10 (1/dil) for
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different serotypes, with a single serotype having a high titre (>80
(1/dil) titre, and 5 times higher than other titres); and ‘multi-
typic’, if antibody titres were 10 (1/dil) for different serotypes
without a single predominant titre.
At each site, a designated clinical research associate performed
periodic visits to monitor implementation. All serum samples were
checked for quantity and storage temperature by a lot quality
assurance method.
2.5. Statistical analysis
Descriptive statistics reported baseline characteristics and
immunogenicity results. Associations between all demographic–
socio-economic factors and dengue serostatus were assessed by
univariate analysis using the Chi-square test or t-test (for age) and
multiple logistic regression with backward selection (significant if
the p-value is 0.05). JE serostatus was not included as a covariate
due to possible cross-reaction between flavivirus antibodies.
Statistical significance was considered at and below a p-value of
0.05. Statistical analyses were performed using SAS software
version 9.1 (SAS Institute, Cary, NC, USA) and Stata v. 12.1
(StataCorp LP, College Station, TX, USA).
2.6. Role of the funding source
The sponsor participated in all operational aspects of the study,
including data collection, statistical analyses, and the writing of the
study report. The sponsor funded medical writing support for the
development of this publication. The corresponding author had full
access to all of the data in the study and had final responsibility for
the decision to submit for publication.
3. Results
3.1. Demographic characteristics of the study population
Overall, 2609 participants from eight health centres were
enrolled in the study. A total of 18 participants were excluded, due
to age <5 years or >10 years (n = 8) and/or assent form not signed
(n = 13). Thus, 2591 participants were included, all of whom had a
blood sample drawn; 1364 (52.6%) were female, and the mean age
of all participants was 7.8 (standard deviation (SD) 1.6) years.
3.2. Socio-economic characteristics
The mean number of people living in the participants’ house-
holds was 5.4 (SD 2.3), including 2.6 (SD 1.2) children under
15 years of age. Most (2170/2591; 83.8%) participants lived in a
house, with 381 (14.7%) living in precarious lodgings; 1121 (43.3%)
had an indoor piped public water supply, 2343 (90.4%) had water
storage in the house, 1675 (64.6%) were connected to the public
sewer, and 1339 (51.7%) had regular organized waste collection.
3.3. Medical history
A notable medical history was recorded for 94 (3.6%) children;
61 (2.4%) children were undergoing at least one current treatment
at the time of enrolment. A history of dengue or a family history of
dengue was reported by 15 (0.6%) and 48 (1.9%) participants,
respectively. No participants reported a history or family history of
JE infection. Only one participant reported receiving JE vaccination.
3.4. Dengue IgG seroprevalence
Anti-dengue IgG results were available for 2558/2591 (98.7%)
participants. Serology data were missing for 33 participants;
22 samples from a single site (Mumbai) could not be analysed due
to haemolysed red blood cells. Overall, 1525/2591 (59.6%)
participants were dengue seropositive, with similar prevalence
in males and females. Six of the eight sites had dengue
seropositivity ranging from 58.2% to 69.0%. The sites in Kalyani
and Mumbai had the lowest (23.2%) and highest (80.1%)
seroprevalence, respectively (Figure 1). Overall, dengue IgG
seroprevalence increased with age, from 40.7% (95% CI 36.0–
45.5%) in children aged 5 years to 73.4% (95% CI 67.9–78.5%) in 10-
year-olds (Figure 2). At the Bangalore site, seroprevalence
remained relatively stable across the age strata (varying from
58.8% in 7-year-olds to 70.9% in 8-year-old children).
3.5. Socio-economic characteristics associated with dengue
seroprevalence status
In univariate analyses, children seropositive for dengue were
found more likely to be from homes with more than two children
(p < 0.0001), more likely to have water storage (p < 0.0001) and
[(Figure_1)TD$FIG]
Figure 1. Dengue IgG seroprevalence by site.
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indoor piped water from the public water supply (p < 0.0001), and
less likely to be living in precarious housing (p = 0.0048) compared
with dengue seronegative children (Table 1). Multiple logistic
regression confirmed possible positive associations with house-
hold water storage (odds ratio (OR) 5.00, 95% CI 3.54–7.06) and
indoor piped water from the public water supply (OR 1.49, 95% CI
1.19–1.85). Increasing participant age (p < 0.0001) and living in
precarious lodgings compared to a house (OR 1.54, 95% CI 1.17–
2.03) were also associated with dengue status. In terms of
geography, Kalyani was associated with decreased exposure (OR
0.18, 95% CI 0.10–0.31), while Wardha (OR 1.49, 95% CI 1.07–2.08)
and Mumbai (OR 2.49, 95% CI 1.70–3.65) had an elevated risk, in
comparison with Delhi. The pseudo R2 of the final model was 0.085.
3.6. Dengue serotype analysis
Of 1525 IgG seropositive participants tested, 1511 had PRNT50
data available for all four serotypes. Of these, 1468 (97.2%) had
antibody titres 10 for at least one serotype and 1205 (79.7%) had
antibody titres 10 against all four serotypes. Nearly half (736/
1511; 48.7%) had a multitypic antibody profile and 732/1511
(48.4%) had a monotypic profile. DENV-1, DENV-2, and DENV-3
were nearly equally represented among dominant serotypes in
participants with monotypic profiles overall (Figure 3).
3.7. Japanese encephalitis IgG seroprevalence
Anti-JE IgG results were available for 2544 (98.2%) participants.
Of these, 345 (13.6%; 95% CI 12.3–15.0%) participants were
seropositive against JE, 327 (94.8%) of whom were also dengue
seropositive (Table 2). JE seroprevalence ranged from 4.3% (95% CI
2.4–7.1%) in Kalyani to 20.5% (95% CI 16.2–25.3%) in Wardha.
4. Discussion
These findings demonstrate a high intensity of dengue
transmission among children in India; more than 50% of the
children had been infected at least once by the age of 6 years,
results which are broadly consistent with existing, limited dengue
seroprevalence data for adults and children in Chennai and
Hyderabad.10,11 All four serotypes were found to circulate, varying
by geographic location. Nearly half of all participants had a
multitypic dengue antibody profile. Dengue IgG seroprevalence
increased with age at all but one study site, consistent with age-
related cumulative exposure to dengue.10 The exception in
Bangalore could be related to epidemiological, behavioural, or
environmental factors moderating exposure risk, such as the
occurrence of large, infrequent outbreaks.
The observed level of dengue exposure was comparable to that
reported in other highly endemic countries of Southeast Asia and
Latin America: 56.2% for 4–9-year-olds in Yogyakarta, Indonesia
(1995–1996),12 65% for 11-year-olds in Rayong, Thailand (2010),13
34.4% for under 7-year-olds to 70.5% in 14–16-year-olds from a
primary health care facility in Sri Lanka (2013–2014),14 53% for
under 7-year-olds and 88% by the age of 13 years among primary
school children in southern Vietnam,15 and 35.7% and 52.2% for
5–9 and 10–14 years age groups, respectively, in two localities in
Mexico in 2011.16 A higher seroprevalence was observed in a study
in Managua, Nicaragua (2001–2003), where 80% of enrolled
children were seropositive by 5 years of age.17
Considering these similarities in exposure history, it might be
expected that rates of symptomatic, reported dengue are similar in
India and other countries. In fact, there are huge disparities: from
2007 to 2011, India reported an approximate average annual
incidence of 1.4 cases/100 000 population,5 whereas case
notifications in Cambodia, Malaysia, the Philippines, and Sri Lanka
for 2011 were 119, 70.4, 134, and 135 per 100 000, respective-
ly.18,19 Despite their significant and often multitypic infection
history, very few participants in the present study reported a
history of dengue. Similarly low reporting was observed in the
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Figure 2. Percentage of participants with antibody titres10 (1/dil) against dengue
according to age group (all study sites). Error bars show 95% confidence intervals. n,
number of participants with available results per age group.
Table 1
Demographic and socio-economic characteristics associated with dengue seroprevalence status
Dengue IgG positive Dengue IgG negative p-Value (ORa)
Demographic characteristics
Overall, n 1525 1033
Age, mean (SD) years 8.13 (1.56) 7.39 (1.56) <0.0001b,*
Socio-economic characteristics
Number of children living in the household (%) <0.0001c
2 children 855 (56.07) 671 (64.96)
>2 children 670 (43.93) 362 (35.04)
Type of housing (%) 0.0048c,*
House 1290 (84.6) 855 (82.8) (1.00)
Apartment 29 (1.9) 7 (0.7) (2.16)
Precarious lodgings 206 (13.5) 171 (16.6) (1.54)
Water storage in the house (%) 1465 (96.1) 845 (81.9) <0.0001c,* (5.00)
Indoor piped public water supply (%) 721 (47.3) 380 (36.8) <0.0001c,* (1.54)
Connected to public sewer (%) 959 (62.9) 688 (66.6) 0.0541c
IgG, immunoglobulin G; SD, standard deviation.
a The odds ratio (in parentheses) is provided for significant categorical multivariate results.
* p<0.05 in multivariate analysis.
b t-test.
c Chi-square test.
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recent household-based study in Chennai,10 in which 744/800
(93%) subjects were dengue IgG seropositive, but only 1% of
participants reported a history of dengue. The present authors are
unaware of virological or genetic factors that might disassociate
infection history from the incidence of symptomatic disease; likely
explanations include a lack of health-seeking for patients with
apparent infection, lack of recognition of the disease, or
misdiagnosis of dengue.1,4 For these reasons, and because dengue
surveillance reports are collected from only sentinel sites,3 it must
be assumed that dengue burdens reported in the routine
surveillance system represent only a fraction of symptomatic
episodes.
In the current study, serotype-specific analyses identified
historical circulation of all four dengue virus serotypes at each
site, with DENV-1 present in a high proportion of samples in New
Delhi and DENV-3 in Kalyani. These serological findings in children
are worrying: co-circulation of multiple serotypes is a population
risk factor for severe dengue because it allows for sequential
infection, and because secondary infection is a risk factor for severe
disease.20,21
Multivariate risk factor analysis suggested relationships be-
tween water availability/storage practices and dengue infection
risk, an association with biological plausibility due to the aquatic
larval and pupal stages of the vector life-cycle. However, these
results should be interpreted with caution because they were
mainly driven by data from Kalyani and are thus highly susceptible
to confounding with site-specific socio-demographic covariates, or
other factors. After excluding Kalyani data from the multivariate
analysis, only participant age remained significantly associated
with dengue positivity. Furthermore, the determination coefficient
(R2) of the model was lower than 0.1, confirming the limited
predictive value of these variables for dengue serostatus, in
agreement with inconclusive/variable socio-economic drivers of
dengue serostatus identified in other studies. In Chennai, univari-
ate logistic regression showed a negative association with
household income and no associations with other household
factors.10 Thai et al. (2005) found associations with littering in and
around the home and the types of sanitary facilities in an initial
univariate analysis, but these associations were not confirmed on
multivariate analysis.15 A community-based study of potential risk
factors for dengue transmission in Venezuela found several
household and socio-economic factors, including storing water
and used tyres (univariate analysis), and crowding, household size,
and living in a shack (multivariate analysis), to be associated with
an increased risk of dengue infection.22
The seroprevalence of anti JE IgG antibodies was also measured
in the participants in the present study. JE is endemic in some
regions in India, particularly in the south and north-east;23
however, during the current study period, none of the study sites
were considered to be within a JE endemic area and none were in
an area subject to routine JE vaccination. The observed seropreva-
lence of JE in the current study (13.6%; 95% CI 12.3–15.0%) confirms
circulation of the virus, but is lower than that reported in a number
of other studies on JE seroprevalence in endemic countries,14,24,25
perhaps because these sites are located within less-endemic areas
of India.
Cross-reaction between anti-flavivirus IgG antibodies has been
documented26 and cannot be excluded here from affecting the
observed JEV or dengue IgG rates. The PRNT is a more specific assay
and may be used to distinguish between cross-reactive and
pathogen-specific responses. Encouragingly, 99% of dengue IgG-
positive samples in the current study were also dengue PRNT-
positive. However, the lack of JEV PRNT data and dengue PRNT in
dengue-negative samples remains a limitation in conclusively
addressing this risk.
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Figure 3. Proportion of participants with PRNT50 results showing monotypic profiles, according to dominant serotype, by site and overall.
Table 2




JE IgG n 2591 1525 1033
Positive 345 327 18
Negative 1794 801 990
JE, Japanese encephalitis; n, number of participants with results corresponding to
the specified category.
a 33/2591 total samples had no results available for dengue IgG; 47 were
inconclusive and 405 were missing for JE IgG.
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Other limitations include the use of different dengue-specific
IgG ELISAs at different sites, but the sensitivity test showing 100%
concordance was reassuring. In this study, a convenience sample
was selected, including some low-income settings, to provide
geographical spread across India. However, sites were not
randomly selected, subjects were consecutively recruited, and
these data cannot be considered nationally or locally representa-
tive. As with other epidemiological studies, recall bias (during the
questionnaire) and selection bias (e.g., self-selection of healthy
subjects) cannot be excluded. Despite these sampling limitations,
these data provide a first multi-centre view on dengue seropreva-
lence in India. The use of a single protocol and consistent methods
between the sites strengthens the validity of the data.
In conclusion, high levels of dengue exposure were observed in
Indian children, and age-stratified data describe transmission
intensity at these locations. This information may inform dengue
burden estimates and populate transmission models to assess the
potential impact of prevention and control measures, including
vaccination programmes.
Author contributions
SG, AC, and GF designed the study. SG, RS, NRRM, RCG, GRJ, EG,
NS, MMS, and SO refined the study design, performed the study,
and collected demographic and clinical data from study subjects, in
the field. AC performed laboratory assays for dengue and JE virus in
accordance with good laboratory practice. JN and AM analysed the
data. JN provided an initial interpretation and worked to develop a
manuscript outline. All authors interpreted the data with
refinements and contributed to writing the manuscript. All authors
critically reviewed the manuscript while in preparation and
approved the final draft.
Acknowledgements
This study was sponsored by Sanofi Pasteur. The authors wish
to thank the following investigators for their contributions to the
conduct of the study: Suman Kumar, Gandhari Basu, Chitra
Chatterjee, Ganesh Oruganti, Sathish Chandra MR, and Malatesh
Undi. The authors also thank Shelke Pallavi who was involved in
the conduct of the study and Claire Dakowski for statistical advice
(Sanofi Pasteur), and Jo-Ann West for editorial assistance and
manuscript coordination on behalf of Sanofi Pasteur. Editorial
assistance with the preparation of the manuscript was provided by
professional medical writers, Simon Lancaster and Juliette Gray of
inScience Communications, Springer Healthcare, funded by Sanofi
Pasteur. The wider DNG10 authorship group included Suman
Kumar, Gandhari Basu, Chitra Chatterjee, Ganesh Oruganti, and
Shelke Pallavi.
Conflict of interest: JN, AM, and SO are employees of Sanofi
Pasteur. AC, EG, MMS, RM, and RS have no conflicts of interest to
declare.
References
1. World Health Organization. Global strategy for dengue prevention and control:
2012-2020. Geneva: WHO; 2012 , Available at: http://www.who.int/
denguecontrol/9789241504034/en/ (accessed July 7, 2016)
2. Chakravarti A, Arora R, Luxemburger C. Fifty years of dengue in India. Trans R Soc
Trop Med Hyg 2012;106:273–82.
3. Shepard DS, Halasa YA, Tyagi BK, Adhish SV, Nandan D, Karthiga KS, et al.
Economic and disease burden of dengue illness in India. Am J Trop Med Hyg
2014;91:1235–42.
4. Bhatt S, W Gething P, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The
global distribution and burden of dengue. Nature 2013;496:504–7.
5. National Vector Borne Disease Control Programme. Dengue cases and deaths in
the country since 2010. India: National Vector Borne Disease Control Pro-
gramme, Ministry of Health and Family Welfare; 2014 , Available at: http://
nvbdcp.gov.in/den-cd.html (accessed May 27, 2016)
6. Farrington CP, Kanaan MN, Gay NJ. Estimation of the basic reproduction number
for infectious diseases from age-stratified serological survey data. J R Stat Soc Ser
C Appl Stat 2001;50:251–92.
7. Ferguson NM, Donnelly CA, Anderson RM. Transmission dynamics and epide-
miology of dengue: insights from age-stratified sero-prevalence surveys. Philos
Trans R Soc Lond B Biol Sci 1999;354:757–68.
8. International Epidemiological Association. Good epidemiological practice. Lon-
don, UK: International Epidemiological Association; 2007, Available at: http://
ieaweb.org/good-epidemiological-practice-gep/ (accessed May 27, 2016)
9. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for
dengue virus neutralizing antibodies. J Immunol 1967;99:285–90.
10. Rodriguez-Barraquer I, Solomon SS, Kuganantham P, Srikrishnan AK, Vasude-
van CK, Iqbal SH, et al. The hidden burden of dengue and chikungunya in
Chennai, India. PLoS Negl Trop Dis 2015;9:e0003906.
11. Oruganti G, Dinaker M, Tez KS, Kattula SR, Rajesh JG, Yeldandi VV, et al. High
sero-prevalence of dengue IgG antibodies among healthy individuals in Andhra
Pradesh, India. Indian J Public Health Res Dev 2014;5:131–5.
12. Graham RR, Juffrie M, Tan R, Hayes CG, Laksono I, Ma’roef C, et al. A prospective
seroepidemiologic study on dengue in children four to nine years of age in
Yogyakarta, Indonesia I. Studies in 1995-1996. Am J Trop Med Hyg 1999;61:
412–9.
13. Rodriguez-Barraquer I, Buathong R, Iamsirithaworn S, Nisalak A, Lessler J,
Jarman RG, et al. Revisiting Rayong: shifting seroprofiles of dengue in Thailand
and their implications for transmission and control. Am J Epidemiol 2014;179:
353–60.
14. Jeewandara C, Gomes L, Paranavitane SA, Tantirimudalige M, Panapitiya SS,
Jayewardene A, et al. Change in dengue and Japanese encephalitis seropreva-
lence rates in Sri Lanka. PLoS One 2015;10:e0144799.
15. Thai KT, Binh TQ, Giao PT, Phuong HL, Hung le Q, Van Nam N, et al. Seropreva-
lence of dengue antibodies, annual incidence and risk factors among children in
southern Vietnam. Trop Med Int Health 2005;10:379–86.
16. Amaya-Larios IY, Martinez-Vega RA, Mayer SV, Galeana-Hernandez M, Comas-
Garcia A, Sepulveda-Salinas KJ, et al. Seroprevalence of neutralizing antibodies
against dengue virus in two localities in the state of Morelos, Mexico. Am J Trop
Med Hyg 2014;91:1057–65.
17. Balmaseda A, Hammond SN, Tellez Y, Imhoff L, Rodriguez Y, Saborı́o SI, et al.
High seroprevalence of antibodies against dengue virus in a prospective study
of schoolchildren in Managua, Nicaragua. Trop Med Int Health 2006;11:935–42.
18. Arima Y, Chiew M, Matsui T. Epidemiological update on the dengue situation in
the Western Pacific Region, 2012. Western Pac Surveill Response J 2015;6:82–9.
19. National Dengue Control Unit. Sri Lankan Situation. Sri Lanka: National Dengue
Control Unit, Ministry of Health; 2014 , Available at: http://www.dengue.
health.gov.lk/index.php/information-on-dengue/sri-lankan-situation
(accessed July 22, 2016)
20. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S,
et al. Dengue viremia titer, antibody response pattern, and virus serotype
correlate with disease severity. J Infect Dis 2000;181:2–9.
21. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue
infections in Bangkok. Am J Trop Med Hyg 1988;38:172–80.
22. Velasco-Salas ZI, Sierra GM, Guzman DM, Zambrano J, Vivas D, Comach G, et al.
Dengue seroprevalence and risk factors for past and recent viral transmission in
Venezuela: a comprehensive community-based study. Am J Trop Med Hyg
2014;91:1039–48.
23. Tiwari S, Singh RK, Tiwari R, Dhole TN. Japanese encephalitis: a review of the
Indian perspective. Braz J Infect Dis 2012;16:564–73.
24. Conlan JV, Vongxay K, Khamlome B, Jarman RG, Gibbons RV, Fenwick SG, et al.
Patterns of flavivirus seroprevalence in the human population of Northern Laos.
Am J Trop Med Hyg 2015;93:1010–3.
25. Chatterjee S, Chattopadhyay D, Bhattacharya MK, Mukherjee B. Serosurveil-
lance for Japanese encephalitis in children in several districts of West Bengal,
India. Acta Paediatr 2004;93:390–3.
26. Centers for Disease Control and Prevention. Laboratory guidance and diagnostic
testing. Atlanta, GA: CDC; 2010 , Available at: http://www.cdc.gov/dengue/
clinicalLab/laboratory.html (accessed January 20, 2016)
S. Garg et al. / International Journal of Infectious Diseases 54 (2017) 25–3030
RESEARCH ARTICLE
Dengue seroprevalence and force of primary
infection in a representative population of
urban dwelling Indonesian children
Ari Prayitno1☯, Anne-Frieda Taurel2☯*, Joshua Nealon2, Hindra Irawan Satari1, Mulya
Rahma Karyanti1, Rini Sekartini1, Soedjatmiko Soedjatmiko1, Hartono Gunardi1, Bernie
Endyarni Medise1, R. Tedjo Sasmono3, James Mark Simmerman2, Alain Bouckenooghe4,
Sri Rezeki Hadinegoro1
1 Department of Child Health, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, 2 Epidemiology
and Health Economics & Outcomes Research, Sanofi Pasteur Asia & JPAC Region, Singapore, 3 Eijkman
Institute for Molecular Biology, Jakarta, Indonesia, 4 Medical Affairs & Clinical Sciences Department, Sanofi
Pasteur Asia and JPAC Region, Singapore




Indonesia reports the second highest dengue disease burden in the world; these data are
from passive surveillance reports and are likely to be significant underestimates. Age-strati-
fied seroprevalence data are relatively unbiased indicators of past exposure and allow
understanding of transmission dynamics.
Methodology/Principal Findings
To better understand dengue infection history and associated risk factors in Indonesia, a
representative population-based cross-sectional dengue seroprevalence study was con-
ducted in 1–18-year-old urban children. From October to November 2014, 3,210 children
were enrolled from 30 geographically dispersed clusters. Serum samples were tested for
anti-dengue IgG antibodies by indirect ELISA. A questionnaire investigated associations
between dengue serologic status and household socio-demographic and behavioural fac-
tors. Overall, 3,194 samples were tested, giving an adjusted national seroprevalence in
this urban population of 69.4% [95% CI: 64.4–74.3] (33.8% [95% CI: 26.4–41.2] in the
1–4-year-olds, 65.4% [95% CI: 69.1–71.7] in the 5–9-year-olds, 83.1% [95% CI: 77.1–
89.0] in the 10–14-year-olds, and 89.0% [95% CI: 83.9–94.1] in the 15–18-year–olds).
The median age of seroconversion estimated through a linear model was 4.8 years. Using
a catalytic model and considering a constant force of infection we estimated 13.1% of chil-
dren experience a primary infection per year. Through a hierarchical logistic multivariate
model, the subject’s age group (1–4 vs 5–9 OR = 4.25; 1–4 vs. 10–14 OR = 12.60; and
1–4 vs 15–18 OR = 21.87; p<0.0001) and the number of cases diagnosed in the house-
hold since the subject was born (p = 0.0004) remained associated with dengue serological
status.
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Conclusions/Significance
This is the first dengue seroprevalence study in Indonesia that is targeting a representative
sample of the urban paediatric population. This study revealed that more than 80% of chil-
dren aged 10 years or over have experienced dengue infection at least once. Prospective
incidence studies would likely reveal dengue burdens far in excess of reported incidence
rates.
Author summary
Indonesia reported to the WHO the world’s second highest average number of dengue
cases and the highest in Asia from 2004 to 2010. These passive surveillance reports vary
widely within the country and are likely to be a severe under-estimation of the full disease
burden as frequently only dengue haemorrhagic fever is captured. Understanding the
intensity of dengue virus transmission and associated risk factors nationwide is necessary
to guide and prioritize appropriate prevention and control measures against dengue dis-
ease, especially considering the availability of the first dengue vaccine and recent recom-
mendations for its use in areas of high endemicity, as measured by seroprevalence and
other indicators. Age-stratified seroprevalence data provide robust estimates of past expo-
sure and can inform on transmission intensity. Therefore, we conducted a seroprevalence
study of anti-dengue IgG antibodies in a representative sample of urban-dwelling Indone-
sian children. We found an overall dengue seroprevalence of 69.4% with half of the chil-
dren having been infected at least once by the age of 5 years. Age of the subject and the
number of dengue cases diagnosed in the household were associated with serostatus.
These results confirm the high dengue disease burden in Indonesia and the urgency of
implementation of effective prevention and control measures.
Introduction
Dengue is an arbovirus transmitted to humans via the bites of infected Aedes mosquitoes. It
is the most rapidly spreading mosquito-borne viral disease with a global incidence that has
increased 30-fold over the last 50 years [1]. While reliable burden estimates remain elusive,
two studies have estimated the global symptomatic disease burden to be 96 million and 58.4
million cases/year, with 70–80% of cases occurring in the Asia-Pacific region [2, 3]. Tradition-
ally an urban disease, dengue disease is increasingly reported in rural areas and its geographic
range has expanded to more than 125 tropical countries [1]. There is no specific antiviral treat-
ment; clinical management is focused on careful fluid management and detection of early
warning signs of severe disease. Historically, prevention measures have focused on vector con-
trol, education and behavioural changes to reduce interactions between humans and vector
mosquitoes [4, 5]. Improved clinical management and public awareness have contributed to
declining case fatality rates to below 1% in most countries [1]. While this represents important
progress, overall dengue incidence continues to rise and fatalities remain unacceptably high,
suggesting that traditional control approaches are not sufficient. Vector control measures are
important yet operationally challenging, of variable effectiveness and costly to sustain [6]. Rou-
tine vaccination is becoming a reality: several dengue vaccines are at different stages of clinical
development [7] and a chimeric tetravalent vaccine from Sanofi Pasteur is being licensed in an
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increasing number of countries in Latin America and Asia [7, 8]. In this new era of dengue as
a vaccine-preventable disease, an accurate understanding of disease burden and transmission
patterns will be essential to inform vaccine policy decisions.
Dengue is hyper-endemic with frequent epidemic cycles in Indonesia. The disease is most
common in urban areas and in recent years has reportedly spread to smaller, more rural vil-
lages. Reported incidence remains highest in children 1–15 years of age, but since the 1980s
incidence in persons over 15 years of age has gradually increased [9, 10]. Reporting of dengue
haemorrhagic fever (DHF) is mandatory in Indonesia and the country typically reports the
highest number of cases in the WHO Southeast Asia Region [1]. Between 2001 and 2011, there
was an average of 94,564 reported cases and between 472 and 1,446 reported deaths per year
[1, 11]. Dengue disease reporting is acknowledged by Indonesian experts to be incomplete
and to vary widely between provinces, with reported incidence rates ranging from 2.2 to 168.5
cases per 100,000 inhabitants in 2013 [12].
An improved understanding of dengue epidemiology, burden and its dynamic characteris-
tics are important for public health planning. Seroprevalence studies in healthy volunteers pro-
vide information on infection history in the population, from which inferences about disease
burden may be drawn. Since age reflects duration of exposure, age-stratified data provide
insights into transmission dynamics [13–17]. There is a lack of dengue seroepidemiological
data from Indonesia and no previous study has used a population representative sample of
urban Indonesian children [18–20]. This is a particularly important gap as it will provide infor-
mation on whether the variations in reported incidence from different Indonesian provinces
are reflective of underlying transmission dynamics or to the result of the reporting or surveil-
lance practices employed. We conducted a seroprevalence study in urban-dwelling Indonesian
children to improve understanding of dengue epidemiology and infection risk factors and
inform future dengue vaccine policy decisions.
Methods
The present study is reported according to STrengthening the Reporting of OBservational
studies in Epidemiology (STROBE) recommendations (supporting information file).
Ethic statement
The protocol was reviewed and ethical approval was obtained from the Health Research Ethics
Committee of Faculty of Medicine of University of Indonesia.
Study area
Indonesia is the largest country in Southeast Asia, with an area of 1.91 million km2. The
country has a population of 252.2 million living on five main islands and four archipelagos
(>17,000 islands) administratively divided into 34 provinces [21]. In 2014/2015, approxi-
mately 60% of Indonesians were living on the island of Java and 53.3% lived in urban areas
[21, 22]. Indonesia is divided into five administrative levels: provinces (n = 34), regencies
(n = 416), cities (n = 98), subdistricts (n = 7,024), and villages (n = 81,626). Villages are consid-
ered either as rural (desa) or urban (kelurahan) based on population density, percentage of
agricultural household and number of urban facilities such as schools and hospitals [21, 23].
Sampling design
A population-based cross-sectional study design was adapted from the World Health Organi-
zation (WHO) Expanded Program on Immunization (EPI) cluster survey method. This
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approach considers 30 clusters as an adequate number for their means to be normally distrib-
uted, thus permitting statistical theory based on the normal distribution to be used to analyse
the data [24, 25]. Based on the probability proportional to population size, 30 urban subdis-
tricts were selected using demographic data from 2009 or 2010, provided by the Sub-Director-
ate of Statistical Services and Promotion, Statistics Indonesia.
The geographical coordinates of Indonesian administrative units were retrieved from the
Global Rural-Urban Mapping Project, maintained by the Socioeconomic Data and Applications
Center [26]. Provinces were listed based on their mean geographical coordinates from West to
East (Fig 1) and the cumulative urban population of their subdistricts was calculated using
2010 population data. To ensure the population of clusters was sufficient to enrol the desired
sample, a minimum population of 1,000 persons per subdistrict was defined and any smaller
subdistricts were removed from the list. The first cluster was selected by generating a random
number between 1 and 1/30th of the total urban population, using Epi Info Version 7, and
selecting the first subdistrict for which the cumulative population was superior or equal to this
random number. Subsequent clusters were selected by adding 1/30th of the urban population
to the random number and selecting the first corresponding subdistrict for which cumulative
population was higher or equal so that:
Clusteri cumulative population  random number þ i  1=30 of urban population
The 30 subdistricts selected by this method are listed in Appendix 1. Each subdistrict in
Indonesia contains one main health centre (puskesmas kecamatan) whose catchment area
was the site of the study. Households in the five neighbourhood associations located closest to
the health centre (each comprising 30–50 households, giving a total of 150–250 households)
were eligible to participate in the study. Household visits were conducted, inviting one child
from each household to participate, until the sample size was reached. A table indicating the
required number of children from each of four age groups was provided to the health centre
study teams. If a household had only one eligible child, the child was invited. When a house-
hold had several eligible children, a child in the age group with the fewest children already
Fig 1. Map of Indonesia showing the ranking of provinces from West to East and study sites’ geographic distribution. Provinces with at least
one site are coloured in grey. Developed with QGIS 1.8.0 using data from Global Rural-Urban Mapping Project18.
https://doi.org/10.1371/journal.pntd.0005621.g001
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participating was selected. Towards the end of the survey, survey teams were allocated a spe-
cific number of subjects in each age group to recruit to avoid over-sampling. If the parents
refused the participation of the selected child, the household was not included. This process
was continued until the desired sample size was achieved in each of the 30 clusters.
Sample size
The sample size was calculated using EpiInfo Version 7 to estimate seroprevalence in each of
four age groups (1–4, 5–9, 10–14 and 15–18 years old) with 95% confidence, a margin error of
5% and accounting for clustering with a design effect of 2. The expected national seropreva-
lence, based on Indonesian expert opinion and published regional data [14, 19, 27, 28], was
25% in the 1–4-year-old group, 45% in the 5–9-year-old group, 55% in the 10–14-year-old
group and 65% in the 15–18-year-old group. To account for incomplete data, a 10% contin-
gency was applied. The total sample size was 3,210 children, 660 from the 1–4-year-old group
(22 per cluster), 870 from the 5–9-year-old group (29 per cluster), 870 from the 10–14-year-
old group (29 per cluster) and 810 from the 15–18-year-old group (27 per cluster). In total, 107
children were enrolled in each cluster.
Enrolment
The study was presented to families during monthly neighbourhood association meetings.
After household visits, eligible subjects were invited to the healthcare centre for enrolment and
blood sampling if they were healthy, 1–18 years of age on inclusion day, and had lived in the
location for at least 1 year. An informed consent form was signed by a parent or legal guardian,
and by the subject if aged 13–18 years. Subjects aged 8–12 years provided signed assent.
A questionnaire was administered to collect information on demographics, knowledge
of dengue symptoms and transmission, vector control practice, and medical history in the
household.
Blood sampling and laboratory analysis
For each subject, 2mL of venous blood was drawn into plain vacutainer tubes. After centrifuga-
tion, serum aliquots were frozen at -20˚C before refrigerated transport by courier to a central
laboratory for analysis. Each specimen was tested for dengue IgG antibodies by ELISA using
the commercial Panbio Dengue IgG Indirect ELISA kit (sensitivity = 96.3%; specificity = 91.4–
100% according to manufacturer’s instructions; Panbio, Alere, Australia) [29]. Samples were
considered positive for previous dengue infection according to the standard protocols of the
manufacturer (Panbio units <9 is negative; 9–11 is equivocal; and>11 is positive).
Data analysis and statistics
All analyses were run using SAS 9.4.
Dengue antibody seroprevalence and associations between serologic status and socio-
demographic and behavioural factors. The statistical unit was the individual subject.
Seroprevalence and the 95% confidence interval (95% CI) were calculated taking account of
the cluster effect. Univariate logistic regression was used to identify variables significantly asso-
ciated with serologic status. As the data structure was hierarchical with subjects included in
clusters, hierarchical logistic regression models were used to consider subject intra-cluster cor-
relation. The clusters account for the random effect and the covariates were taken as fixed
effects. As these analyses were considered exploratory, a level of significance (p-value) of
<0.15 was applied at univariate level.
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The multivariate hierarchical model was reduced by applying a backward descending selec-
tion of the non-significant variables at p-value >0.05.





ij ¼ b  Parameter þ m  cluster þ ε
Where P Y ¼ 1
0
  
ij was the probability for a j subject from a i cluster to be seropositive, the βs
were the fixed effect describing the subject variables associated with socio-demographic and
behavioural factors, μ the cluster random effect and ε the error term.
Median age of conversion. The median age of seroconversion was estimated by fitting a
weighted linear regression model to age-specific seroprevalence data. Seroprevalence data
were transformed into probits and age values were log transformed to fit the model [30, 31].
However, goodness of fit parameters were not respected. Therefore, a simple linear regression
was used.
Force of infection. Catalytic models use seroprevalence data as cumulative markers of
past infections that result in life-long immunity from which force of primary infection esti-
mates can be derived. [32, 33], Two force of infection models were developed to describe the
rate of infection over the last 18 years and to examine its variability over time. The first model
assumed a constant force of infection (model 1) and the second one assumed a force of infec-
tion that varied with age (model 2) [13].
The probability of a person living in the area being infected in one year, the force of infec-
tion, is estimated by [34]:
  p ¼ 1   e  m
Where μ is the mean number of infections per year.
The variable force of infection model can be estimated by allowing a separate risk of infec-
tion for each age group, were pi is the mean number of infections per year for the ith age group
and A is the age midpoint of the ith age group [34]. By fitting a binomial model with a comple-
mentary log-log link function and by using X = log(A) as an offset term, α = log(μ) can be esti-
mated as an intercept parameter [34]. The probability of being infected for the ith group at
midpoint age A is pi = 1- exp(-μi Ai), so that:
Logð  logð1   piÞÞ ¼ logðmiÞ þ logðAiÞ
Results
Site selection and baseline demographics
From a total of 6,299 Indonesian subdistricts, 2,823 with urban population were identified,
2,756 of which had an urban population >1,000 and were thus used for sampling. A map of
the 30 selected clusters is presented in Fig 1. From 30 October 2014 to 27 November 2014, a
total of 3,210 subjects were enrolled in the study; 39 subjects (1.2%) were excluded due to at
least one criteria of eligibility not being fulfilled and four subjects (0.1%) due to missing or
incomplete data (demographic or serologic status result). A total of 3,194 subjects (98.7%)
were included in the analyses (Fig 2); there were 107 subjects per site with the exception of
four sites with 106 subjects, three sites with 105 subjects and one site with 101 subjects.
There were 672 subjects in the 1–4-year-old age group, 861 subjects in the 5–9-year-old age
group, 886 in the 10–14-year-old age group and 775 in the 15–18-year-old age group. Among
them, 47.8% were male and the mean age was 9.7 years.
Dengue seroprevalence and force of infection in Indonesian children
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005621 June 15, 2017 6 / 16
Dengue antibody seroprevalence and association between serologic
status and socio-demographic and behavioural factors
The age-specific seroprevalence ranged from 26.4% (95% CI: 15.8–37.1) in those aged 1-year-
old to 95.3% (95% CI: 89.8–100) in the 18-year-old subjects (Fig 3). The median age at sero-
conversion was 4.8 years. The overall nationwide seroprevalence was 69.4%, with a minimum
of 34.6% and a maximum of 87.9% observed per site, and the seroprevalence per age group
was 33.8% in the 1–4year-old group, 65.4% in the 5–9-year-old group, 83.1% in the 10–
14-year-old group and 89.0% in the 15–18-year-old group (Table 1).
In the final data set, the level of non-response (“no data”) varied from 0.4 to 14.0%
(Table 1). Subjects were familiar with dengue disease, with 92% having heard about dengue
and 91.4% able to cite at least one symptom. Control practices reported included use of repel-
lent cream or mosquito spray (43.8%), elimination of mosquito breeding sites by covering
water containers (59.0%) and eliminating stagnant water around the home (85.1%). Most sub-
jects (75.3%) reported they had never been diagnosed with dengue.
Fig 2. Study flow chart.
https://doi.org/10.1371/journal.pntd.0005621.g002
Fig 3. Mean age-specific dengue antibody seroprevalence distribution and 95% confidence interval.
https://doi.org/10.1371/journal.pntd.0005621.g003
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Table 1. Description of subject demographics and knowledge of dengue symptoms and transmission, vector control practice, and medical history










Overall urban seroprevalence 3,194 69.4 [64.4–74.3]
Subject demographics
Gender 100%
Male 1527 (47.8%) 67.4 [62.4–72.5] Ref. 0.018
Female 1667 (52.2%) 71.1 [65.9–76.3] 1.21 [1.03;1.41]
Age 100%
1–4 672 (21.0%) 33.8 [26.4–41.2] Ref. <0.0001
5–9 861 (27.0%) 65.4 [59.1–71.7] 4.40 [3.50;5.52]
10–14 886 (27.7%) 83.1 [77.1–89.0] 12.95
[10.0;16.79]




Temporary/unplanned or slum 291 (9.1%) 62.2 [50.1;74.3] Ref.
Multi-floored building 277 (8.7%) 68.6 [59.0;78.0] 1.16 [0.79;1.71]
Single-story attached building 1780 (55.7%) 69.0 [63.3;74.7] 1.25 [0.94;1.67]
Single-story detached house 769 (24.1%) 72.4 [67.6;77.3] 1.47 [1.07;2.02]
No data 77 (2.4%) 77.9 [69.5;86.3] 1.93 [1.04;3.59]
Living in the house since birth 98.3% 0.547
Yes 2790 (87.3%) 69.7 [64.6;74.8] Ref.
No 351 (11.0%) 66.1 [58.4;73.7] 1.04 [0.81;1.35]
No data 53 (1.7%) 75.5 [67.3;83.6] 1.47 [0.74;2.95]
Average monthly household income 99.0% 0.320
<200000 910 (28.5%) 68.4 [63.0;76.7] Ref.
200,000–400,000 241 (7.5%) 68.0 [60.8;75.3] 0.86 [0.71;1.03]
>400,000 2011 (63.0%) 69.9 [64.0;75.8] 1 [0.74;1.36]
No data 32 (1%) 75 [65.8;84.2] 1.37 [0.60;3.16]
Parents/guardian highest education level 99.4% <0.0001
University 366 (11.5%) 60.4 [53.8;67.0] Ref.
Never went to formal school 92 (2.9%) 85.9 [79.0;92.8] 3.62 [1.87;7.00]
Finished elementary school 628 (19.7%) 72.8 [64.8;80.7] 1.77 [1.30;2.40]
Finished junior high school 707 (22.1%) 72.0 [65.8;78.2] 1.50 [1.12;2.00]
Finished senior high school 1383 (43.3%) 67.7 [63.1;72.4] 1.18 [0.91;1.52]
No data 18 (0.6%) 72.2 [56.8;87.6] 1.55 [0.52;4.60]
How many persons live in the household 99.6% <0.0001
1–3 491 (15.4%) 61.1 [54.4;67.8] Ref.
4–5 1803 (56.4%) 71.2 [66.4;76.1] 1.66 [1.33;2.07]
>5 886 (27.7%) 70.2 [63.1;77.3] 1.52 [1.18;1.95]
No data 14 (0.4%) 71.4 [50.4;72.4] 1.56 [0.47;5.19]
Dengue knowledge, exposure and control
Heard about dengue before the study 99.4% 0.168
No 236 (7.4%) 64.8 [52.0;77.6] Ref.
Yes 2940 (92.0%) 69.8 [65.0;74.5] 1.34 [0.99;1.82]
No data 18 (0.6%) 66.7 [47.0;86.3] 1.29 [0.45;3.72]
Knowledge of dengue illness symptoms* 91.7% 0.145
(Continued )
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No symptoms known 9 (0.3%) 55.6 [11.5;99.6] Ref.
At least one symptoms 2919 (91.4%) 69.8 [65.1;74.5] 1.94 [0.47;7.97]
No data 266 (8.3%) 65.4 [53.8;77.1] 1.50 [0.36;6.29]
How is dengue virus spreading among human 91.1% 0.444
Mosquito bite 2573 (80.6%) 70.0 [65.6;74.4] Ref.
Other 336 (10.5%) 66.7 [57.1;76.3] 0.96 [0.72;1.28]
No data 285 (8.9%) 67.0 [55.8;78.2] 0.83 [0.63;1.10]
When do mosquito bite 86.0% 0.380
During the day 2603 (81.5%) 69.5 [65.1;73.3] Ref.
At night 145 (4.5%) 73.8 [62.1;85.5] 1.14 [0.76;1.69]
No data 446 (14.0%) 67.3 [56.7;77.8] 0.87 [0.69;1.10]
Use insecticide spray to kill mosquitoes 98.1% 0.903
No 2037 (63.8%) 68.6 [62.7;74.5] Ref.
Yes 110 (3.4%) 75.4 [57.3;93.6] 1.09 [0.67;1.78]
Yes, all year long 733 (22.9%) 71.5 [67.3;75.6] 1.03 [0.84;1.27]
Yes, during epidemics 254 (7.9%) 67.3 [60.2;74.4] 0.88 [0.65;1.20]
No data 60 (1.9%) 68.3 [57.8;78.4] 0.92 [0.52;1.65]
Use mosquito mat/coil/liquid vaporizer 97.8% 0.905
No 1385 (43.4%) 70.5 [64.8;76.2] Ref.
Yes 123 (3.8%) 71.5 [54.4;88.7] 1.04 [0.66;1.62]
Yes, all year long 1210 (37.9%) 69.1 [64.2;74.0] 1.00 [0.83;1.21]
Yes, during epidemics 406 (12.7%) 66.0 [58.2;73.8] 1.08 [0.83;1.40]
No data 70 (2.2%) 67.1 [56.4;77.9] 0.81 [0.47;1.40]
Sleep under insecticidal bed net 97.2% 0.555
No 2890 (90.5%) 70.1 [65.3;74.8] Ref.
Yes 23 (0.7%) 78.3 [60.0;96.6] 1.21 [0.42;3.44]
Yes, all year long 179 (5.6%) 61.4 [49.1;73.8] 0.88 [0.62;1.24]
Yes, during epidemics 13 (0.4%) 46.1 [10.5;81.8] 0.57 [1.18;1.81]
No data 89 (2.8%) 65.2 [55.9;74.4] 0.74 [0.46;1.19]
Sleep under untreated bed net 97.0% 0.102
No 2563 (80.2%) 70.7 [66.2;75.3] Ref.
Yes 43 (1.3%) 72.1 [57.2;86.9] 0.92 [0.46;1.86]
Yes, all year long 454 (14.2%) 63.4 [52.2;74.7] 0.75 [0.59;0.95]
Yes, during epidemics 39 (1.2%) 48.7 [32.9;64.5] 0.58 [0.30;1.13]
No data 95 (3.0%) 69.5 [58.5;80.4] 0.86 [0.55;1.44]
Use air conditioner at home 97.0% 0.168
No 2854 (89.3%) 69.8 [64.6;75.0] Ref.
Yes 20 (0.6%) 65.0 [36.6;93.4] 0.61 [0.23;1.62]
Yes, all year long 208 (6.5%) 64.9 [55.1;74.7] 0.70 [0.51;0.96]
Yes, during epidemics 16 (0.5%) 62.5 [38.8.86.2] 0.71 [0.25;2.05]
No data 96 (3.0%) 68.7 [60.0;77.4] 0.82 [0.31;1.31]
Use mosquito repellent cream or spray 97.5% 0.259
No 1714 (53.7%) 65.8 [59.7;71.9] Ref.
Yes 118 (3.7%) 72.0 [54.7;89.4] 0.90 [0.57;1.44]
Yes, all year long 940 (29.4% 74.6 [70.2;78.9] 1.20 [0.98;1.47]
Yes, during epidemics 341 (10.7%) 72.1 [66.2;78.0] 1.25 [0.95;1.66]
(Continued )
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Age and gender were associated with dengue serological status, with seroprevalences
increasing with age (p<0.0001) and values of 71.1% (95% CI: 65.9–76.3) in females versus
67.4% (95% CI: 62.4–72.5) in males (p = 0.018) (Table 1). After univariate analysis, the type of
household (p = 0.08), the level of education of the parents/guardians (p<0.0001), the number
of persons living in the household (p<0.0001), knowledge about dengue symptoms (p = 0.14),
sleeping under an untreated bed net (p = 0.10), the number of dengue cases identified since
the subject was born (p<0.0001), and a previous clinical diagnosis of dengue for the subject
(p<0.0001) were also associated with dengue serological status. In the multivariate model
(Table 2), two variables remained associated with the dengue serologic status, the subject
age group (1–4 vs 5–9 OR = 4.25; 1–4 vs. 10–14 OR = 12.60; and 1–4 vs 15–18 OR = 21.87;












No data 81 (2.5%) 69.1 [58.3;79.9] 1.01 [0.60;1.69]
Wear long clothing to protect from insect bite 97.2% 0.791
No 2283 (71.5%) 69.3 [64.1;74.4] Ref.
Yes 112 (3.5%) 73.2 [55.5;91.0] 0.89 [0.56;1.43]
Yes, all year long 521 (16.3%) 71.8 [64.2;79.4] 1.05 [0.83;1.33]
Yes, during epidemics 187 (5.8%) 62.0 [51.9;72.1] 0.84 [0.59;1.19]
No data 91 (2.8%) 69.2 [60.6;77.8] 0.91 [0.56;1.47]
Water container in the household 99.3% 0.204
No 605 (18.9%) 72.1 [67.3;76.8] Ref.
Yes not covered 682 (21.3%) 67.7 [61.8;73.7] 0.94 [0.72;1.23]
Yes tightly covered 1884 (59.0%) 69.3 [62.4;76.2] 0.94 [0.75;1.17]
No data 23 (0.7%) 52.2 [34.9;69.4] 0.38 [0.16;0.92]
Check and eliminate stagnant water in the property 97.3% 0.306
No 388 (12.1%) 72.4 [67.9;76.9] Ref.
Yes 329 (10.3%) 77.2 [65.7;88.7] 1.18 [0.81;1.73]
Yes, all year long 2204 (69.0%) 68.4 [63.0;73.8] 0.86 [0.66;1.12]
Yes, during epidemics 185 (5.8%) 64.9 [48.5;81.3] 0.87 [0.58;1.30]
No data 88 (2.7%) 60.2 [54.2;66.2] 0.96 [0.55;1.67]
Dengue disease history
Number of dengue cases in the household since the
subject is born
93.7% <0.0001
No case 1500 (47.0%) 63.5 [56.2;70.7] Ref.
One case 288 (9.0%) 83.7 [78.7;88.7] 2.54 [1.80;3.60]
>1 case 66 (2.1%) 87.9 [78.3;97.5] 3.83 [1.77;8.24]
Don’t know 1140 (35.7%) 71.3 [66.2;76.4] 1.16 [0.93;1.46]
No data 200 (6.3%) 76 [62.0;90.0] 1.27 [0.80;2.02]
Has a doctor ever diagnosed the subject with dengue 92.9% <0.0001
No 2406 (75.3%) 66.7 [61.4;72.1] Ref.
Yes 335 (10.5%) 81.5 [74.6;88.4] 2.27 [1.67;3.10]
Don’t know 227 (7.1%) 69.2 [57.7;80.7] 1.05 [0.76;1.44]
No data 226 (7.1%) 79.6 [70.0;89.3] 1.47 [0.95;2.28]
*Dengue symptoms: bleeding, fever, headache, muscular pain, nausea and rash
https://doi.org/10.1371/journal.pntd.0005621.t001
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Force of infection
The constant force of infection model was valid and estimated a force of primary infection of
13.1% per year in dengue-naïve children. As a result of the goodness of fit statistic being close
to 0.05, a model of varying force of infection (age groups of one year) was run to examine the
homogeneity of the force of primary infection estimates per age group. As suggested by the
first model, there was no clear trend in changes in force of infection with age; the estimates
were overlapping, ranging from 10.2% to 18.5% per year. The highest force of primary infec-
tion was observed in the 1-year-old age group (Table 3).
Table 2. Result of the multivariate hierarchical logistic model of variables associated with dengue seropositive status.
Variable N Odd ratio [95% CI] P-value
Age group <0.0001
1–4 672 (21.0%) Ref.
5–9 861 (27.0%) 4.25 [3.39;5.37]
10–14 886 (27.7%) 12.60 [9.72;16.35]
15–18 775 (24.3%) 21.87 [16.16;29.59]
Number of dengue cases in the household since the subject is born 0.0004
No 1500 (47.0%) Ref.
One 288 (9.0%) 2.05 [1.39;3.01]
>1 66 (2.1%) 2.96 [1.29;6.79]
Don’t know 1140 (35.7%) 1.06 [0.82;1.38]
No data 200 (6.3%) 0.81 [0.48;1.36]
https://doi.org/10.1371/journal.pntd.0005621.t002
Table 3. Dengue virus force of infection time varying and constant risk model.
Model Estimated force of infection (%) [95% CI] P- value Goodness of fit statistics
Model 1 1–18 13.1 12.5–13.6 <0.0001 >0.05**
Model 2 1 18.5 13.2–24.8 <0.0001 1.00***
2 13.1 9.9–16.7 <0.0001
3 10.2 8.0–12.7 <0.0001
4 12.5 10.1–15.3 <0.0001
5 11.7 9.5–14.3 <0.0001
6 13.9 11.6–16.5 <0.0001
7 14.8 12.4–17.5 <0.0001
8 11.5 9.5–13.7 <0.0001
9 15.9 13.3–18.8 <0.0001
10 13.6 11.5–16.0 <0.0001
11 12.6 10.5–14.9 <0.0001
12 14.4 12.0–17.2 <0.0001
13 12.9 10.7–15.3 <0.0001
14 13.7 11.5–16.1 <0.0001
15 12.5 10.8–14.5 <0.0001
16 13.4 11.4–15.5 <0.0001
17 11.1 9.4–13.0 <0.0001
18 15.2 10.9–21.3 <0.0001
** Pearson (0.063) and Deviance tests (0.068)
*** Hosmer and Lemeshow test
https://doi.org/10.1371/journal.pntd.0005621.t003
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Discussion
This is the first dengue antibody seroprevalence study conducted in a representative popula-
tion of urban dwelling Indonesian children. The findings benefit from a cluster sampling
design with probability proportional to size method, and sensitive and specific dengue diag-
nostic assays performed in the same laboratory.
This study found that 69.4% of children had been previously infected with dengue virus,
more than 80% of children aged 10 years or over, indicating that the disease burden is
extremely high. A seroprevalence study conducted in 1995 in healthy children in Yogyakarta,
Indonesia, using the plaque reduction neutralization test to determine previous exposure,
reported the presence of neutralizing antibodies in 56.2% of 4–9-year-old children, ranging
from 37.2% in 4-year-old subjects to 69.7% in those 9 years of age. These are slightly lower
than the rates observed in our study (Fig 3 and Table 1) and may be reflective of increasing
dengue endemicity in the intervening decades, or geographic variability [19]. Our results also
show higher levels of dengue virus exposure than those reported in other dengue endemic
countries such as Sri Lanka (Colombo, 2008, 52.0% in those<12 years of age, and median age
of seroconversion of 4.7 years) [13, 35], and Vietnam (Binh Thuan, 2003, 65.7% in 7–13 year
olds) [14]. This elevated dengue exposure risk was also observed during a 2011 dengue vaccine
trial in 5 Asian countries, where baseline dengue seroprevalence was highest in Indonesian
children [36].
Our constant force of infection model estimated a 13.1% annual rate of primary infection
among 1–18-year-old children, while the variable model estimated a force of infection that var-
ied from 10.2% to 18.5%. These estimates are similar to those reported in Sri Lanka in 2008
(14.1% in those aged<12 years) and Southern Vietnam in 2003 (11.7% in 7–13-year-old
children) [13, 14]. Despite these similarities between Vietnam and Indonesia in terms of trans-
mission dynamics, the reported incidence of disease in Vietnam is more than twice that in
Indonesia. [37]. A number of hypotheses could explain this difference in findings: most likely,
it is reflective of Indonesia’s specific case definition for reported dengue disease (only DHF is
reported), but underlying virological, genetic or epidemiological differences could play a role.
From the constant force of primary infection model, it can be assumed that the average rate of
primary infection was not highly variable over the past 18 years. Additional analysis may be
needed to better understand infection risk over time. The recently observed increase in age dis-
tribution of reported cases may have been driven by more variable virologic, demographic,
reporting or other determinants of disease [10]. A similar phenomenon was illustrated by a
study conducted in Thailand showing that the upward shift in dengue case age was associated
with demographic changes [38].
It can be assumed that dengue awareness, through social mobilization and education cam-
paigns, begun in the 1970s, and the increasing public health importance associated with high
media coverage, has steadily increased [39]. Knowledge of dengue transmission and symptoms
was high within the study subjects; 92% of households had heard about dengue before our
study and were able to cite at least one of the disease symptoms, and more than 80% knew that
dengue virus is transmitted by diurnal mosquito bites. In term of exposure, household prac-
tices were focused on destroying mosquito breeding sites rather than personal protection. The
level of exposure to the virus, however, is strong evidence that these reported behaviours are
inadequate to protect against infection and additional prevention and control measures are
urgently required.
In the multivariate model, only subject age group and the number of dengue cases that
occurred in the household were associated with seropositive status. Some of the parameters
significantly associated with dengue seropositivity in univariate models were also implicated in
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other dengue studies conducted in Latin America and Asia. For example, parental level of edu-
cation and dengue illness history in the household have been associated with dengue seroposi-
tivity [17]. Other parameters, such as household size, exhibit an association inverse to that
previously reported in the literature [40]. This is most likely explained by confounding effects
from known risk factors such as age or unknown, socio-demographic drivers of exposure risk.
The lack of significant associations between socio-demographic and behavioural factors with
serological status provides evidence that essentially everyone is at risk of infection; that knowl-
edge of prevention and control at the individual/household level is not protective against infec-
tion; and that additional measures to prevent transmission are required. The retrospective
nature of our questionnaire limits the robustness of our results; recall bias may have been an
issue.
A recent expansion in dengue virus transmission from urban to peri-urban and rural areas
has been described [15] and the identification of provinces or areas of high transmission risk is
a focus of prevention and control planning. This study showed a high level of exposure across
urban Indonesia and, while we excluded rural areas from this study for operational reasons, it
is likely that nearby peri-urban populations may have experienced similar high levels of expo-
sure [40]. Another possible limitation is that cross-reaction between flaviviruses has been
documented and the risk of false positives cannot be excluded. We consider this risk as low,
because reports of other viruses such as Japanese encephalitis and Zika, in Indonesia, are rare.
This study was not designed to make national-level infection or disease burden estimates but
the observation that 13.1% of children suffer a primary infection per year translates into many
millions of infections per year. Adults are presumably infected with a similar frequency. A pro-
portion of these infections will be secondary, predisposing to symptomatic and severe disease.
While a modelling approach would be required to quantify this burden, these data are strongly
suggestive that dengue infections result in a significant burden of symptomatic and severe dis-
ease in urban Indonesia.
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Dengue is a febrile illness transmitted by mosquitoes, causing disease across the tropical
and sub-tropical world. Antibody prevalence data and serotype distributions describe popu-
lation-level risk and inform public health decision-making.
Methodology/Principal findings
In this cross-sectional study we used data from a pediatric dengue seroprevalence study to
describe historical dengue serotype circulation, according to age and geographic location. A
sub-sample of 780 dengue IgG-positive sera, collected from 30 sites across urban Indone-
sia in 2014, were tested by the plaque reduction neutralization test (PRNT) to measure the
prevalence and concentration of serotype-specific neutralizing antibodies according to sub-
ject age and geography. PRNT results were obtained from 776 subjects with mean age of
9.6 years. 765 (98.6%) neutralized one or more dengue serotype at a threshold of >10 (1/
dil). Multitypic profiles were observed in 50.9% of the samples; a proportion which increased
to 63.1% in subjects aged 15–18 years. Amongst monotypic samples, the highest proportion
was reactive against DENV-2, followed by DENV-1, and DENV-3, with some variation
across the country. DENV-4 was the least common serotype. The highest anti-dengue anti-
body titers were recorded against DENV-2, and increased with age to a geometric mean of
516.5 [1/dil] in the oldest age group.
Conclusions/Significance
We found that all four dengue serotypes have been widely circulating in most of urban Indo-
nesia, and more than half of children had already been exposed to >1 dengue serotype,
demonstrating intense transmission often associated with more severe clinical episodes.
These data will help inform policymakers and highlight the importance of dengue surveil-
lance, prevention and control.
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Author summary
Dengue is a febrile illness transmitted by mosquitoes, causing disease across the tropical
and sub-tropical world. Antibody prevalence data and serotype distribution describe
population-level risk and inform public health decision-making. We present data from a
dengue seroprevalence study in children in Indonesia; circulation of the four dengue sero-
types (DENV-1, -2, -3, -4) was assessed, by age and location. Samples collected from 30
urban Indonesian sites were tested using the plaque reduction neutralization test (PRNT),
which enabled us to measure prevalence and concentration of antibodies specific to den-
gue virus serotypes. Results were obtained from 776 subjects (mean age: 9.6 years). 765
(98.6%) neutralized1 dengue serotype; the highest proportion was reactive against
DENV-2, followed by DENV-1, and DENV-3, with some variation across the country.
Reaction to multiple serotypes was observed in 50.9% of samples. The highest anti-dengue
antibody titers were recorded against DENV-2, and increased with age. The fact that all
four dengue serotypes have been widely circulating in urban Indonesia, and more than
half of children had been exposed to>1 dengue serotype, shows intense transmission,
often associated with more severe clinical episodes. These data will help inform policy-
makers and highlight the importance of dengue surveillance, prevention and control.
Introduction
Dengue is a febrile illness caused by dengue virus (DENV) infection. The clinical manifesta-
tions of dengue occur on a spectrum, ranging from asymptomatic or a mild flu-like syndrome
known as classic dengue fever (DF), to a more severe form known as dengue hemorrhagic
fever (DHF) and the potentially fatal dengue shock syndrome (DSS) [1]. DENV, which belongs
to the family Flaviviridae, is transmitted by mosquitoes of the genus Aedes; predominantly
Aedes aegypti. There are four evolutionarily distinct, antigenically related DENV serotypes;
DENV-1, -2, -3, and -4 causing disease across the tropical and sub-tropical world [2, 3].
Neutralizing antibodies (NAbs) against the four serotypes are considered a critical compo-
nent of the protective immune response which is achieved when adequate, specific antibody
titers circulate [4]. Accordingly, plaque reduction neutralization tests (PRNT), which quantify
serum concentrations required to neutralize live viruses, are the most specific assays for
detecting flavivirus exposure history [5]. The dengue PRNT is able to target individual viral
serotypes, and therefore can infer serotype-exposure history, however, interpretation of het-
erotypic responses is complicated for reasons including original antigenic sin [6, 7].
Indonesia is the largest archipelago country in the world with over 17,000 islands, inhabited
by around 240 million people. Dengue was first reported in 1968, and has been expanding ever
since, in both incidence and geography, with an annual burden of>750,000 cases [8]. The
disease is likely hyperendemic across most islands [9, 10]. Reporting of DHF in Indonesia is
mandatory within 72 hours of diagnosis, health centers and public/private hospitals use the
World Health Organization’s (WHO) 1997 case definitions [11] and only DHF/DSS cases are
reported. Laboratory confirmation of dengue is rare, especially in health services with limited
facilities although dengue IgG/IgM and NS1 rapid tests are increasingly used in hospitals and
health clinics. Indonesia does not conduct nationally-representative dengue serotype surveil-
lance. Genotypic and serological surveillance has been undertaken by some Indonesian institu-
tions, on a project basis which confirmed the dengue serotypes in symptomatic individuals
[12–14]. Those studies include in Makassar, South Sulawesi from 2007–2010, where dengue
infection was confirmed in>100 patients, many of whom were aged 11–20 years old.
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Serotyping revealed that DENV-1 was the most common form (41%) followed by DENV-2
(31%), DENV-3 (20%), and DENV-4 (7%) [15]. In Surabaya, East Java, in 2012, dengue RNA
was isolated from 79 of 148 suspected dengue patients (53%), with DENV-1 as the predomi-
nant serotype (73%), followed by DENV-2 (8%), DENV-4 (8%), and DENV-3 (6%), while 5%
were found to have mixed serotypes [16]. In Semarang, Central Java in 2012, 66 of 120 sus-
pected cases (55%) were serologically confirmed and viral RNA was detected in 31 samples
[12]. DENV-1 was the predominant serotype, followed by DENV-2, DENV-3, and DENV-4.
DENV-1 predominance has also been reported from other studies and cities in Indonesia,
including Surabaya [17] and Makassar [15]. Finally, from urban and rural areas of Bali (Den-
pasar and Gianyar), in 2015, 205 adult patients with suspected dengue were recruited in a pro-
spective cross-sectional study. Of these, 161 patients had virologically-confirmed dengue;
DENV-3 was predominant (48%), followed by DENV-1 (28%), DENV-2 (17%), and DENV-4
(4%). Five samples (3%) were detected which contained two different serotypes, and it was
noted that the proportions varied in urban and rural areas [18].
Understanding antibody prevalence is an important consideration in the interpretation of
epidemiological data, especially when reviewing interactions with other flaviviruses or consid-
ering vaccine introduction. The co-circulation of multiple dengue serotypes is a population-
level risk factor for severe dengue disease because of the increased likelihood of a second or
subsequent infection, and also due to the fact that sequential infections are associated with
increased severity [19]. Serotype distribution may be predictive of future epidemiology and is
important information for dynamic transmission models. The objective of this study was to
use data from a dengue seroprevalence survey to describe the historical serotype (DENV-1, 2,
3, 4) circulation based on the prevalence of serotype-specific anti-DENV antibodies, according
to age and geographic location, in a pediatric population in Indonesia.
Materials and methods
Study design
In this cross-sectional study, serum samples and data from a national-level pediatric dengue
seroprevalence study were used to describe historical dengue serotype circulation, according
to age and geographic location. Dengue IgG-positive sera, collected from 30 sites across urban
Indonesia, were tested by the PRNT to measure the prevalence and concentration of serotype-
specific dengue neutralizing antibodies according to subject age and geography.
Sample collection and selection
Surveillance and sample collection methods were previously described [20]. Ethical approval
was obtained from the Health Research Ethics Committee of Faculty of Medicine of University
of Indonesia (No. 462/H2.F1/ETIK/2014). Briefly, between 30 October 2014–27 November
2014, blood samples were collected from 3,210 children aged 1–18 years in 30 urban Indone-
sian subdistricts, randomly selected from west to east based on the probability proportional to
population size. The blood samples were to be tested for dengue IgG by enzyme-linked immu-
nosorbent assay (ELISA). A sub-sample of 780 dengue IgG positive sera was used to estimate
the prevalence of serotype-specific neutralizing antibodies by PRNT. The sample size was esti-
mated to provide 95% confidence and a margin error of 5%; this is accounting for the 30 clus-
ters with a design effect of two and assuming the “worst case” of 50% exposure to any one
serotype. The sample was not strictly representative of the dengue IgG positive population as
the samples were selected equally from each of the four age groups, i.e. 195 samples per age
group, and, to provide geographical representativeness, from clusters in proportion to dengue
IgG seroprevalence rates. This method over-sampled from younger subjects to; 1) increase the
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number of samples tested from children recently infected with dengue, to provide a record of
recent dengue circulation; 2) reduce the number of PRNTs performed on samples from older
children, likely to have been infected with many serotypes, which may therefore be impossible
to meaningfully interpret.
Dengue plaque reduction neutralization test (PRNT)
The PRNT method was performed based on optimized and validated PRNT50 assay for the
detection of neutralizing antibodies to four serotypes of DENV [21]. Each serum sample was
heat inactivated at 56˚C and assayed in four separate PRNT runs, which corresponded to four
different DENV serotype challenge viruses. Vero cells (CCL-81) were obtained from American
Type Culture Collection (ATCC). Cells were grown and maintained in Minimum Essential
Medium (MEM) (Gibco-Thermo Fisher Scientific, CA, USA), supplemented with 5% heat-
inactivated Fetal Bovine Serum (FBS), 2 mM of L-glutamine, and 1% of antibiotic/antimycotic
(Gibco-Thermo Fisher Scientific, CA, USA) at 37˚C in an atmosphere of 5% CO2. Working
banks of Vero cells were prepared in-house, qualified, and confirmed to be free of any micro-
bial, mycoplasma, and viral contaminants. Purified mouse monoclonal antibodies (MAbs) spe-
cific to the DENV serotype envelope protein were used as the primary antibodies for virus
detection according to the corresponding serotype: anti-DENV-1 (D2-1F1-3), anti-DENV-2
(3H5-1-12), anti-DENV-3 (8A1-2F12), and anti-DENV-4 (1H10-6-7) (Biotem, Le Rivier
d’Apprieu, France). Alkaline phosphatase-conjugated goat anti-mouse IgG (Jackson Immu-
noresearch Laboratories, West Grove, PA, USA) was used as the secondary antibody. The
parental DENVs of the recombinant CYD vaccine viruses, i.e., DENV-1 strain PUO-359,
DENV-2 strain PUO-218, DENV-3 strain PaH881/88, and DENV-4 strain 1228, were used as
challenge viruses in the PRNT. The initial source, and the suitability of these four DENV sero-
types to be used in dengue neutralization assay have been described elsewhere [21–23]. Den-
gue-antibody positive and negative human serum sample controls were obtained from healthy
adult donors from Indonesia. The serum controls were used in each assay run, and served to
monitor its performance and validity.
The neutralization titer (PRNT50) of the test serum sample was defined as the reciprocal
of the highest test serum dilution for which the virus infectivity was reduced by 50% when
compared with the average plaque count of the challenge virus control, calculated using a
four-point linear regression method. Since the lowest starting dilution of serum in the assay
was 1:5, the theoretical lower limit of quantitation of the assay was a titer of 10 (reciprocal
dilution).
Statistical analysis
This is a descriptive analysis, no hypotheses were tested. The study population mean age was
calculated and geographic distribution described. Dengue serotype specific PRNT profiles
were defined according to the following algorithm; categorizing samples as naïve (no previous
dengue infection), monotypic (infection with one serotype), or multitypic (>1 serotype)[24]:
• Naïve: antibody titers <10 for the four serotypes
• Monotypic: antibody titers >10 (1/dil) to only one serotype or titers 10 for different sero-
types with a high titer (>80 (1/dil)) and for a single predominant serotype (> 5 times higher
than other titers)
• Multitypic: antibody titers10 (1/dil) for different serotypes without a single predominant
titer.
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PRNT profile distribution by age and geography were described. PRNT profile prevalence
and their 95% confidence intervals (95% CI) were calculated, the clusters results were aggre-
gated at province level and a map was generated using QGIS 2.16.2 “Nødebo”.
The mean PRNT titer, GMT (Geometric Mean Titer), and the 95% CI for each age group
and dengue serotype was calculated for all samples based on their DENV PRNT results. To cal-
culate the GMT, samples with an antibody titer T <10 (1/dil) were given the value 5 and the
mean titer was calculated using the equation:








Where dGMT jh is the mean titer for the dengue serotype h of the age group j, Ti is the PRNT
titer of the subjects i and n the number of subjects with a PRNT titer in the age group j for the
serotype h.
All statistical analyses were performed using Excel 2013.
Results
Description of sample set
Blood samples were collected from 3,210 children aged 1–18 years in 30 urban Indonesian sub-
districts, randomly selected from west to east. From a sub-sample of 780 dengue IgG positive
sera, PRNT50 results were obtained from 776 participants, equally sampled from each age
group (1–4, 5–9, 10–14 and 15–18 years old). In the youngest, 1–4 years old group, four serum
samples were of insufficient quantity to be tested. The mean age was 9.6 years old (95% CI
[9.3–10.0]. The 30 clusters were represented with 14–39 samples per cluster. Of these, 765
(98.6%) neutralized one or more dengue serotypes at a threshold of>10 (1/dil), a proportion
which varied by age: 95.3% in the 1–4 years old, 99.5% in the 5–9 years old, 99.5% in the 10–14
years old and 100% in the 15–18 years old.
PRNT profile distribution stratified by age and geographic level
Samples were categorized according to PRNT50 profile. Multitypic profiles were observed in
50.9% of the subjects, with 28.3% in those aged 1–4 years old, 48.2% in the 5–9 years old,
63.6% in the 10–14 years old and 63.1% in those aged 15–18 (Fig 1). The proportion of mono-
typic profiles decreased with increasing age, representing 67.0% of those aged 1–4 years, 51.3%
of the 5–9 year old group, 35.9% of the 10–14 years old group, 36.9% of the 15–18 years old
and 47.7% of the overall sample. There were no naïve subjects in the 15–18 years old group
whereas 4.7% of the 1–4 years old group; 0.5% of the 1–9 and 10–14 years old groups, and
1.4% of the overall sample had no detectable neutralizing dengue antibodies at the 10 (1/dil)
threshold. Amongst monotypic samples, the highest proportion of samples were reactive
against DENV-2, followed by DENV-1, and DENV-3, a trend which was also observed in the
two youngest age groups, while the three serotypes were more evenly distributed amongst the
10–14 and 15–18 years old age groups (Fig 1).
The clusters were aggregated within 14 provinces, resulting in samples per province ranging
from 15 to 183 serum samples. In seven provinces multitypic profiles were the most common
(from 52.2% to 69.4% of samples). In seven provinces the monotypic profile was more preva-
lent (from 49.7% to 68.8%). DENV-4 was dominant in one province, in the 13 other provinces
DENV-1, DENV-2, DENV-3 or a combination of these serotypes were dominant, with
DENV-2 dominance being more common (Fig 2). The four monotypic serotypes were
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Fig 1. Proportion of individuals with naïve, monotypic (for each dengue serotype), or multitypic PRNT profiles, by age group.
https://doi.org/10.1371/journal.pntd.0006616.g001
Fig 2. Map showing the proportion of monotypic dengue antibody profiles against each dengue serotype, by Indonesian province containing at least one study
site (shown in grey).
https://doi.org/10.1371/journal.pntd.0006616.g002
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identified in every province, with the exception of DENV-2 in Nanggroe Aceh Darussalam
and DENV-4 in Sulawesi Tenggara and Sulawesi Selatan.
GMT stratified by age
GMTs increased with age. DENV-2 had the highest GMT overall (406.5 [1/dil]) and for three
of the four age groups with titers of 208.8, 502.2, 497.4 and 516.5 [1/dil], respectively (Fig 3).
DENV-4 had the lowest GMT for each age group (51.2, 98.9, 138.1 and 128.2 [1/dil]) and over-
all (97.6 [1/dil]). In the oldest subjects, titers against DENV-1 were highest (593.08 [1/dil]) fol-
lowed by DENV-3 (550.2 [1/dil]) and DENV-2.
Discussion
We conducted a dengue seroprevalence study which identified serological evidence for the cir-
culation of all four dengue serotypes across urban areas of Indonesia, in children who were
exposed to infection from 1996 to 2013. The proportion of children with exposure to>1 sero-
type increased with age, and children were more likely to have been infected with DENV-2,
DENV-1 and DENV-3 than DENV-4. Nonetheless, these results show that all four serotypes
have been widely circulating in most of Indonesia, as is common in hyper-endemic countries.
This study generated data on serotype-specific prevalence in areas where little or no data were
previously available, with the exception of historical data from Yogyakarta, Java island [32].
Available dengue serotype data collated from 1994 to 2012 (n = 596) [25] and recent publi-
cations from all over Indonesia confirm the concomitant presence of the four DENV serotypes
[10, 12, 15–18, 26–28]. Samples were collected from suspected cases and therefore suffer a
potential selection bias towards serotypes associated with more symptomatic/severe cases. The
Fig 3. Dengue serotype specific GMT by age-group.
https://doi.org/10.1371/journal.pntd.0006616.g003
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serological data we report here indicate a consistent pattern of distribution of serotypes, a find-
ing which may indicate that the cases captured within these surveillance studies is broadly
reflective of the DENV serotype circulation in the country.
PRNT enables the interrogation of samples according to their exposure history. In this
study, it was remarkable to observe that in this pediatric population more than half (50.9%)
had already been exposed to>1 dengue serotype, a proportion which increased with age. This
rate is important because it demonstrates early and intense transmission in Indonesia; and we
know that second infections have been described as more likely to be symptomatic, severe and
hemorrhagic [29]. Individuals of an age likely to have received one natural exposure, but
before their second, may represent an attractive target for dengue vaccination programs [30].
The observed GMT increase with age is most likely explained by continuous re-exposure to
DENVs over time, further boosting antibody levels. These profiles imply that existing vector
control activities in urban areas are largely insufficient at preventing infection; and that invest-
ments in novel methods may be warranted. The prevalence of multitypic profiles further rein-
forces the requirement for development of a safe and effective, quadrivalent dengue vaccine
which could be used in children at highest risk of developing symptomatic and severe disease
episodes. Additionally, these data can be useful for the calibration of dengue transmission
models which may help to understand disease dynamics and the likely effects of dengue con-
trol interventions.
There are several limitations to our study. Sera collected during the convalescent phase rep-
resent infection history in the population, but are limited by the sensitivity and specificity of
the serological methods used to quantify antibodies. We had the benefit of analyzing samples
in this study by PRNT; however interpretation of data can be confused by heterotypic cross-
neutralization between serotypes. For this reason, we did not interpret the serotype distribu-
tions of multitypic infections. Only samples positive for dengue IgG in ELISA screening assay
were selected to undergo PRNT, therefore these may not be fully representative of dengue pos-
itive sera. We also observed discrepancies between IgG ELISA and PRNT data in which some
samples that were positive by IgG ELISA were negative in PRNT (1.4%). This may be a conse-
quence of the well-documented serological cross-reactivity across the flavivirus group [31]
Our sample collection was also limited to urban areas and subjects consenting to the study
which may have introduced additional bias.
In conclusion, this study confirmed the distribution of multiple dengue serotypes across
urban Indonesia. Many children were infected with multiple serotypes, and the accompanying
risk of severe disease, from an early age. DENV-1, DENV-2 and DENV-3 may play a more sig-
nificant epidemiological role than DENV-4. It is hoped that these data influence policymakers
to afford increased attention to dengue surveillance, prevention and control.
Supporting information
S1 Checklist. STROBE checklist.
(DOC)
S1 Table. Description of mean age, sample size and dengue serotype specific prevalence
(naïve, monotypic, or multitypic) per province.
(DOCX)
S2 Table. IgG seroprevalence distribution per cluster and age group and derived PRNT
sample size.
(DOCX)
Dengue serotype distribution in Indonesian pediatric urban population
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006616 June 28, 2018 8 / 11
Acknowledgments
The authors would like to thank Annick Moureau for her support in the data analysis method;
William Cheng, Yuni Astri, Andhika Manggalaputra Moeljadi, Karina Maharani Pramudya
and Arnesya Pramadyani for their role as field investigator; technical help from Febrina Meu-
tiawati is highly appreciated. Editorial assistance with the preparation of the manuscript was
provided by Rebecca Hornby, inScience Communications, Springer Healthcare.
Author Contributions
Conceptualization: R. Tedjo Sasmono, Anne-Frieda Taurel, Alain Bouckenooghe, Sri Rezeki
Hadinegoro, Joshua Nealon.
Data curation: Anne-Frieda Taurel.
Funding acquisition: Anne-Frieda Taurel, Alain Bouckenooghe, Joshua Nealon.
Investigation: R. Tedjo Sasmono, Ari Prayitno, Benediktus Yohan, Rahma F. Hayati, Sri
Rezeki Hadinegoro.
Methodology: R. Tedjo Sasmono, Anne-Frieda Taurel, Joshua Nealon.
Project administration: Anne-Frieda Taurel, Ari Prayitno, Hermin Sitompul, Sri Rezeki
Hadinegoro, Joshua Nealon.
Resources: Anne-Frieda Taurel, Hermin Sitompul, Alain Bouckenooghe, Joshua Nealon.
Software: Anne-Frieda Taurel.
Supervision: R. Tedjo Sasmono, Anne-Frieda Taurel, Sri Rezeki Hadinegoro, Joshua Nealon.
Validation: R. Tedjo Sasmono, Anne-Frieda Taurel, Ari Prayitno, Hermin Sitompul, Benedik-
tus Yohan, Rahma F. Hayati, Alain Bouckenooghe, Sri Rezeki Hadinegoro, Joshua Nealon.
Visualization: Anne-Frieda Taurel, Joshua Nealon.
Writing – original draft: R. Tedjo Sasmono, Anne-Frieda Taurel, Joshua Nealon.
Writing – review & editing: R. Tedjo Sasmono, Anne-Frieda Taurel, Ari Prayitno, Hermin
Sitompul, Benediktus Yohan, Rahma F. Hayati, Alain Bouckenooghe, Sri Rezeki Hadine-
goro, Joshua Nealon.
References
1. World Health Organization. World Health Organization. Comprehensive guidelines for prevention and
control of dengue and dengue haemorrhagic fever. WHO Regional Publication SEARO. 2011.
2. Holmes EC, Twiddy SS. The origin, emergence and evolutionary genetics of dengue virus. Infect Genet
Evol. 2003 May; 3(1):19–28. PMID: 12797969
3. Simmons CP, Farrar JJ, Nguyen v V, Wills B. Dengue. N Engl J Med. 2012 Apr 12; 366(15):1423–32.
https://doi.org/10.1056/NEJMra1110265 PMID: 22494122
4. Pierson TC, Diamond MS. Molecular mechanisms of antibody-mediated neutralisation of flavivirus
infection. Expert Rev Mol Med. 2008 May 12; 10:e12. https://doi.org/10.1017/S1462399408000665
PMID: 18471342
5. Maeda A, Maeda J. Review of diagnostic plaque reduction neutralization tests for flavivirus infection.
Vet J. 2013 Jan; 195(1):33–40. https://doi.org/10.1016/j.tvjl.2012.08.019 PMID: 23036176
6. Roehrig JT, Hombach J, Barrett AD. Guidelines for Plaque-Reduction Neutralization Testing of Human
Antibodies to Dengue Viruses. Viral Immunol. 2008 Jun; 21(2):123–32. https://doi.org/10.1089/vim.
2008.0007 PMID: 18476771
Dengue serotype distribution in Indonesian pediatric urban population
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006616 June 28, 2018 9 / 11
7. van Panhuis WG, Gibbons RV, Endy TP, Rothman AL, Srikiatkhachorn A, Nisalak A, et al. Inferring the
serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing anti-
body titers. J Infect Dis. 2010 Oct 01; 202(7):1002–10. https://doi.org/10.1086/656141 PMID: 20738205
8. Wahyono TYM, Nealon J, Beucher S, Prayitno A, Moureau A, Nawawi S, et al. Indonesian dengue bur-
den estimates: review of evidence by an expert panel. Epidemiol Infect. 2017 Aug; 145(11):2324–9.
https://doi.org/10.1017/S0950268817001030 PMID: 28545598
9. Karyanti MR, Uiterwaal CS, Kusriastuti R, Hadinegoro SR, Rovers MM, Heesterbeek H, et al. The
changing incidence of dengue haemorrhagic fever in Indonesia: a 45-year registry-based analysis.
BMC Infect Dis. 2014 Jul 26; 14:412. https://doi.org/10.1186/1471-2334-14-412 PMID: 25064368
10. Suwandono A, Kosasih H, Nurhayati, Kusriastuti R, Harun S, Ma’roef C, et al. Four dengue virus sero-
types found circulating during an outbreak of dengue fever and dengue haemorrhagic fever in Jakarta,
Indonesia, during 2004. Trans R Soc Trop Med Hyg. 2006 Sep; 100(9):855–62. https://doi.org/10.1016/
j.trstmh.2005.11.010 PMID: 16507313
11. World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control,
second edition. ISBN 92 4 154500 3. World Health Organization, Geneva. 1997.
12. Fahri S, Yohan B, Trimarsanto H, Sayono S, Hadisaputro S, Dharmana E, et al. Molecular surveillance
of dengue in Semarang, Indonesia revealed the circulation of an old genotype of dengue virus serotype-
1. PLoS Negl Trop Dis. 2013; 7(8):e2354. https://doi.org/10.1371/journal.pntd.0002354 PMID:
23951374
13. Porter KR, Beckett CG, Kosasih H, Tan RI, Alisjahbana B, Rudiman PI, et al. Epidemiology of dengue
and dengue hemorrhagic fever in a cohort of adults living in Bandung, West Java, Indonesia. Am J Trop
Med Hyg. 2005 Jan; 72(1):60–6. PMID: 15728868
14. E. Setiati TFPW, Jiri D. de Kruif, Martijn T.A Mairuhu, Albert C.M van Grop, Eric Soemantri, Augustinus.
Changing Epidemiology of Dengue Haemorrhagic Fever in Indonesia. WHO Regional Office for South-
East Asia. http://appswhoint/iris/handle/10665/170263. 2006.
15. Sasmono RT, Wahid I, Trimarsanto H, Yohan B, Wahyuni S, Hertanto M, et al. Genomic analysis and
growth characteristic of dengue viruses from Makassar, Indonesia. Infect Genet Evol. 2015 Jun;
32:165–77. https://doi.org/10.1016/j.meegid.2015.03.006 PMID: 25784569
16. Wardhani P, Aryati A, Yohan B, Trimarsanto H, Setianingsih TY, Puspitasari D, et al. Clinical and viro-
logical characteristics of dengue in Surabaya, Indonesia. PLoS One. 2017; 12(6):e0178443. https://doi.
org/10.1371/journal.pone.0178443 PMID: 28575000
17. Yamanaka A, Mulyatno KC, Susilowati H, Hendrianto E, Ginting AP, Sary DD, et al. Displacement of
the predominant dengue virus from type 2 to type 1 with a subsequent genotype shift from IV to I in
Surabaya, Indonesia 2008–2010. PLoS One. 2011; 6(11):e27322. https://doi.org/10.1371/journal.pone.
0027322 PMID: 22087290
18. Megawati D, Masyeni S, Yohan B, Lestarini A, Hayati RF, Meutiawati F, et al. Dengue in Bali: Clinical
characteristics and genetic diversity of circulating dengue viruses. PLoS Negl Trop Dis. 2017 May; 11
(5):e0005483. https://doi.org/10.1371/journal.pntd.0005483 PMID: 28531223
19. Huy NT, Van Giang T, Thuy DH, Kikuchi M, Hien TT, Zamora J, et al. Factors associated with dengue
shock syndrome: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2013; 7(9):e2412.
https://doi.org/10.1371/journal.pntd.0002412 PMID: 24086778
20. Prayitno A, Taurel AF, Nealon J, Satari HI, Karyanti MR, Sekartini R, et al. Dengue seroprevalence and
force of primary infection in a representative population of urban dwelling Indonesian children. PLoS
Negl Trop Dis. 2017 Jun; 11(6):e0005621. https://doi.org/10.1371/journal.pntd.0005621 PMID:
28617803
21. Timiryasova TM, Bonaparte MI, Luo P, Zedar R, Hu BT, Hildreth SW. Optimization and validation of a
plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of den-
gue virus used in support of dengue vaccine development. Am J Trop Med Hyg. 2013 May; 88(5):962–
70. https://doi.org/10.4269/ajtmh.12-0461 PMID: 23458954
22. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, et al. Recombinant chimeric
yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000
Jun; 74(12):5477–85. PMID: 10823852
23. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, et al. Construction, safety, and
immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J
Virol. 2001 Aug; 75(16):7290–304. https://doi.org/10.1128/JVI.75.16.7290-7304.2001 PMID: 11462001
24. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, et al. Relationship of preexisting
dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort
study of DV infection in Thailand. J Infect Dis. 2004 Mar 15; 189(6):990–1000. https://doi.org/10.1086/
382280 PMID: 14999601
Dengue serotype distribution in Indonesian pediatric urban population
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006616 June 28, 2018 10 / 11
25. Muhadir A. Epidemiology of Dengue in Indonesia. Presented at: Cooperation among first-to-introduce
countries for dengue vaccines meeting Brazilia 2013.
26. Haryanto S, Hayati RF, Yohan B, Sijabat L, Sihite IF, Fahri S, et al. The molecular and clinical features
of dengue during outbreak in Jambi, Indonesia in 2015. Pathog Glob Health. 2016 May; 110(3):119–29.
https://doi.org/10.1080/20477724.2016.1184864 PMID: 27215933
27. Kusmintarsih ES, Hayati RF, Turnip ON, Yohan B, Suryaningsih S, Pratiknyo H, et al. Molecular charac-
terization of dengue viruses isolated from patients in Central Java, Indonesia. J Infect Public Health.
2017 Oct 19. PMID: 29056517
28. Lestari CSW, Yohan B, Yunita A, Meutiawati F, Hayati RF, Trimarsanto H, et al. Phylogenetic and evo-
lutionary analyses of dengue viruses isolated in Jakarta, Indonesia. Virus Genes. 2017 Dec; 53(6):778–
88. https://doi.org/10.1007/s11262-017-1474-7 PMID: 28600724
29. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic
fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement
of infection. Arch Virol. 2013 Jul; 158(7):1445–59. https://doi.org/10.1007/s00705-013-1645-3 PMID:
23471635
30. Flasche S, Jit M, Rodriguez-Barraquer I, Coudeville L, Recker M, Koelle K, et al. The Long-Term Safety,
Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenu-
ated Dengue Vaccine (Dengvaxia): A Model Comparison Study. PLoS Med. 2016 Nov; 13(11):
e1002181. https://doi.org/10.1371/journal.pmed.1002181 PMID: 27898668
31. Muller DA, Depelsenaire AC, Young PR. Clinical and Laboratory Diagnosis of Dengue Virus Infection. J
Infect Dis. 2017 Mar 1; 215(suppl_2):S89–S95. https://doi.org/10.1093/infdis/jiw649 PMID: 28403441
32. Graham RR, Juffrie M, Tan R, Hayes CG, Laksono I, Ma’roef C, et al. A prospective seroepidemiologic
study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996.
Am J Trop Med Hyg. 1999 Sep; 61(3):412–9. PMID: 10497982
Dengue serotype distribution in Indonesian pediatric urban population
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006616 June 28, 2018 11 / 11
Japanese Encephalitis in Asia • JID 2018:XX (XX XXXX) • 1
The Journal of Infectious Diseases
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Circulation in Asian Children From Dengue-Endemic 
Countries
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Background. Japanese encephalitis virus (JEV) is a zoonotic, mosquito-borne flavivirus, distributed across Asia. Infections are 
mostly mild or asymptomatic, but symptoms include neurological disorders, sequelae, and fatalities. Data to inform control strate-
gies are limited due to incomplete case reporting.
Methods. We used JEV serological data from a multicountry Asian dengue vaccine study in children aged 2–14 years to describe 
JEV endemicity, measuring antibodies by plaque reduction neutralization test (PRNT50).
Results. A total 1479 unvaccinated subjects were included. A minimal estimate of pediatric JEV seroprevalence in dengue-naive 
individuals was 8.1% in Indonesia, 5.8% in Malaysia, 10.8% in the Philippines, and 30.7% in Vietnam, translating to annual infection 
risks varying from 0.8% (in Malaysia) to 5.2% (in Vietnam). JEV seroprevalence and annual infection estimates were much higher in 
children with history of dengue infection, indicating cross-neutralization within the JEV PRNT50 assay.
Conclusions. These data confirm JEV transmission across predominantly urban areas and support a greater emphasis on JEV 
case finding, diagnosis, and prevention.
Keywords. epidemiology; flavivirus; encephalitis; Japanese; seroepidemiologic studies.
 
Japanese encephalitis virus (JEV) is a mosquito-borne flavivi-
rus, distributed across endemic or epidemic-prone countries in 
East, Southeast, and South Asia. Extending from North Korea, 
southeastern Russia, Japan, and Northern China to Western 
Pacific islands including the Philippines, Papua New Guinea, 
and the far north of Australia, and west to India and southern 
Pakistan: >3 billion people are at risk of infection [1]. A vari-
ety of vertebrate hosts sustain transmission in zoonotic cycles 
with mosquitoes, predominantly Culex tritaeniorhynchus [2]. 
Humans are infected as incidental, dead-end hosts and may be 
at particular risk when in proximity to pigs and ardeid birds, 
which experience durations and levels of viremia capable of 
infecting vector mosquitoes [2, 3].
After humans are bitten by an infected mosquito, the virus is 
thought to amplify in the cells of the peripheral lymphatic system 
causing a transient and mostly low-grade viremia for ~1 week. 
Although infections are common in endemic areas, most are 
either asymptomatic or resolve after acute undifferentiated fever 
and are unlikely to be diagnosed as Japanese encephalitis [2, 4]. 
Estimates of the proportion of infections that lead to symptom-
atic disease vary widely from 1:25 to 1:1000 [5]. Estimates of the 
proportion of symptomatic disease are higher in studies from 
non-indigenous US servicemen in Asia than indigenous popula-
tions, perhaps a consequence of (1) viral or human genetics, (2) 
level of health, (3) immune status, (4) more sensitive surveillance, 
and (5) increased laboratory confirmation [6–8].
A small proportion of infections proceed to more severe dis-
ease after invasion of the central nervous system, leading to an 
encephalitis; this results in a broad range of neurological dis-
orders including convulsions, prolonged seizures, respiratory 
abnormalities, and spasms [9]. In hospitalized individuals, 
approximately 30% will die, and approximately 50% of survi-
vors will suffer severe residual neurological disease [9, 10].
Although considered rare, Japanese encephalitis cases cause 
significant morbidity and mortality with an estimated 67 900 
incident symptomatic cases per year across affected countries 
[11]. Even severe cases may be unreported to public health 
authorities due to a combination of low level of clinical sus-
picion, infrequent use of laboratory confirmation, and a wide 
spectrum of symptoms [9, 12]. Several licensed vaccines are 
available, and vaccination is recommended both for those living 
in and traveling to endemic areas. Underrecognition of disease 
contributes to undervaccination [1, 13].
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In the absence of reliable incidence data, seroepidemiological 
methods can be used to measure exposure and make inferences 
around endemicity of diseases [2, 14]. Age reflects duration of 
exposure, and because JEV antibodies persist for life, age-strat-
ified data describe the proportion of individuals historically 
infected, from which the infection rate can be calculated [15]. 
A challenge in this approach stems from the specificity of diag-
nostics that have well documented cross-reactivity between 
members of the flavivirus family [16]. Assays detecting immu-
noglobulin G antibodies, raised after recent vaccination or 
recent wild-type infection, are particularly cross-reactive, and 
a positive result cannot be considered specific in areas where 
multiple flaviviruses cocirculate [17, 18]. Cross-reactivity typi-
cally decreases as the immune response evolves from an initial 
more heterotypic to a homotypic response. Neutralizing assays 
including the plaque reduction neutralization test (PRNT), in 
which the dilution of serum required to neutralize live viruses 
is quantified, are more specific and are considered the gold stan-
dard in detecting historical flavivirus exposure [19]. For JEV, 
a PRNT titer ≥1:10 dilution by PRNT50 is considered protec-
tive from infection; a more stringent threshold, PRNT90, may 
be preferred for epidemiological studies of historical exposure, 
reducing the risk of background serum cross-reactivity [20, 21].
CYD14 (ClinicalTrials.gov number NCT01373281) was an 
observer-blinded dengue vaccine study conducted in 2011–
2017 in 10 275 children aged 2–14 years in Indonesia, Malaysia, 
Thailand, the Philippines, and Vietnam [22]. From an immuno-
logical study subset, JEV seroprevalence was ascertained by PRNT 
at the study start before any vaccines were administered. Sites were 
urban, selected based on their high dengue incidence rates, and 
most were not considered areas of high JEV endemicity, although 
some (eg, Bali, Indonesia) have recorded JEV cases and outbreaks 
in the past [11]. At the time of the study, Japanese encephalitis vac-
cine was not in routine use at most study sites [23].
In this study, we used the age-stratified serological data to 
describe JEV endemicity, and we estimated the force of infec-
tion (FOI) at the sites where this clinical trial was conducted. 
To account for cross-reactive, anti-flavivirus neutralizing anti-
bodies, we stratified by dengue virus (DENV) serological sta-
tus thereby providing minimal estimates of JEV infection in 
individuals who had never experienced a dengue infection; and 




This was a secondary analysis using records from a vaccine clin-
ical trial, CYD14. The original clinical trial that generated the 
data (ClinicalTrials.gov number NCT01373281) underwent eth-
ics committee approval of the protocol, amendments, consent, 
and assent forms and was funded by Sanofi Pasteur [22].
Study Sample Set and Data
CYD14 was an observer-masked, randomized, controlled, mul-
ticenter, phase 3 dengue vaccine trial conducted in children 
aged 2–14 years old in 5 countries in the Asia-Pacific (3 sites 
in Indonesia [Bandung, Jakarta, and Bali]; 2 sites in Peninsular 
Malaysia [Kuala Lumpur and Penang]; 2 sites in the Philippines 
[San Pablo City and Cebu]; 2 sites in Thailand [Ratchaburi and 
Kamphaeng Phet]; and 2 sites in Southern Vietnam [My Tho 
and Long Xuyen]) and has been described previously [22]. 
Parents or legal guardians provided informed consent before 
participation, and written assent was obtained from older 
children, in compliance with the regulations of each country. 
Subjects received either 3 doses of a recombinant, live, atten-
uated, tetravalent dengue vaccine or placebo at months 0, 6, 
and 12.
In an immunological subset of approximately 20% of par-
ticipants, serum was collected at baseline (before injection at 
month 0). Baseline concentrations of neutralizing antibody 
against JEV and DENV were measured by PRNT at the Centre 
for Vaccine Development (Mahidol Univeristy, Thailand) (for 
JEV) and at Sanofi Pasteur’s Global Clinical Immunology labo-
ratory (Swiftwater, PA) (for DENV) using the method described 
by Timiryasova [24]. For DENV, challenge viruses were for 
DENV-1 strain PUO-359, DENV-2 strain PUO-218, DENV-3 
strain PaH881/88, and DENV-4 strain 1228. Neutralizing anti-
body titers were expressed as the reciprocal serum dilution (1/
dil) achieving 50% reduction in plaque count and a lower limit 
of quantification of ≥10, as calculated by probit analysis [25]. 
After an observation that JEV seroprevalence varied accord-
ing to DENV serostatus, neutralizing JEV titers achieving 90% 
plaque reduction (PRNT90) were subsequently calculated from 
the same laboratory data to explore the impact of increasing 
specificity of the assay by decreasing the background serum 
cross-reactivity from other flaviviruses [21].
Individuals with a history of JEV or another flavivirus vac-
cination before blood sampling were removed from the anal-
ysis to ensure that serological status was a consequence of 
natural infection. Subjects from Thailand were excluded 
because Japanese encephalitis vaccination had been practiced 
nationwide for several years before the study and >95% of chil-
dren were vaccinated, leaving a sample too small for meaningful 
analysis (n = 15).
Japanese Encephalitis Virus Seroprevalence
Japanese encephalitis virus seroprevalence, defined as the pro-
portion of subjects with a JEV-neutralizing antibody concen-
tration of ≥10 (1/dil), was calculated according to PRNT50 and 
PRNT90, overall, and by age for each country. To control for the 
influence of cross-reactive DENV antibodies and generate a 
minimal estimate of true JEV-positive samples, JEV seropreva-
lence by PRNT50 was calculated separately for DENV seroposi-
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Force of Infection
Catalytic models use seroprevalence data as cumulative 
markers of past infections that result in lifelong antibod-
ies, from which force of primary infection estimates can be 
derived [26, 27]. An FOI model was developed to describe 
the rate of JEV infection over the period of time covered by 
the subjects’ age. The model assumed a constant FOI that 
does not vary with age whereby the probability of an indi-
vidual being infected in 1 year is estimated by the following 
[28, 29]:




Where pi is the probability for the i
th group of Ai years old of 
being positive and μ is the proportion of individuals infected 
per year, FOI. Using a maximum likelihood regression method, 
fitting a binomial model with a complementary log-log link 
function and using X = log(A) as an offset term, the intercept 
parameter α = log (µ) was estimated as follows:
  Log log 1 p log log A( ( ))− − = ( ) + ( )i iµ
The exponential of α provided an estimate of the FOI, μ. 
Model fit was assessed using the Pearson and deviance test 
for goodness-of-fit statistics with a significance level of 
P < .05.
The proportion of individuals seropositive per age group, pi 
was subsequently estimated with the following:
  pi e eAi e Ai= − = −− −1 1µ
α( )
We considered that JEV serostatus in the DENV-naive popu-
lation could not have been affected by cross-reactive flavivirus 
antibodies and therefore treated the resulting FOI estimate as a 
minimal estimate of annual infection risk.
All data were analyzed anonymously. Analyses were con-
ducted using SAS 9.4, and figures were developed using 
Microsoft Excel 2013 and STATA, version 15.
RESULTS
Sample Set Description
We conducted an epidemiological reanalysis of clinical trial data to 
document historical JEV exposure in 1479 children from 4 Asian 
countries, as shown in the study flow chart (Figure 1). The database 
included 239 subjects from Vietnam, 295 subjects from Malaysia, 
345 subjects from Indonesia, and 600 subjects from the Philippines 
(Table 1). The mean age in each country was 8.24 in Indonesia, 8.25 
in Malaysia, 8.18 in Philippines, and 7.55 in Vietnam.
Japanese Encephalitis Virus Seroprevalence and Rate of Infection
By PRNT50, overall JEV seroprevalence was 46.1% in 
Indonesia, 22.4% in Malaysia, 45.7% in the Philippines, and 
47.5% in Vietnam. Seroprevalence increased with age, reach-
ing >70% in the 13- to 14-year-old children in Indonesia, 
the Philippines, and Vietnam and 40% in Malaysia (Table 1). 
When stratified by DENV serostatus, JEV seroprevalence 
was 54.4% in Indonesia, 41.0% in Malaysia, 55.3% in the 
Philippines, and 59.4% in Vietnam in DENV seropositive 
individuals and 8.1% in Indonesia, 5.8% in Malaysia, 10.8% in 
the Philippines, and 30.7% in Vietnam in DENV seronegative 
individuals. By JEV PRNT90, seroprevalence was considera-
bly lower: 1.7% in Indonesia, 2.4% in Malaysia, 3.7% in the 
Philippines, and 11.3% in Vietnam. FOI  estimates revealed 
an annual infection rate within DENV-positive subjects of 
9.1% (95% confidence interval [CI], 7.7–10.7) in Indonesia, 
5.4% (95% CI, 4.1–6.9) in Malaysia, 9.3% (95% CI, 8.2–10.6) 
in the Philippines, and 11.1% (95% CI, 8.8–13.8) in Vietnam. 
In DENV seronegative subjects, FOI was considerably lower: 
Subjects tested for JEV at 
CYD14 baseline  (N=1992)
Subject included in the 
reanalysis  (N=1,479)
Subjects from Thailand, (n=338), 
history of JEV vaccination or 












PRNT90 (n=9), or socio-
demographic data (n=1)
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1.4% (95% CI, 0.5–3.0) in Indonesia, 0.8% (95% CI, 0.4–1.4) 
in Malaysia, 1.8% (95% CI, 1.0–2.9) in the Philippines, and 
5.2% (95% CI, 3.6–2.3) in Vietnam. The goodness-of-fit sta-
tistics were respected for all models (Pearson test, P  >  .05; 
deviance test, P > .05), except for the DENV-positive popula-
tion in Vietnam (Figure 2).
DISCUSSION
This study documented serological evidence of JEV circula-
tion in urban and periurban areas of Indonesia, Malaysia, the 
Philippines, and Vietnam, countries with differing epidemi-
ology and JEV risk. Our study assessed historical exposure 
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Figure 2. Force of infection-derived Japanese encephalitis age-specific seroprevalence estimates by country in dengue virus (DENV)-positive (DENV+) and DENV-negative 
(DENV−) subjects. *, Pearson and deviance test P < .05 for the DENV+ population in Vietnam. Abbreviations: CI, confidence interval; JEV, Japanese encephalitis virus.
Table 1. Number of Subjects Included by Age (N) and Japanese Encephalitis Seroprevalence by PRNT50 (%) According to DENV Serostatus
Indonesia Malaysia Philippines Vietnam
Dengue Status Positive Negative Positive Negative Positive Negative Positive Negative
Age N % N % N % N % N % N % N % N %
2 13 23% 11 9% 1 0% 21 0% 21 19% 18 22% 3 100% 7 14%
3 19 37% 10 0% 9 11% 12 0% 33 30% 24 8% 9 56% 11 46%
4 18 56% 13 8% 12 42% 12 0% 33 30% 20 10% 14 43% 8 38%
5 27 33% 6 0% 6 50% 25 8% 35 40% 17 6% 13 15% 22 9%
6 14 21% 2 0% 8 75% 10 0% 41 51% 14 7% 12 33% 10 30%
7 21 52% 2 50% 4 0% 9 11% 29 52% 6 0% 8 75% 4 25%
8 14 43% 3 0% 9 22% 10 10% 20 55% 5 20% 11 72% 8 38%
9 14 36% 3 0% 9 44% 9 11% 31 61% 4 25% 9 67% 6 50%
10 23 52% 3 0% 8 25% 4 0% 21 67% 1 0% 13 54% 7 43%
11 13 69% 2 50% 11 36% 8 0% 29 45% - - 12 75% 4 25%
12 51 75% 6 17% 30 57% 20 5% 58 64% 12 0% 28 71% 13 39%
13 34 74% 1 0% 24 42% 14 14% 68 75% 8 25% 6 100% 1 100%
14 22 73% - - 8 38% 2 50% 51 80% 1 0% - - - -
Total 283 54% 62 8% 139 41% 156 6% 470 55% 130 11% 138 59% 101 31%
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However, the World Health Organization’s vaccine-preventable 
disease monitoring system reports an annual average for these 
countries over recent years varying from 35.2 cases (Malaysia) 
to 310.6 cases (Vietnam) [30]. Even after correcting for a low 
proportion of symptomatic infections, the levels of pediatric 
infection documented here imply a significant level of under-
reporting of symptomatic cases. Measures to improve disease 
awareness and increase use of confirmatory diagnostics and 
surveillance enhancements may be justified in response.
Seroprevalence, a function of exposure, increased with age. 
Therefore, these age-stratified data allowed estimation of FOI, 
and, to our knowledge, this is the first time this has been done in 
a multicountry JEV study. JEV seroprevalence varied according 
to DENV status, which is likely a consequence of cross-reac-
tive antibodies raised after DENV infections. Indeed, these sites 
were selected for their high levels of dengue endemicity, with 
annual attack rates of symptomatic dengue of 2%–11% per year 
[31]. Therefore, we estimated JEV FOI for individuals with no 
previous DENV exposure, resulting in minimal JEV exposure 
estimates, which provide strong evidence for JEV circulation 
within these study populations. By this measure, between 0.8% 
and 5.2% of children were estimated to be naturally infected by 
JEV annually, findings that may be considered high in areas that 
do not include JEV vaccination in their national immunization 
programs. The estimated JEV FOI in DENV-exposed indi-
viduals was considerably higher, and the true infection rate is 
likely somewhere in between. Although direct comparisons of 
JEV FOI are unavailable, historically, Japanese encephalitis has 
been a pediatric disease in endemic areas with seroprevalence 
increasing to 100% in adults [2].
For Vietnam, the goodness-of-fit statistics for the constant 
FOI risk model was statistically significant (P < .05), indicating 
that the assumption of constant risk of infection was not cor-
rect. This may be due to differential exposure at different ages or 
epidemic prone rather than endemic epidemiology. Vietnam is 
the country with highest infection risk, a finding aligned with 
the current knowledge of risk and epidemiology [32].
It is well known that flavivirus genera share epitopes that 
induce cross-reactive antibodies, which leads to difficulty in 
differentially diagnosing flaviviral infections [16, 17]. More 
recent or secondary infections generate broader, heterotypic, 
cross-reactive responses, and—because these sites were chosen 
due to their high level of DENV endemicity—we considered 
that anti-DENV antibodies would be more likely to cross-react 
with JEV virus in the PRNT than the reverse [16]. However, it 
is important to remember that cross-reactivity or neutralization 
does not mean cross-protection, and interactions between fla-
vivirus antibodies are complex and poorly understood [17, 33]. 
Our additional observation that JEV seroprevalence by PRNT50 
in DENV-naive children was higher than corresponding 
rates derived from JEV PRNT90 implies that PRNT90 is overly 
specific, excluding true-positive samples, for epidemiological 
studies such as this.
We assumed that the association between JEV and DENV 
serostatus was a product of cross-reactive antibodies, but 
this could also be caused by confounding by similar expo-
sure risk to JEV and DENV. Japanese encephalitis virus 
and DENV are transmitted by different vector mosquitos, 
but behavioral or ecological risk factors such as increased 
outdoor exposure time or use of mosquito protective tools 
may predispose to risk of both [6, 34]. Well defined behav-
ioral or ecological risk factors for these infections are poorly 
understood or lacking, and results of studies conducted 
across different geographies and time periods are seldom in 
agreement. In addition, although JEV infection in DENV-
naive individuals provides confirmation of JEV circulation 
in a population with a low risk of flavivirus cross-reactivity, 
this may represent a specific population with less exposure to 
mosquito vectors, a selection bias that would underestimate 
true JEV transmission risk.
Limitations of this study include that subjects were not 
selected using a randomized or representative method and that, 
in the absence of virological confirmation of historical infec-
tions, it remains impossible to quantify the relative contribution 
of cross-reactivity in the PRNT assays. Interpretations cannot 
be generalized nationwide, and local experts and policymakers 
will need to decide the broader relevance of these findings for 
their countries.
CONCLUSIONS
We report a clear demonstration of JEV infection risk and 
human transmission in regions of 4 countries. These regions 
were previously considered of low JEV risk and have no JEV 
vaccination programs in place.
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Dengue is associated with significant economic expenditure and it is estimated that the Asia
Pacific region accounts for >50% of the global cost. Indonesia has one of the world’s highest
dengue burdens; Aedes aegypti and Aedes albopictus are the primary and secondary vec-
tors. In the absence of local data on disease cost, this study estimated the annual economic
burden during 2015 of both hospitalized and ambulatory dengue cases in Indonesia.
Methods
Total 2015 dengue costs were calculated using both prospective and retrospective methods
using data from public and private hospitals and health centres in three provinces: Yogya-
karta, Bali and Jakarta. Direct costs were extracted from billing systems and claims; a
patient survey captured indirect and out-of-pocket costs at discharge and 2 weeks later.
Adjustments across sites based on similar clinical practices and healthcare landscapes
were performed to fill gaps in cost estimates. The national burden of dengue was extrapo-
lated from provincial data using data from the three sites and applying an empirically-derived
epidemiological expansion factor.
Results
Total direct and indirect costs per dengue case assessed at Yogyakarta, Bali and Jakarta
were US$791, US$1,241 and US$1,250, respectively. Total 2015 economic burden of den-
gue in Indonesia was estimated at US$381.15 million which comprised US$355.2 million for
hospitalized and US$26.2 million for ambulatory care cases.
Conclusion
Dengue imposes a substantial economic burden for Indonesian public payers and society.
Complemented with an appropriate weighting method and by accounting for local
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Author summary
Dengue, an infection transmitted by mosquitos, is a public health concern particularly in
tropical/subtropical areas and the Asia Pacific region where it is associated with a signifi-
cant cost to society. Indonesia has one of the world’s highest dengue burdens but Indone-
sia-specific data on cost are lacking. To estimate the annual economic burden of dengue
in Indonesia, this study collected data from public/private hospitals and health centres in
three provinces (Yogyakarta, Bali and Jakarta) during 2015. We estimated cost of illness
using the societal perspective: calculations of costs included those that were directly paid
by the healthcare system, as well as costs incurred by the patients (or their family/care giv-
ers) and their lost productivity. The costs from the three provinces were then used as the
basis for extrapolating cost of illness in Indonesia. The authors confirmed that dengue
imposed a substantial economic burden for Indonesian public payers and society. Based
on 2015 data, the authors estimated total economic burden of dengue in Indonesia at US
$381.15 million. Of this, US$355.2 million related to patients treated in hospitals and US
$26.2 million was for patients treated in health centres. Establishing a better understand-
ing of the burden of dengue in Indonesia will help to guide public health decision-making
at a national level and support prevention and control initiatives for this disease.
Introduction
Dengue is an arboviral infection transmitted between humans by Aedes mosquitoes. Globally,
dengue is a major public health concern that has rapidly spread across the tropics and subtrop-
ics.[1, 2] Between 1990 and 2013 the estimated number of global dengue cases doubled every
decade,[3] and up to 3.9 billion people remain at risk in endemic countries.[4] Recent global
modelling studies estimate between 55–100 million dengue cases occur annually; and estimate
an increasing dengue mortality reaching over 38,000 deaths in 2016.[3, 5, 6] Of the global pop-
ulation at risk, more than 70%–or about 1.8 billion people–live in the Asia-Pacific region and
as such, Asians contribute the most to the overall burden of dengue.[1] In addition, the inci-
dence of the severe forms of disease is higher in Asia-Pacific compared with other endemic
regions perhaps for reasons of genetic susceptibility, but more likely because secondary infec-
tion is more common, due to the higher levels of endemicity and that all four dengue virus
serotypes continually co-circulate.[7–10]
In Indonesia, Ae. aegypti and Ae. albopictus are the primary and secondary vectors for
transmission, respectively. The average number of annual dengue cases reported to health
authorities in Indonesia was more than 129,000 for the period between 2004 and 2010, the sec-
ond highest incidence rate in the world after Brazil.[1] Reporting of dengue in Indonesia is
acknowledged to be incomplete and reporting procedures vary widely among the provinces.
[11] A 2013 cartographical modelling study estimated that approximately 7.6 million dengue
infections may have occurred in in Indonesia in 2010, the majority of which went unreported.
[5] The disease typically is most common in urban areas, however, rural areas are increasingly
affected.[7] Furthermore, the traditionally cyclical epidemic outbreaks of dengue appear to
have become more erratic in recent decades.[9]
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The costs associated with dengue illness are substantial, in 2012 the WHO ranked dengue
as the most important mosquito-borne viral disease across the globe, noting that outbreaks
“exert a huge burden on populations, health systems and economies in most tropical countries
of the world”.[1] Recognizing the substantial impacts in endemic regions, several economic
burden studies have been conducted in various regions of the Americas,[12–18] and several
countries in Asia and South Asia including Thailand,[19] Malaysia,[20, 21] India,[22] Singa-
pore,[23] Cambodia [24] and the Philippines.[25] These studies confirmed the considerable
direct and indirect impact of dengue on individuals, families and communities.
In Indonesia, some initial insights could be derived from the study by Shepard and col-
leagues, who estimated the annual economic burden of dengue in 12 countries of Southeast
Asia at US$950 million; for Indonesia the annual cost over the period 2001–2010 was US$323
million.[26] A subsequent estimate based on revised global dengue incidence estimates and
extrapolations of costs from scientific literature estimated the costs in Indonesia in 2016 to
have been US$2 billion.[27] Another study by Stahl and colleagues estimated the cost of den-
gue outbreaks by conducting a literature review and case studies in four countries including
Indonesia.[28] The estimated costs of an Indonesia dengue outbreak in 2011 were US$6.75
million (adjusted to 2012 US$). However, these studies did not collect local empirical cost data
and instead relied on estimates derived from a literature review on unit costs for inpatient and
outpatient care and used extrapolations of proportionality of costs from other nearby coun-
tries.[26–28] One study conducted in Surabaya, Indonesia in 2007 examined treatment costs
at the hospital level and estimated inpatient costs per episode related to dengue were in the
range of 1–2 million Indonesian Rupiah (IDR) or approximately US$106–212. However, the
scope of this study was limited to that single area and did not provide country-wide estimates
for total healthcare costs.[29]
We are not aware of a study which has collected comprehensive primary data on the eco-
nomic burden of dengue in Indonesia. Such studies are needed to inform policy making,
provide information to support healthcare resource allocation including prioritizing
research and disease prevention and control measures, as well as promote public awareness.
[30] Due to the country’s economic, geographic and sociological heterogeneity, the best way
to represent national level burden and expenditure would be to use data from multiple sites
and treatment facilities, taking a broad economic perspective. The aim of this study was to
estimate the economic burden–including direct and indirect costs–associated with hospital-
ized and ambulatory dengue cases in Indonesia, first by determining costs at the facility
level across three provinces, then extrapolating these using local epidemiological data to
make the first, empirically-derived national economic burden of dengue estimates for
Indonesia.
Methods
This study used a combination of retrospective and prospective methods and multiple data
sources to estimate the direct and indirect costs of dengue in Indonesia as of 2015.
Ethical considerations
The ethics Committee of the Faculty of Public Health at Universitas Indonesia approved this
study. Ethical approval for data collection at public hospitals and health centres was received
from the local authorities (Dinas Kesehatan or District Health Office). Interview participants
or their parents/guardians signed informed consent (signed assent forms were also required
for those aged 8–18 years) before study entry.
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Study sites
In Indonesia, tertiary healthcare facilities are divided into type A facilities, which provide the
full spectrum of specialist medical services and type B facilities, where specialist services are
limited. Both types provide basic and supportive care to both in- and out-patients. Of the 34
provinces in Indonesia, three were selected to represent low- (Yogyakarta), medium- (Bali)
and high-income (Jakarta); from these three a total of nine facilities were selected for inclusion
in the study. Public and private healthcare facilities were selected according to their research
experience; and to provide a range of dengue and cost perspectives, including those treating
inpatients and outpatients. Four facilities were selected in Jakarta: RSUPN Cipto Mangunku-
sumo (public type A hospital), RSUD Pasar Rebo (public type B hospital), RS Pelni (private
hospital) and Tambora (Puskesmas [a sub-district level public health centre]); three facilities
in Yogyakarta: RSUD Wirosaban (public type B hospital), RS Bethesda (private hospital), Pus-
kesmas kota Yogyakarta (Puskesmas); two facilities in Bali: Sanglah Hospital (public hospital)
and Puskesmas VI Denpasar (Puskesmas).
Sampling strategy
Patient records were randomly selected from a list of all age-stratified dengue diagnoses, main-
tained in facility diagnosis log books, in the 12 months preceding the beginning of the study.
We planned to assess 50 inpatient and 50 outpatient records from each hospital (total sample
from six hospitals = 600); and 50 outpatient records from each Puskesmas (total sample from
three sites = 150). It was expected that the sample would comprise an equal number of children
(�18 years old) and adults (� 19 years old) due to the approximately equal distribution of den-
gue cases occurring in these categories. Additionally, we intended to interview 30 inpatients
and 30 outpatients or their respective parents/guardians at each hospital (total sample from six
hospitals = 360) and 30 outpatients or their parents/guardians from each Puskesmas (total
sample from three sites = 90). Sample sizes were chosen to be operationally feasible and suffi-
ciently large that analysis methods based on the normal distribution may be used for the
analysis.
Sources of data–direct medical costs from patient records
Direct medical costs were retrospectively assessed through review of medical records and bill-
ing/charges made to patients who received treatment at selected hospitals or Puskesmas (sub-
district level health centres) in the 12 months prior to the beginning of the study (April 1st
2014 until March 31st 2015) with a diagnosis of dengue or dengue haemorrhagic fever (with
ICD 10 code A90 and A91).
Sources of data–direct non-medical and indirect medical costs from
interviews
Direct non-medical costs and indirect costs were assessed from data collected during face-to-
face interviews with patients or their parents/guardians at selected hospitals or Puskesmas.
Patients with clinically diagnosed/laboratory confirmed dengue or those with evidence of fever
>38˚C for>1 day, plus symptoms compatible with dengue fever were recruited to participate
in two interviews. The first was a face-to-face interview with patients or their parents/guard-
ians using a questionnaire and conducted at the health facility at discharge/during an ambula-
tory visit. The second interview was conducted by telephone two weeks later to determine
subsequent costs of treatment and any absenteeism from work/school. Direct non-medical
costs were defined to include all expenses incurred due to the treatment, such as meals,
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transport, accommodation for care givers, etc. The interviews documented: the use of medical
services; missed schooling; lost work productivity; out-of-pocket spending (e.g. transportation,
meals, hotel/house rental, etc) and income lost due to the episode of illness. In the event that
participants chose not to disclose their income and in the absence of reliable data on average
wages including in the informal economy, we applied the standard minimum wages as a
proxy, which are regulated in Indonesia and differ by province. Lost productivity was not cal-
culated for children; rather, for each affected school child lost productivity was calculated for
the caregiver (as a result of leaving work to care for the child).
Cost of dengue cases
Costs were expressed in US dollars (as of 2016 with a conversion rate: US$1 = IDR13,000). For
those regions where a particular type of facility was not included in the study, gaps in the data
were filled via weighted adjustment from neighbouring sites. For example, private outpatient
costs were captured by recording treatment bills paid by the patient in Jakarta. Because private
outpatient facilities were absent in Yogyakarta, these costs were estimated by adjusting Jakarta
values weighted according to outpatient public costs for Jakarta and Yogyakarta. In Bali, pri-
vate outpatient and inpatient costs were estimated based on the ratio observed in Yogyakarta.
Extrapolation of the dengue cost burden to the national level
Passive reporting of dengue in Indonesia is mandatory within 72 hours of diagnosis according
to SEARO-WHO dengue diagnosis guidelines 2011.[31] Notification follows diagnosis by clin-
ical and/or laboratory confirmation (by detection of NS1 antigen and/or IgM/IgG). Cases are
reported to provincial health offices and pooled at the provincial and national levels by the
Directorate General of CDC.[32]
Costs at the national level were estimated by multiplying cost per case (outpatient/inpa-
tient) by an estimate of the number of cases occurring in Indonesia in 2015. National burden
estimates were generated using a) provincial-level surveillance data from each of the 34 prov-
inces; b) estimates of hospitalization rate derived from an expert consensus technique in Indo-
nesia;[11] and c) a study which observed a magnitude of dengue under-reporting of 11.5-fold
in the placebo group of a dengue vaccine clinical trial in Jakarta, Bandung and Denpasar, Bali.
[33]
The expert panel that gave rise to the estimates of hospitalization rate has been described
previously;[11] briefly, it comprised a group of Indonesian dengue experts (clinicians, hospital
managers, epidemiologists and Ministry of Health officials) who reviewed existing data sources
and made iterative estimates of epidemiological parameters by which full burden estimates
could be made. These were balanced against published analyses.[3, 5, 33–37] The panel con-
cluded that 60% of dengue cases in Indonesia were hospitalized; a figure which, when com-
bined with an estimated reported hospitalization rate and under-reporting factor of 11.5,
generated the final expansion factor for hospitalized patients (EFH; 7.65) and expansion factor
for ambulatory patients (EFA; 45.90) used for calculation of the cost-of-illness. The numbers
of ambulatory and hospitalized dengue cases for each province in Indonesia during 2015 were
estimated by multiplying these expansion factors by the numbers of reported cases in each
province.
To calculate the economic burden of dengue nationally the three sites in our study: Jakarta,
Yogyakarta and Bali, were used as references for other provinces arranged into three groups
according to their fiscal capacity index (FCI). Yogyakarta was the reference for low FCI prov-
ince (FCI <0.5), Bali for middle FCI (0.5–2.0) and Jakarta for high FCI (>2.0) provinces. Unit
outpatient and inpatient costs of each province were proportionally weighted by the consumer
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price index (CPI) or Indeks Harga Konsumen (IHK) using Jakarta, Bali and Yogyakarta den-
gue unit costs as the baseline. By multiplying the number of ambulatory/hospitalized cases by
the unit cost estimates for each province, the total economic burden in each province was cal-
culated.[11]
Sensitivity analyses
To assess the uncertainty surrounding estimated overall dengue burden,[38] deterministic sen-
sitivity analyses were performed to examine the effect of parameters’ variations i.e. costs in
each setting (inpatient, outpatient, by region) and expansion factor. Each parameter was man-
ually varied by an arbitrary value of ±10% to examine the impact on the total economic bur-
den. Calculations were performed using Microsoft Office Excel 2010.
Results
Data collection, recruitment and timelines
A total of 615 patient records were reviewed for the retrospective, direct medical cost calcula-
tion (262 in Jakarta, 251 in Yogyakarta and 102 in Bali) during the period from the 15th of June
to the 31st of July 2015. The regional distribution of patients included, by province, inpatient/
outpatient and dengue classification is shown in Table 1. A total of 199 patients were involved
in the prospective phase of the study (94, 43 and 62 from each site); data were collected from
interviews during the period from the 3rd of August to the 15th of September 2015. Combining
both retrospective and prospective elements, the study sample was 68% of the enrolment
target.
Direct and indirect medical cost for inpatient and outpatient care of
dengue cases in Jakarta, Yogyakarta and Bali
The total costs (combined direct and indirect costs) per patient episode for outpatient cases
were, US$103, US$252 and US$179 for Yogyakarta, Bali and Jakarta, respectively. For inpa-
tients these costs were US$689, US$989 and US$1071 respectively. With the exception of inpa-
tient costs in Jakarta, direct medical costs were higher from private hospitals compared with
public facilities. Table 2 describes cost of illness results per episode for each site. Direct medical
cost were the largest proportion of costs for inpatient care, while indirect costs were the largest
proportion of costs for outpatient care. Outpatient costs in Jakarta were slightly lower than in
Bali. Overall, the mean length of hospital stay was 3.9 days. By region, it was 4.4 days in Yogya-
karta, 3.5 for Bali and 3.8 days in Jakarta.
Table 1. Distribution of patient records used in the retrospective analyses, by province, type of service and severity of dengue during the period from 15th of June to
31st of July 2015.
Province Type of services Dengue fever Dengue haemorrhagic fever Dengue shock syndrome Total
Yogyakarta Outpatient 33 15 48
Inpatient 3 48 3 54
Bali Outpatient 109 8 117
Inpatient 50 82 2 134
Jakarta Outpatient 62 56 118
Inpatient 43 94 7 144
Total 300 303 12 615
https://doi.org/10.1371/journal.pntd.0007038.t001
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Total economic burden due to dengue in the provinces of Indonesia
The results of the extrapolated regional costs (by CPI and FCI) are shown in Table 3. Jakarta
was the province with the highest dengue-related cost, followed by Yogyakarta, West Java and
West Kalimantan.
Total economic burden due to dengue in Indonesia
The annual total cost of dengue-related illness in Indonesia was estimated at US$381.5 million,
with US$354,802,570 for hospitalised and US$26,249,519 for ambulatory cases (Table 3). Con-
sidering the total number of inpatient cases and costs, the average cost per dengue patient was
lowest in region 1 ($346.38) and highest in region 3 (US$535.91). Similarly, average cost per
outpatient was lowest in region 1 (US$34.38) and highest in region 2 (US$84.48).
Sensitivity analysis
Results from the sensitivity analyses are presented in the Tornado diagram (Fig 1), which rep-
resents baseline value (per US$ million). The parameters included in sensitivity analysis were
the costs of outpatient and inpatient treatment by province; and EFA and EFH. Variation in
any of these parameters resulted in overall economic burden varying from US$166–557 mil-
lion. The greatest variation in the final estimate followed variation in outpatient costs in
Jakarta; followed by costs in outpatient facilities in type A clinics, and in Bali.
Discussion
We estimated the average annual economic burden of dengue-related illness in Indonesia in
2015 to be US$381.5 million with more than 90% of this cost associated with hospitalized care.
Jakarta was the province associated with the greatest cost, which is a function of the greater
population and the higher average costs of treating hospitalized dengue episodes. In Jakarta,
inpatient, direct medical costs were higher from public facilities than in private hospitals. This
was thought to result from the fact that the public study sites included Ciptomangunkusumo
Hospital which is a type A public hospital, a top referral hospital in Indonesia and therefore
Table 2. Cost of illness per patient per episode (in US$) by component and site in Yogyakarta, Bali and Jakarta.
Province Type of services Health facility Direct costs: medical (US$) Direct cost: non-medical (US$) Indirect cost (US$) Total cost (US$)
Yogyakarta Outpatient Puskesmas 3.32 21.15 8.02 32.49
Public hospital 7.33 10.00 8.02 25.35
Private hospital 26.66 10.00 8.02 44.68
Inpatient Public hospital 222.89 18.31 46.16 287.35
Private hospital 334.30 24.19 43.06 401.55
Bali Outpatient Puskesmas 16.73 15.14 30.64 62.51
Public hospital 20.08 21.31 49.54 90.92
Private hospital 28.13 21.31 49.54 98.98
Inpatient Public hospital 229.55 76.89 122.31 428.75
Private hospital 344.30 101.61 114.11 560.01
Jakarta Outpatient Puskesmas 14.53 6.64 13.77 34.94
Public hospital 23.41 10.47 30.32 64.19
Private hospital 32.80 17.64 29.08 79.52
Inpatient Public hospital 407.07 84.33 153.79 645.19
Private hospital 248.61 73.24 104.12 425.97
https://doi.org/10.1371/journal.pntd.0007038.t002
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responsible for treating the most severe cases requiring intensive, expensive, specialist care.
Sensitivity analyses identified uncertainty around outpatient cost in Jakarta as the variable
with the largest impact on the overall economic burden, due to the relatively higher cost of epi-
sodes in Jakarta, and their frequency. Notably, the overall estimates are directly influenced by
the expansion factors used to estimate the number of cases. These numbers were derived from
high-quality epidemiological studies in tandem with local expert opinion. But studies have
Table 3. Extrapolated total economic burden (in US$) of dengue in Indonesian provinces by income-category (Region 1: Low income context, Region 2: Medium
income context, Region 3: High-income context). Number of cases estimated by extrapolation from cases reported from passive surveillance in 2015 using expansion
factors.
Actual inpatient cases Total inpatient cost (US$) Actual outpatient cases Total outpatient cost (US$) Total economic burden (US$)
REGION 1
Yogyakarta 139,556 48,070,196 92,635 3,165,523 51,235,719
Bengkulu 4,317 1,535,502 2,866 101,116 1,636,618
Banten 34,331 12,152,270 22,788 800,252 12,952,522
West Sumatra 26,376 9,233,246 17,508 608,029 9,841,274
North Sumatra 36,549 12,738,624 24,260 838,865 13,577,489
Jambi 23,534 8,146,013 15,622 536,432 8,682,445
West Java 113,638 39,173,980 75,431 2,579,688 41,753,669
Special Region of Aceh 10,457 3,521,684 6,941 231,910 3,753,594
South Sumatra 6,951 2,340,043 4,614 154,097 2,494,140
North Kalimantan 4,484 1,628,835 2,976 107,262 1,736,097
West Kalimantan 74,179 25,967,594 49,238 1,710,020 27,677,614
East Java 20,866 7,209,095 13,851 474,734 7,683,829
Central Java 23,701 8,186,530 15,732 539,100 8,725,631
West Nusa Tenggara 10,395 3,637,047 6,900 239,507 3,876,554
Maluku 3,368 1,177,939 2,236 77,570 1,255,509
East Nusa Tenggara 1,601 551,161 1,063 36,295 587,456
Southeast Sulawesi 10,887 3,732,207 7,227 245,774 3,977,980
North Sulawesi 10,409 3,546,774 6,909 233,562 3,780,337
West Sulawesi 4,983 1,696,603 3,307 111,725 1,808,328
South Sulawesi 5,059 1,721,320 3,358 113,353 1,834,673
Gorontalo 25,419 8,546,321 16,873 562,793 9,109,114
Central Sulawesi 44,754 15,659,385 29,707 1,031,203 16,690,588
Special Region of Papua 457 60,387 304 10,562 170,949
Lampung 12,439 4,467,725 8,257 294,209 4,761,934
Total region 1 648,710 224,700,481 430,603 14,803,581 239,604,063
REGION 2
Bali 27,540 13,615,216 18,280 1,538,048 15,153,264
Special Region of West Papua 825 396,267 547 44,764 441,031
Riau 22,599 11,207,903 15,001 1,266,105 12,474,008
Bangka–Belitung Islands 21,795 11,038,270 14,467 1,246,942 12,285,212
Riau Islands 9,383 4,609,852 6,228 520,754 5,130,605
Central Kalimantan 8,676 4,246,122 5,759 479,665 4,725,787
South Kalimantan 3,507 1,704,769 2,328 192,580 1,897,349
North Maluku 541 272,137 359 30,742 302,879
Total region 2 94,866 47,090,536 62,969 5,319,600 52,410,135
REGION 3
Jakarta 147,172 78,822,769 97,690 5,817,201 84,639,971
East Kalimantan 7,727 4,188,784 5,129 309,137 4,497,920
Total region 3 154,899 83,011,553 102,819 6,126,338 89,137,891
NATIONAL TOTAL 898,475 354,802,570 596,391 26,249,519 381,152,089
https://doi.org/10.1371/journal.pntd.0007038.t003
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shown reporting completeness can be affected by changes in disease severity, level of epidemic
activity and other external factors, which could limit the generalizability of these numbers at
different time points. 2015 was a fairly “typical” year in Indonesia, with the number of cases
being close to the average from 2010–2016.[39, 40] Future analyses will hopefully allow for a
more refined understanding of the level of dengue reporting in Indonesia.
Our estimate of the cost per episode in type B hospital was~US$150 (~IDR 2 million),
which is consistent with a previous Indonesian estimate from East Java of IDR1–2 million pub-
lished in 2008.[29] Our unit cost estimates are also similar to those reported in the regional
analyses of Shepard in 2013 and 2016.[26, 27] Our study found that dengue is associated with
considerable economic burden, which is in agreement with other studies conducted in Asian
countries, especially those in Thailand and the Philippines. In Thailand, Philippines and
Malaysia, total economic burdens were estimated at US$486 million (in 2005 costs),[19] US
$345 million (in 2012 costs),[25] US$102.25 million (in 2009 costs),[20, 21] respectively. How-
ever, estimates in the much smaller (Singapore) and larger (India) countries were considerably
higher than our estimate at more than US$1 billion in each country.[23, 41]
With regard to existing national level burden estimates for Indonesia, our results are similar
to those published by Shepard and colleagues in 2013 who concluded that the annual
Fig 1. Tornado diagram for the deterministic sensitivity analysis of variability of the Indonesian national-level, annual cost of dengue illness in US$ million. Black
represents the lowest value, grey represents the largest value. Parameters were varied by ±10% as a subjective scenario and the base case was US$381.15 million. The
point estimate for each parameter is included in the label for each bar.
https://doi.org/10.1371/journal.pntd.0007038.g001
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economic burden of dengue for Indonesia was US$323 million.[26] This was slightly lower
than our 2015 estimate, caused by an increasing disease burden; and slightly higher outpatient
unit costs. However, this group refined their estimates in a 2016 [27] publication using a differ-
ent method of epidemiological burden estimation and concluded that the dengue burden in
Indonesia was US$2 billion.[27] Costs in our study were calculated from primary data sources
and clinically diagnosed dengue, including medical record review and patient interview. Unit
costs were broadly similar to those estimated by Shepard and colleagues and the variation is
predominantly driven by different epidemiological estimates: Shepard and colleagues’ esti-
mated>11 million annual dengue cases, while we assumed ~640,000. Such variation in den-
gue burden estimates are difficult to reconcile; the paper by Shepard and colleagues applied
regression methods from the Global Disease Burden group; in contrast we used local surveil-
lance data combined with expert opinion and empirical under-reporting calculation. Much of
this variation likely stems from case definitions, particularly those around mild cases of dengue
whose clinical and economic significance is very difficult to calculate with confidence, and
whose full economic impacts are very difficult to measure. In addition, the Shepard 2016 study
included estimates for non-medical cases (i.e. patients that did not seek professional medical
advice but may have had laboratory testing or purchased therapeutic products outside the pro-
fessional healthcare system), which we did not include in this analysis.
The strength of this study is that it is based on empirical, patient-specific data for medical
care and out-patient costs in Indonesia. Furthermore, it considered both public and private
hospitals and included costs derived from different treatment settings and economic back-
grounds. To address limitations in the available passive surveillance data, expansion factors
were used to fully describe the number of dengue cases and expert opinion employed to deseg-
regate data into outpatient and inpatient cases. We consider this approach, underpinned by
gold-standard epidemiological clinical trial data with local expert opinion to stratify cases by
severity, is likely a realistic representation of the health-seeking dengue case population in
Indonesia. The costs captured from the three reference provinces (Jakarta, Bali and Yogya-
karta) were extrapolated to other regions based on weighted average costs linked to the con-
sumer price index to ensure relevant estimates from other regions. Other variables such as
type of hospitals (private/public, type A or B) were also taken into account in the extrapolation
to get a mixed representation of healthcare setting throughout the country.
We acknowledge several limitations to our study, mostly due to the patients’ clinical
pathway i.e. most patients generally received outpatient services at type B hospitals, hence
had an impact on type A sample size; also the number of ambulatory patients was generally
lower than expected (potentially due to the local regulation at Jakarta and Yogyakarta
whereby laboratory-confirmed dengue patients were referred directly to hospital). Further-
more, we did not enroll as many patients as planned and were only able to achieve 68% of
the target enrolment. The primary reason for lower-than-expected enrolment was the rela-
tively small number of dengue cases occurring in 2015, especially in Yogyakarta in which
enrolment was especially challenging. Outpatient recruitment was additionally complicated
by local clinical practice guidelines which advise that all dengue cases should be hospital-
ized. There is uncertainty in income loss calculations due to illness because most patients or
their parents/guardians did not disclose their actual income during the interviews; so the
national minimum wage was used as proxy. Some studies also included ‘outside hospital
costs’, such as vector control activities, in the overall cost estimates, but this was beyond the
scope/focus of our study. Lastly, our estimates are based on data from one year (2015), cor-
responding to the period over which primary data were collected. As a result, the estimates
are subject to vary with epidemic activity.
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Conclusion
The total direct costs of dengue illness in Indonesia were estimated at US$381.15 million. Our
analysis provides results that are relevant to public health policymakers in Indonesia, helping
to strengthen local knowledge and informing decision-making regarding the prevention and
control of dengue in public health priority lists. These results can also be used in health eco-
nomic studies of novel dengue prevention and control technologies or vaccine programs.
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a b s t r a c t
Background: The world’s first dengue vaccine [Dengvaxia; Sanofi Pasteur] was licensed in 2015 and
others are in development. Real-world evaluations of dengue vaccines will therefore soon be needed.
We assessed feasibility of case control (CC) and test-negative (TN) design studies for dengue vaccine
effectiveness by measuring associations between socio-demographic risk factors, and hospitalized den-
gue outcomes, in Malaysia.
Methods: Following ethical approval, we conducted hospital-based dengue surveillance for one year in
three referral hospitals. Suspected cases aged 9–25 years underwent dengue virological confirmation by
RT-PCR and/or NS1 Ag ELISA at a central laboratory. Two age- and geography-matched hospitalized non-
dengue case-controls were recruited for a traditional CC study. Suspected cases testing negative were
test-negative controls. Socio-demographic, risk factor and routine laboratory data were collected.
Logistic regressionmodels were used to estimate associations between confirmed dengue and risk factors.
Results: We recruited 327 subjects; 155 were suspected of dengue. The planned sample size was not met.
124 (80%) of suspected cases were dengue-confirmed; seven were assessed as severe. Three had missing
RT-PCR results; the study recruited 28 test-negative controls. Only 172 matched controls could be
recruited; 90 cases were matched with 1 controls. Characteristics of cases and controls were mostly
similar. By CC design, two variables were significant risk factors for hospitalized dengue: recent household
dengue contact (OR: 54, 95% CI: 7.3–397) and recent neighbourhood insecticidal fogging (OR: 2.1; 95% CI:
1.3–3.6). In the TN design, no risk factors were identified. In comparison with gold-standard diagnostics,
routine tests performed poorly.
Conclusions: The CC design may be more appropriate than the TN design for hospitalized dengue vaccine
effectiveness studies. Selection bias in case control selection could beminimized by protocol changesmore
easily than increasing TN design control numbers, because early-stage dengue diagnosis in endemic coun-
tries is highly specific. MREC study approval: (39)KKM/NIHSEC/P16-1334.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
Dengue, a mosquito-borne flavivirus, causes around 100 million
clinical episodes, and likely results in 10.5 million hospitalizations
annually, mostly in Asia [1–3]. The disease has a wide and unpre-
dictable range of clinical presentations, from mild/asymptomatic
flu-like illness, progressing to acute, febrile, and severe/haemor-
rhagic disease and rarely, death [4,5]. Risk factors for severe out-
comes may include the presence of heterologous antibodies from
a previous infection, viral characteristics, and the age and genetic
background of the infected human host [6]. Population-level risk
https://doi.org/10.1016/j.vaccine.2019.07.083
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factors include urbanization, high population density, and pres-
ence of Aedes mosquito vector breeding sites [7].
The world’s first dengue vaccine [Dengvaxia; Sanofi Pasteur]
was licensed in 2015 and has since been introduced in Asia and
Latin America [8]. A number of other dengue vaccines are in clini-
cal development and evaluations of the real-world performance of
dengue vaccines will therefore soon be needed [8–10]. A workshop
of international experts took place in 2014 to discuss the underly-
ing principles; participants agreed that case-control (CC) and test-
negative (TN) designs should be considered for this purpose [11].
CC studies are established methodologies for assessing associa-
tions between vaccine exposure and infectious disease outcomes
including for influenza [12]; Japanese encephalitis [13]; whooping
cough [14], and pneumococcal pneumonia [15]. For dengue, CC
studies have been used to evaluate individual- and population-
level risks factors [16,17]. The TN design is a variant of the CC study
whereby suspected caseswithnegative laboratory results – andwho
are therefore considered absent of the outcomeof interest – are used
as controls, and has been used extensively for evaluating the effec-
tiveness of influenza vaccines [18–21] and other vaccines [22–24].
The TN design has advantages in reducing bias in control recruit-
ment, and has been used to understand dengue risk factors [25].
Post-licensure dengue vaccine effectiveness studies have not
been published and, given the clinical and epidemiological specifici-
ties of dengue, challengesmay be expected which warrant prepara-
tory study [26]. These include the ability to recruit dengue patients
satisfying relevant case definitions; laboratory capacity to confirm
infectionwith adequate specificity and sensitivity; and the practical
infrastructure to identify and recruit suitable control subjects.
In Malaysia, dengue outbreaks occur nationwide with increased
risk in urban and peri-urban areas. Peaks in transmission often
coincide with rainfall but cases occur year-round and reported
cases have doubled since 2010 [27,28]. Although cases showed
some reduction in 2016, the disease was highlighted in the Ele-
venth Malaysia plan of 2016–2020 to expand health promotion
programmes for communicable diseases, which aims primarily to
mitigate dengue risk [29]. Dengvaxia was granted a two-year con-
ditional registration in October 2016 by the Drug Control Authority
of Malaysia for post-registration study, with conditions to monitor
long term risks, safety and efficacy over a wider population [30].
To prepare for vaccine introduction, we assessed the feasibility
of conducting traditional CC and TN studies for dengue vaccine
effectiveness evaluation, in Malaysia, by measuring associations
between socio-demographic and environmental risk factors and
dengue outcomes. We considered hospitalized/severe dengue as
policy-relevant and specific endpoints, so we conducted hospital-
based dengue surveillance for a period of one year, matching cases
to control subjects who were hospitalized for a non-dengue condi-
tion. We assessed feasibility of recruitment, logistics, and labora-
tory confirmation as well as likely biases and potential remedies
to minimize them to improve the design of future dengue vaccine
effectiveness studies.
2. Methods
2.1. Ethical approval for study
This study was conducted in accordance with the Declaration of
Helsinki [31], the Guidelines for Good Epidemiology Practices [32]
and local regulatory requirements. Before subjects were enrolled
the protocol and study documents were approved by the Medical
Research and Ethics Committee of the Ministry of Health, Malaysia
(study approval: (39)KKM/NIHSEC/P16-1334). Institutional
approval was obtained from each Hospital Director and relevant
Head of Department before data collection commenced.
2.2. Study design
Prospective, hospital-based enhanced surveillance. Suspected
dengue cases who were laboratory-confirmed were enrolled as
cases and matched to two hospitalized non-dengue, age- and
geography-matched controls, to conduct the traditional CC study.
Laboratory-confirmed dengue cases were considered test-positive
cases for the TN study; suspected cases testing negative were con-
sidered as the TN controls.
2.3. Study sites and population
Surveillance for suspected dengue cases starting from October
2016, over a period of 12 months, among hospitalized patients at
three Malaysian study sites: (1) Raja Permaisuri Bainun Hospital,
Ipoh, Perak; (2) Selayang Hospital, Selangor; and (3) Sungai Buloh
Hospital, Selangor. Study sites are large, tertiary care hospitals
operating within the Malaysian Ministry of Health system. Two
(Selayang and Sungai Buloh Hospitals) are located within large
urban areas and one (Ipoh Hospital) is located in a smaller, more
peri-urban city. The hospitals accept referrals from health districts
within their catchment areas, ranging from 16 km to 76 km.
Nonetheless, patients living outside of the catchment areas (in
regional and rural areas) may be referred for tertiary care services.
An estimated 1000–2000 febrile cases are seen in these hospitals
each month. All hospitals are centres of excellence for dengue,
treating several thousand hospitalized dengue cases, annually.
Study subjects were classified according to the following case
definitions:
 Suspected dengue: patients on whom the attending clinician
makes a diagnosis of probable dengue according to clinical his-
tory, physical examination and results of routine diagnostic
tests which may have been used.
 Virologically-confirmed dengue (VCD): suspected dengue cases
that are virologically confirmed by the central laboratory by
dengue RT-PCR and/or NS1 antigen (Ag) ELISA.
 Severe dengue: a patient presenting with fever of 2–7 days plus
any of the following: severe plasma leakage, severe haemor-
rhage or severe organ impairment, as derived from raw clinical
data, based on WHO 2009 definitions [4].
 Case-controls: non-dengue patients, age- and geographically-
matched to VCD cases.
 TN controls: suspected dengue cases who tested negative for
dengue by both RT-PCR and NS1 Ag.
2.4. Inclusion criteria for cases and controls
Inclusion criteria for suspected dengue were: age 9–25 years;
acutely ill and suspected of dengue infection; admitted to the
study hospital within 5 days of fever onset; resident of the hospital
catchment area. Due to low case enrolment, a protocol amendment
was approved on 31st July 2017, extending the recruitment win-
dow to within 7 days of fever onset.
For each laboratory-confirmed dengue case, study teams
attempted to identify two hospitalized, matched case-controls.
Inclusion criteria were: hospitalized in the same hospital as cases;
with no suspicion of dengue infection; with a final diagnosis other
than dengue; admission within one month (before or after) of the
laboratory confirmation of the case. The last control subject was
enrolled on 3rd December 2017. Controls were age-matched to
cases in three age groups: 9–12 years; 13–17 years; and 18–
25 years; and geographically-matched based on the catchment
areas of district health offices (Pejabat Kesihatan Daerah).
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2.5. Subject screening and enrolment
Screening from medical and paediatric wards was performed
during weekdays and within working hours by the study coordina-
tors. Eligibility was assessed based on clinical history, physical
examination and following discussions with attending physicians.
Typically in Malaysia, individuals are suspected of dengue based
on clinical signs and symptoms and, at these referral centres, it is
likely that most subjects already received either IgM/IgG and/or
NS1 Ag rapid diagnostic tests (RDT) and/or a previous clinical diag-
nosis of dengue at primary care clinics or hospital emergency
departments. Children suspected of dengue are typically admitted,
whereas adults will be hospitalized following a poor or worsening
clinical condition.
Suspected dengue cases were screened by study coordinators
and principal investigators for other inclusion criteria before being
invited to join the study. Informed consent and assent forms, avail-
able in English, Malay, Tamil, and Chinese languages, were
reviewed and signed by subjects and parents of subjects aged
<18 years. Subjects’ identification cards (18 years and above) and
birth certificates (below 18 years old) were collected to verify legal
relationships, as required by the Medical Research and Ethics
Committee.
2.6. Data collection and laboratory analysis
Following enrolment, a standardized questionnaire was admin-
istered by study staff which collected socio-demographic informa-
tion, reported dengue histories of subjects and household contacts,
other risk factor data (e.g., household and neighbourhood vector
control practices; time spent outdoors) and flavivirus vaccination
history. Final discharge diagnoses, made by attending physicians
based on routine clinical practice, were retrieved from electronic
medical records upon discharge, verified by the investigator and
recorded.
For suspected cases, during routine blood sampling in the
wards, an additional aliquot of 5 mL venous blood was collected.
Blood was kept at room temperature for 30–60 min (or refrigerated
at 2–8 C for 24 h) before centrifugation. Serum was transferred
into two 650 mL aliquots, frozen at 20 C and shipped in dry ice
to the central laboratory, the Department of Medical Microbiology,
University of Malaya Medical Center in Kuala Lumpur. Virological
confirmation of dengue was by RT-PCR and NS1 Ag ELISA. RNA
extraction was performed using Roche High Pure viral RNA extrac-
tion kit; RNA purity and concentration were assessed by spec-
trophotometry. One step real-time Sybr Green RT-PCR was
performed using Bio-rad iTaq universal one step Sybr Green pre-
mix and in-house designed primers [33]. The SD Dengue NS1 ELISA
kit was used according to the manufacturer’s instruction.
The results of routinely-performed dengue diagnostic testing,
which could include RDTs and ELISAs detecting IgM, IgG and NS1
Ag, before or during hospitalization, were recorded.
All data were entered into an electronic database by study
teams and verified through computerized logic and consistency
checks to detect errors or omissions.
2.7. Sample size
In the context of vaccine effectiveness study preparation the
sample size was based on a hypothetical effectiveness objective
comparing the odds ratio (OR) of having a virologically confirmed,
hospitalized dengue episode between vaccinees and non-
vaccinees, assuming a power of 80%, a two-sided alpha of 5%, vac-
cine coverage of 50%, and an expected vaccine effectiveness of 50%.
Assuming 70% of suspected cases test positive, the TN design
would require 223 cases and 96 TN controls. A CC design would
require 88 cases and 352 controls (with a case:control ratio of
1:4) or 110 cases and 220 controls (with a 1:2 ratio). Expecting a
minimum of 20% non-evaluable cases, a target of 300 confirmed
cases (meaning 400 suspected cases) and 600 controls was
planned. Targets were provided for each site to enrol equal num-
bers, stratified into age categories, resulting in a total of 100 sus-
pected cases aged 9–12 years, 100 aged 13–17 years, and 200
aged 18–25 years.
2.8. Statistical analysis
We compared socio-demographic characteristics of VCD cases
and controls enrolled for both designs. Univariate logistic regres-
sion models were used to estimate associations between con-
firmed dengue and risk factors using the CC (in which only
subjects with at least 1 matched control was included, by condi-
tional logistic regression) and TN study designs. Variables with a
P-value <0.2 on univariate analysis were included in a final multi-
variable model and were backward-selected to retain in the model
at a P-value of <0.05.
Dengue discharge diagnoses were compared with WHO 2009
case definitions, including severity assessment, as derived from
subjects’ clinical data [4]. The sensitivity and specificity of each
diagnostic test used in routine practice were calculated using RT-
PCR and/or NS1 Ag ELISA positive test results as the reference stan-
dard, with confidence intervals computed using the normal
approximation method.
All statistical analyses were performed with SAS 9.4 using
Enterprise Guide 5.1 software or later.
3. Results
3.1. Characteristics of study subjects
Fig. 1 is a study flow chart. The study recruited 327 subjects; the
mean age was 18 (SD 4.2) years for VCD cases, 18 (SD 3.7) for TN
controls, and 19 (SD 4.3) for case-controls. There were 155 subjects
suspected of dengue within 5 days of fever of whom 18 were aged
9–12 years; 48 were aged 13–17 years, and 89 were aged 18–
25 years. The planned sample size was therefore not met in any
age group. Many suspected cases were ineligible to participate
because they were not aged 9–25 years old; had experienced onset
of fever >5 days previously; parents were unavailable to provide
informed consent and/or birth certificates. Following protocol
amendment, ten suspected dengue cases were enrolled, admitted
between 5 and 7 days of fever, two of whom were VCD. Due to
the low impact on overall results, these subjects were not consid-
ered in further analyses. Table 1 summarises the socio-
demographic characteristics of study subjects. Of the 155 sus-
pected dengue cases, 124 (80%) were VCD. Three subjects had
missing RT-PCR results and the study therefore recruited 28 TN
controls. To match 124 confirmed dengue cases in a 1:2 ratio,
248 controls were required. A total of 172 matched controls were
recruited and some cases therefore lacked controls: 90 cases were
matched with 1 or 2 controls. Time between case and matched
control recruitment was on average 74 days.
3.2. Dengue risk factors – univariate analysis
The characteristics of cases and controls were similar in terms
of most baseline clinical characteristics, individual dengue history
and educational and socio-demographic dengue risk factors
(Table 1; complete table of risk-factors in supplementary
Table S1). Differences were observed in the sex distribution: of
VCD cases, 43 (34.7%) were female in comparison with 98
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Fig. 1. Study flow chart. VCD = virologically confirmed dengue.
Table 1
Numbers (%; SD for Mean age) of subjects with different socio-demographic characteristics and risk factors recruited as VCD cases and case- or test-negative controls. P-values are
in bold font with ORs below, vs the reference category.
Case-control design Test-negative design






N 90 172 124 28
Mean age, years (SD) 18 (4.3) 19 (4.3) 18 (4.2) 18 (3.7)
Sex 0.003 0.181
M 57 (63) 74 (43) Ref 81 (65) 22 (79) Ref
F 33 (37) 98 (57) 0.4 (0.3; 0.8) 43 (35) 6 (21) 1.9 (0.7; 5.2)
Site# – 0.1697*
Ipoh, Perak 31 (34) 59 (34) – 45 (36) 5 (18) Ref
Selayang, Selangor 32 (36) 62 (36) – 44 (36) 14 (50) 0.3 (0.1; 1.1)
Sungai Buloh, Selangor 27 (30) 51 (30) – 35 (28) 9 (32) 0.4 (0.1; 1.4)
Education level 0.270 0.110*
No formal or primary 5 (5.6) 14 (8.1) Ref 10 (8) 2 (7.1) Ref
Secondary 58 (64.4) 114 (66) 4.4 (0.5; 37) 76 (61) 23 (82) 0.7 (0.1; 3.2)
Tertiary 27 (30.0) 44 (26) 5.6 (0.6; 50) 38 (31) 3 (101) 2.5 (0.4; 17)
Type of dwelling 0.135* 0.589
Individual house 58 (64) 127 (74) Ref 82 (66) 17 (61) Ref
Apartment/flat/others 32 (36) 45 (26) 1.5 (0.9; 2.6) 42 (34) 11 (39) 0.8 (0.3; 1.8)
Number of family members in household 0.596 0.224
3 11 (12) 31 (18) Ref 14 (11) 7 (25.0) Ref
4–5 32 (36) 54 (31) 1.8 (0.8; 4.2) 44 (36) 11 (39) 2 (0.7; 6.1)
6–7 31 (34) 59 (34) 1.6 (0.7; 3.7) 45 (36) 7 (25) 3.2 (1; 10.7)
8 16 (18) 28 (16) 1.7 (0.7; 4.3) 21 (17) 3 (10.7) 3.5 (0.8; 16)
Household member diagnosed with dengue within the past
month?
<0.001*,z 0.630
No 62 (69) 171 (99) Ref 92 (74) 22 (79) Ref
Yes 28 (31) 1 (0.6) 54 (7.3397) 32 (26) 6 (21) 1.3 (0.5; 3.4)
Subject previously diagnosed with dengue? 0.589 0.202
Yes 12 (13) 19 (11) Ref 15 (12) 6 (21) Ref
No 78 (87) 153 (89) 0.8 (0.4; 1.8) 109 (88) 22 (79) 2 (0.7; 5.7)
Average time spent outdoors, daily (hours) 0.213 0.280
<4 h 17 (19) 19 (11) Ref 23 (19) 3 (11) Ref
4 h  time < 8 h 57 (63) 122 (71) 0.5 (0.2; 1.1) 77 (62) 16 (57) 0.6 (0.2–2.3)
8 h 16 (18) 31 (18) 0.6 (0.2–1.4) 24 (19) 9 (32) 0.3 (0.1–1.4)
Insecticidal fogging in neighbourhood in the past month? 0.0049*,z 0.174*
No 39 (43) 108 (63) Ref 55 (45) 16 (59) Ref
Yes 51 (57) 64 (37) 2.1 (1.3–3.6) 68 (55) 11 (41) 1.8 (0.8–4.2)
# Study site not included in CC design because controls were matched to cases based on site.
^ Includes only cases with 1 matched control.
* Variables included in multivariate model.
z Variables retained in final multivariate model.
Ref = reference category.
Columns totals may vary due to lack of responses; or not equal 100% due to rounding.
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(57.0%) case-controls and 6 (21.4%) TN controls. There were also
differences in reported recent dengue history in the household
(32 [25.8%] cases; 6 [21.4%] TN controls and one [0.6%] case con-
trol) and reports of recent neighbourhood fogging (68 [55.3%]
VCD; 11 [40.7%] TN controls and 64 [37.2%] case-controls). Previ-
ous flavivirus vaccination was rare: only one subject reported hav-
ing received a yellow fever vaccine.
3.3. Utility of case-control and test-negative design for risk factor
identification
In the CC study, only the 90 VCD cases with at least one
matched control were included in the analysis. Two variables
remained significant in the final model: respondents who reported
a recent household dengue contact (OR: 54; 95% CI: 7.3–397;
P < 0.001) and those reporting neighbourhood insecticidal fogging
in the last month (OR: 2.1; 95% CI: 1.3–3.6; P = 0.005) were associ-
ated with an increased risk of hospitalized dengue as compared to
subjects without household dengue contacts or neighbouring fog-
ging. In the TN analysis, no risk factors were identified. This might
be partially a result of the number of controls (n = 28), resulting in
imprecise estimates. No risk factors associated with severe VCD
could be calculated as the number of severe dengue cases was
too small (n = 7).
3.4. Dengue severity
Of the 124 hospitalized VCD cases, according to discharge diag-
noses 69 (55.6%) were dengue fever (clinically/serologically diag-
nosed); one (0.8%) was dengue fever (virologically confirmed); 53
(42.7%) were dengue with warning signs and one (0.8%) was severe
dengue. According to WHO 2009 criteria, classified from clinical
data, seven (5.6%) were severe, and 117 were non-severe. The
seven cases classified as severe presented with severe bleeding,
mainly epistaxis and gum bleeding, either at admission (4 subjects)
and/or during the hospitalization (3 subjects). The one case who
was additionally diagnosed as severe also presented with severe
plasma leakage. No severe organ impairment was observed.
3.5. Routine laboratory diagnosis of dengue
The most commonly-used dengue confirmatory test in routine
practice was the NS1 Ag RDT, in 148 (95.5%) of 155 suspected
cases, followed by the IgM RDT (110; 71.0%) and the IgG RDT
(109; 70.3%). The IgM ELISA, IgG ELISA and NS1 ELISA were used
in 45 (29.0%), 31 (20.0%) and 2 (1.3%) subjects, respectively. The
NS1 Ag RDT correctly identified 108 of the 118 VCD cases on which
the test was used, a sensitivity of 91.5% (95% CI 86.5–96.6%). How-
ever, 14 of 27 negative samples were incorrectly classified as pos-
itive, giving a specificity of 48.1% (29.3–67.0%). IgM rapid tests
correctly identified 8 out of 87 VCD cases, a sensitivity of 9.2%
(3.1–15.3%) and specificity of 81.0% (64.2–97.7%; correctly identi-
fying 17 of 21 negative cases). The IgM ELISA had a sensitivity of
47.2% (30.9–63.2%; 17/36 VCD cases positive) and specificity of
25.0% (0–55.0%; 2/8 negative cases correctly identified). The NS1
Ag ELISAmisclassified both VCD cases on which it was used as den-
gue negative (Table 2).
4. Discussion
We aimed to assess feasibility in recruitment, logistics and lab-
oratory confirmation of a traditional CC or TN design to evaluate
dengue vaccine effectiveness in Malaysia. The study also aimed
to assess biases, stemming primarily from the methods of control
recruitment and misclassification of disease and vaccine status
[34]. We considered that such an assessment was needed because
many of these aspects depend on the characteristics of specific
pathogens and healthcare systems and will therefore be different
for dengue than for other vaccine-preventable disease studies in
the past [26]. Primarily due to low levels of TN design control
recruitment and selection bias resulting in unbalanced case and
control populations in the CC study, it is likely that protocol
changes would be required before embarking on a hospitalized
dengue effectiveness evaluation. Selection bias in case control
selection could potentially be minimized whereas low recruitment
of TN design controls will likely persist in current healthcare set-
tings where dengue diagnoses prior to hospitalization are specific.
Key challenges and possible solutions are provided in Table 3.
4.1. Identified dengue risk factors
The exposures under assessment were a selection of socio-
demographic and behavioural risk factors which were generally
well-matched between cases and controls, and were therefore
not identified as risk factors in multivariable models. Two risk fac-
tors were identified with the CC method: living with household
members recently diagnosed with dengue (OR: 54), and neigh-
bourhood insecticidal fogging conducted in the last month (OR:
2.1). Biologically plausible explanations could explain these find-
ings: case-contacts may be more likely than other individuals to
become infected with dengue due to geographical clustering of
cases; [35] and it may be reasonable to suggest that insecticidal
fogging is directed towards outbreak-prone areas. Alternatively,
recall or reporting bias may be responsible: perhaps hospitalized
Table 2
Results (number of subjects) of diagnostic tests used in routine practice and confirmed VCD using the gold standard of PCR and/or NS1 ELISA; and resulting sensitivity and
specificities. RDT = rapid diagnostic test. ND = not done.
VCD
Test Result Positive Negative Sensitivity, % Specificity, %
NS1 Ag, RDT Positive 108 14 91.5 (86.5; 96.6) 48.1 (29.3; 67.0)
Negative 10 13
ND 6 1
IgM, RDT Positive 8 4 9.2 (3.1; 15.3) 81 (64.2; 97.7)
Negative 79 17
ND 37 7
NS1 Ag, ELISA Positive 0 0 – –
Negative 2 0
ND 122 28
IgM, ELISA Positive 17 6 47.2 (30.9; 63.5) 25 (0; 55)
Negative 19 2
ND 88 20
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dengue cases preferentially recall dengue episodes in household
contacts; are more likely to report fevers and thus become hospi-
talized because of recent dengue cases at home; and recall vector
control activities having been conducted in their communities
more readily than non-dengue controls. Reported rates of house-
hold dengue/recent fogging were higher in TN than case-controls,
providing evidence for reporting bias.
4.2. Recruitment challenges
We recruited a lower-than-expected number of suspected den-
gue cases and controls. This is partially associated with epidemiol-
ogy: Malaysia reported 20,000 fewer dengue cases in 2017 than
in preceding years [36]. But even those hospitalized dengue cases
were often ineligible for study inclusion, for a number of interre-
lated reasons associated with local care-seeking and hospitaliza-
tion practices. Some suspected cases were monitored as
outpatients within the emergency department but were never
admitted; others were admitted after >5 days of fever due to late
care-seeking or hospital referral; and a proportion of subjects
and/or their parents declined to participate in the study. Local eth-
ical committee regulations stating that parents must provide birth
certificates at study enrolment were particularly challenging to
satisfy. Scheduled laboratory operating hours resulted in loss of
potential cases, particularly on Friday afternoons or weekends
when clinical samples could not be processed. To remedy this,
we relaxed inclusion criteria, enrolling subjects with onset of fever
7 days. This change is not aligned with WHO guidance on dengue
confirmation; [4] it was included for exploratory purposes only,
and yielded few additional cases during the short period in which
it was implemented.
For each VCD case we also failed to recruit two matched case-
controls. Our study enrolled adolescents, teenagers and young
adults, a healthy demographic unlikely to be hospitalized in Malay-
sia. Additionally, the logistics of identifying suitable controls
within large, complex hospitals was challenging, resulting in
over-sampling from some wards in which eligible controls were
likely to be found (e.g., gynaecology/orthopaedic surgery). Perhaps
the age- and geographical matching used here should be relaxed in
the future; or alternative methods of control selection, including
recruiting community-based controls, could be considered. Such
an approach may facilitate age-matching but would be labour-
intensive for study teams. Because virological confirmation rates
were high and also to reduce potential bias, it may be beneficial
to recruit controls immediately following suspected case enrol-
ment to better-match on exposure risk which may vary over time.
For the TN study, recruitment of controls was low because a
higher-than expected (80% vs. 70%) proportion of suspected cases
was VCD. This may be due to clinical expertise and familiarity with
dengue in Malaysia and/or frequent use of RDTs in Malaysian clin-
ics and emergency departments, and subsequent decisions to
admit based on their results. Indeed, 95.2% of VCD cases had
received an NS1 Ag RDT as part of their routine care; and 87% of
VCD cases had a positive NS1 Ag RDT result. The frequency of
pre-admission testing and subsequent hospitalization are likely
influenced by epidemic activity, availability of RDTs at health facil-
ities and hospital congestion, effects which have been shown to
introduce bias to TN studies of influenza vaccines.[37] The propor-
tion of suspected cases testing negative is also likely to vary across
time and study setting, requiring conservative sample size esti-
mates in future studies. Probably, a TN study would only be effi-
cient if a higher proportion of suspected cases tested negative,
perhaps by using a less specific case definition, and/or enrolment
at an earlier stage of the treatment pathway and before full clinical
assessment, for example in the clinic before RDTs are used, with a
follow-up to assess severity and hospitalization at a later time-
point. This approach would be less specific and require a larger
sample to capture the same number of outcomes.
4.3. Impact of disease severity and routine clinical practice
The efficacy of dengue vaccination varies according to disease
severity, and vaccination has been shown to increase the risk of
hospitalized dengue in seronegative vaccine recipients [8,38]. It
is therefore likely that effectiveness studies should capture severe
disease outcomes and we considered this an indicator of study
Table 3
Requirements for a dengue vaccine effectiveness study; challenges encountered and potential remedies.
Study requirement Challenge encountered Potential remedies
Sufficient sample size and
characteristics of cases
Few hospitalized suspected dengue
cases
- Increase number and/or range of study sites (e.g., include emergency department)
- Assess and improve enrolment mechanisms
- Assess local ethics administrative requirements and incorporate mechanisms to
ease enrolment
Few severe dengue cases - Recruit retrospectively using stored serum samples and/or medical records
- Assess and improve enrolment mechanisms
Sufficient number of case-controls
and test-negative controls
Few case-controls recruited - Consider community-based control recruitment (family members; neighbours;
etc.)
- Assess logistics of hospital-based recruitment during site selection
- Relax matching criteria based on expected exposure status
Few test-negative controls recruited
due to high confirmation rates in
suspected cases
- Enrol suspected cases prior to use of rapid tests
- Recruit from primary health centres or otherwise earlier in the patient pathway
- Recruit TN controls separately from routine clinical practice with a follow-up to
assess severity/hospitalization
Exposure history (e.g., exposure to
risk factors under study) of
controls representative of source
population of cases
Duration between case and control
recruitment may introduce bias in
exposure (during a vaccination
campaign; or if vaccination increases
during an outbreak)
- Enrol controls immediately after identification of suspected cases
- Consider community-based control recruitment (family members; neighbours;
etc.)
- Improve laboratory test turnaround time
Females over-represented as controls
in CC design which could bias results
if vaccination rates are unequal
- Match controls on sex
- Recruit from alternative hospital wards
Controls have similar outcome risk
(e.g., reporting to study site with
hospitalized dengue) as cases
Severity of conditions suffered by
case-controls may have differed from
hospitalized dengue
- Assess impact of using different control populations
- Make changes to study enabling test-negative design after assessing misclassifica-
tion bias arising from imperfect confirmatory diagnostics
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feasibility. Here, only seven cases had symptoms of severe dengue.
This may be associated with changing dengue epidemiology in
Malaysia, the cyclical nature of outbreaks or, perhaps more likely,
due to challenges in recruiting subjects from intensive care units or
who are otherwise clinically severe. This represents an important
study bias, confining analysis to milder cases and prohibiting effec-
tiveness estimation against severe outcomes which may be of par-
ticular relevance for policymakers and in whom vaccine
performance may differ. A study design should consider this bias
– perhaps by retrospective testing of stored biological specimens
after recovery or death of severe cases, for example, or by design-
ing streamlined methods of enrolment of severe patients.
Rates of confirmatory diagnostics used in routine clinical prac-
tice were variable and of inadequate sensitivity/specificity to con-
clude on infection status. This was most concerning for the NS1
Ag RDT which is most-commonly used in Malaysia and displayed
specificity much lower than reported elsewhere (many false-
positive results) [39]. This low specificity could be caused by
false-negative results in the reference assays but we have no evi-
dence of operational failings in sampling, specimen collection and
shipment. RT-PCR is considered the gold-standard. This study was
not designed specifically to assess diagnostic test performance
and subjects are not representative of the full spectrumof suspected
dengue cases in Malaysia. Nonetheless, the observation deserves
additional investigation, for example via clinical assessment of dis-
cordant cases; or programmatic evaluation of RDTs in the field.
4.4. Potential biases identified
CC studies are vulnerable to a number of biases, most notably
due to challenges in control selection [34,40]. Our approach was
to use hospitalized controls, matched to cases and recruited within
a similar time window. Hospitalized dengue is a rare outcome and
in this scenario, resulting ORs approximate the rate/risk ratio [40].
To minimize bias, controls should represent the population at risk;
and should be selected independent of the exposure of interest
[41]. Important biases may therefore arise if family dengue history
or community fogging – rates of which were elevated in cases over
controls – led to the decision to vaccinate. In such a scenario the
case-control population would have lower vaccination exposure
rates than cases, under-estimating the protective effects of vacci-
nation. Consideration of this and other related biases deserves fur-
ther assessment when patterns of dengue vaccine distribution
after launch are better-understood, including by verifying the
accuracy of patient-reported data with family members or public
health authorities to limit recall bias. We similarly observed gen-
der differences between cases and controls, perhaps caused by
the wards used for control identification. This may constitute a bias
because the sex-distribution of dengue in Malaysia is not equal
[27]. Matching controls to cases based on sex may be advisable
in the future.
We considered virological, rather than serological confirmation
essential to avoid misclassifying vaccinated controls as cases due
to false-positive serological test results [42]. However we cannot
exclude misclassification of cases as non-cases due to lack of sen-
sitivity of PCR/NS1 Ag ELISA, which we considered the gold-
standard assays. We also only enrolled subjects reporting 5 days’
fever in whom viremia and NS1 Ag circulation is most likely [4].
Modelling experiments indicate that misclassification in outcome
can constitute a significant source of bias, particularly in TN studies
and under relatively extreme diagnostic test sensitivity/specificity
scenarios, depending on vaccination coverage rate and other
parameters. It may therefore be prudent in future, if practical, to
minimize this bias by restricting TN control enrolment to those
with confirmed alternative discharge diagnoses. We have no data
on exposure misclassification because dengue vaccination is not
practiced in Malaysia, but we expect recollection of dengue vacci-
nation history to be good and the potential bias to be modest.
4.5. Limitations
This study was conducted in three sites in Malaysia over only
one year. Results should be generalized only in the context of local
epidemiology and treatment practices. Lower-than expected
recruitment led to frozen samples being stored for 6 weeks for
shipment but we do not anticipate an adverse impact on results.
Our difficulty in recruiting matched hospitalised controls resulted
in low statistical power which may have prevented identification
of risk factors, an effect difficult to describe because strong socio-
demographic risk factors for hospitalized dengue are unknown.
Practical limitations also led to lower-than-possible recruitment.
5. Conclusions
It is likely the TN design would not be efficient for a dengue vac-
cine effectiveness study in Malaysia unless a less-specific endpoint
were used to recruit subjects, enabling recruitment of higher num-
bers of TN controls. The CC method, with adjustments to methods
of control recruitment,may be feasible: we recruited 124 confirmed
dengue cases, an approximate minimum sample size. However,
there is a risk of significant bias and a full bias assessment after vac-
cination patterns are better-understood would be needed. Case-
basedmethodswith retrospective ascertainment of vaccination sta-
tushave limitations. The feasibility of population-based/community
evaluation methods should be explored to assess VE according to
serostatus prior to vaccination; and measure herd immunity.
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Abstract
Background: Comprehensive, age-stratified dengue surveillance data are unavailable from India and many more
dengue cases occur than are reported. Additional information on dengue transmission dynamics can inform
understanding of disease endemicity and infection risk.
Methods: Using age-stratified dengue IgG seroprevalence data from 2556 Indian children aged 5–10 years, we
estimated annual force of infection (FOI) at each of 6 sites using a binomial regression model. We estimated the
ages by which 50 and 70% of children were first infected; and predicted seroprevalence in children aged 1–10 years
assuming constant force-of-infection. Applying these infection rates to national census data, we then calculated the
number of primary dengue infections occurring, annually, in Indian children.
Results: Annual force-of-infection at all sites combined was 11.9% (95% CI 8.8–16.2), varying across sites from 3.5%
(95% CI 2.8–4.4) to 21.2% (95% CI 18.4–24.5). Overall, 50 and 70% of children were infected by 5.8 (95% CI 4.3–7.9)
and 10.1 (95% CI 7.4–13.7) years respectively. In all sites except Kalyani, > 70% of children had been infected before
their 11th birthday, and goodness-of-fit statistics indicated a relatively constant force-of-infection over time except
at two sites (Wardha and Hyderabad). Nationwide, we estimated 17,013,527 children (95% CI: 14,518,438- 19,218,
733), equivalent to 6.5% of children aged < 11 years, experience their first infection annually.
Conclusions: Dengue force-of-infection in India is comparable to other highly endemic countries. Significant
variation across sites exists, likely reflecting local epidemiological variation. The number of annual primary infections
is indicative of a significant, under-reported burden of secondary infections and symptomatic episodes.
Trial registration: Registered retrospectively with clinicaltrials.gov (NCT01477671; 18/11/2011) and clinical trials
registry of India (ctri.nic.in; CTRI/2011/12/002243; 15/12/2011). Date of enrollment of 1st subject: 22/9/2011.
Keywords: Dengue, Endemic diseases, Flavivirus, India, Infection, Seroepidemiologic studies
Background
Dengue has become hyperendemic in many parts of India [1,
2]. The disease is being reported from an increasing number
of states, and the number of cases reported to the National
Vector Borne Disease Control Program (NVBDCP) has been
increasing over recent years. In 2010, the incidence of re-
ported dengue was 2.3 cases per 100,000 individuals,
increasing to 11.7 per 100,000 in 2017 [3]. In 2016, for the
first time, more than 100,000 cases were reported (total: 129,
166 with 245 deaths). However, reported cases represent only
the tip of the iceberg, and the true disease burden is likely
significantly higher [4]. Mild cases are particularly susceptible
to under-reporting [5]. Notably, a global cartographic model-
ing study by Bhatt et al. provided comprehensive global den-
gue burden estimates, and projected > 32 million cases in
India in 2010 [6]. A complementary study by Stanaway and
colleagues from the Institute for Health Metrics and Evalu-
ation, using verbal autopsy, vital registration and surveillance
data estimated 18.6 million cases in 2013 [7]. A local estimate
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focusing on the city of Chennai (population of 4.7 million)
used seroprevalence data to estimate 89,700 new infections
and 138,100 secondary infections every year [8]. This distinc-
tion is important because dengue has four serotypes; and sec-
ond infections are more commonly severe [2].
In the absence of incidence data including cases which
were not recognized as dengue and those who did not
access healthcare, seroprevalence data provide an alter-
native indicator of transmission intensity. [9] Seropreva-
lence describes historical infection and, when derived
with standardized diagnostics, is a relatively unbiased in-
dicator of viral exposure when compared with surveil-
lance data. Age-stratified surveys provide data from
which one can derive force of infection (FOI) estimates
and therefore understand the infection rate [10, 11]. Un-
derstanding endemicity is important for a wide range of
public health decision-making and, given that the world’s
first dengue vaccine’s efficacy is associated with baseline
serostatus, population level seroprevalence is an important
predictor of population-level vaccine impact [12].
In India, as elsewhere, few studies have documented
the seroprevalence of dengue in healthy subjects. In the
earliest, Padbidri et al. measured exposure to various ar-
boviruses, including dengue serotype-2, in the Andaman
and Nicobar Islands. This 1988–89 study found 25.4% of
subjects with neutralizing antibodies against dengue
type-2 [13]. More recently, Oruganti et al. examined the
presence of antibodies in healthy individuals attending
routine health check-ups in Hyderabad, Andhra Pradesh
by indirect IgG ELISA [14]. They found 89.5% of subjects
aged 19 to 70 years of age were seropositive for dengue:
100% of those 40 years of age or older had seroconverted.
In another community-based study Rodriguez et al. esti-
mated seroprevalence in 5–40 year old healthy subjects in
2011 in Chennai [8] They demonstrated that 93% of sub-
jects in this age group had been exposed to dengue at least
once in their lifetime, a level of exposure which was con-
sistent with long-term endemic circulation.
We previously published results of a community-based
multi-centric, cross-sectional study (DNG10) on dengue
seroprevalence in Indian children aged 5–10 years
(CTRI/2011/12/002243 and NCT01477671) [15]. The
study was conducted at 8 sites in 6 distinct urban and
rural areas in 2011–12. Overall seroprevalence was
59.6% and increased with age. We also described mono-
typic serological profiles demonstrating that all four den-
gue serotypes circulate in India.
No previous analysis has assessed dengue FOI and its
variability across multiple Indian sites. Here, we con-
ducted a secondary analysis to estimate dengue FOI in
healthy children in different geographic regions of India.
In combination with census data, this enabled estimation
of the number of primary dengue infections occurring
annually. We also predicted seroprevalence in children
aged 1–10 years of age and the ages at which 50 and
70% of children have experienced at least 1 dengue in-
fection, to inform vaccination policy.
Methods
Ethics statement
As this was secondary analysis, no additional ethical ap-
provals were needed. Details of ethical approvals for the
original study are provided in Garg et al. [15].
Source of dengue seroprevalence data
DNG10 was a dengue seroprevalence study which col-
lected blood samples from children aged 5–10 years old
between January 2011 and October 2012. There were 8
sites across 6 districts spread over India (two nearby
sites each from Delhi and Hyderabad; and one site each
from Kalyani, Wardha, Mumbai and Bangalore), which
have been described before [15]. Briefly, a convenience
sample of children was drawn from the community by
household visits (6 sites) or school visits (2 sites). Com-
munity health workers obtained informed consent and
drew blood samples. The presence of anti-dengue IgG
antibodies was measured using one of two commercial
ELISA (Focus Diagnostics, California, USA and Panbio
Diagnostics, Brisbane, Australia) whose performances
were shown to be concordant [15]. We performed a re-
analysis of data from this original study after pooling
data from the two Delhi and Hyderabad sites, assuming
that populations in these sites were exposed to a similar
risk of infection because of their geographical proximity
(within a few hundred meters).
Force of infection and seroprevalence estimates
Dengue serostatus was considered a binary outcome
variable, described by the IgG ELISA test result for each
subject and assuming seroconversion is non-reversible.
Assuming constant FOI over this 6-year age group, we
estimated FOI (λ) using a catalytic model which predicts
an increase in the proportion of seropositive individuals
with age: [10, 16].
pa ¼ 1−e−λa
where pa is the proportion seropositive at age a. We es-
timated λ using a binomial regression model with a
complementary log-log link, including seropositivity as
the outcome variable and the natural logarithm of age as
an offset, a parametrization in which the constant equals
the log of average FOI [16, 17]. Separate estimates were
made for each site; and for all sites combined. Clustering
both at the national level, and for Delhi and Hyderabad
where two sites were combined, was accounted for by
relaxing the assumption of independence of observations
within groups and generating robust standard errors.
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Seroprevalence and its 95% confidence intervals for chil-
dren aged from 1 to 10 years old were estimated from
FOI using the formula above. We estimated the ages “a”
at which prevalence “P” was 0.5 and 0.7, and their confi-
dence intervals, using the same formula and by replacing
“λ” with the estimated constant FOI from each site. The
six years of age groups of observed seroprevalence data
were grouped into 12, 0.5 year age categories. Mean
seroprevalence for each group was graphed over the esti-
mated seroprevalence, as shown in Fig. 1.
Force of infection and seroprevalence estimates
Based on Indian 2011 census data [18] and estimated an-
nual seroconversion rates, we estimated the number of
children aged < 11 years experiencing a primary dengue
infection in 2011, assuming constant FOI from 2002 to




Where, δa represents the total size of the Indian popu-
lation aged a years; and pa is the proportion of the
population seropositive by age a years.
Assessment of model fit
In our model, we assumed a constant force of infection.
Goodness of fit was assessed by the Hosmer-Lemeshow
test [19]. The predicted probabilities of being seropositive
and seronegative were calculated for each individual and
the data were grouped into deciles. The expected number
of events, calculated as the sum of the predicted probabil-
ities, was compared with observed events. Pearson’s chi-
squared test was applied to test the null hypothesis that
the observed data approximates the fitted model under an
assumption of constant FOI, with a p-value of > 0.05 ap-
plied to define an acceptable fit.
All analyses were conducted with Stata version 15.0
(Stata Corporation) and Microsoft Excel.
Results
Demographics of study subjects and observed
seroprevalence
In total, the analysis included data from 2556 subjects,
with between 301 and 649 children per site, with approxi-
mate equal age distributions (Table 1, see Additional file 1
for detailed age distributions). 52.6% of the subjects were
female and the mean age of participants was 7.8 years (SD
1.6 years) with a range 5.0–10.0 years.
Estimated force of dengue infection
The overall annual FOI for all sites combined was 11.9%
(95% CI 8.8–16.2%). It varied from a low of 3.5% (95%
CI 2.8–4.4%) in Kalyani, West Bengal, to 21.2% (95% CI
18.4–24.5%) in Mumbai, Maharashtra (Fig. 1). Assuming
constant FOI, the ages by which 50 and 70% of children
were first infected were lowest in Mumbai, 3.3 and 5.7
years respectively (Table 2). In Kalyani FOI was
Fig. 1 Estimated seroprevalence (red lines), 95% confidence intervals (shaded areas) and observed seroprevalence (circles)*. *hollow circles
indicate observed seroprevalence as measured in original study, divided into 6-month age categories [15]
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sufficiently low that we predicted < 50% of children would
have been infected by the age of 11. For other sites, the
median age of infection was between 3.3 and 6.0 years;
70% of children were estimated to have been infected by
between 5.7 and 10.4 years of age. In the study population
overall, 70% of children were estimated to have been in-
fected at least once by the age of 10.1 years. Model good-
ness of fit as assessed by the Hosmer-Lemeshow test was
acceptable for all sites except Wardha (P-value: 0.03),
Hyderabad (P = 0.01) and for India overall (P = 0.01).
Estimated number of primary dengue infections
In 2011, India had a population of ~ 260,000,000 chil-
dren aged < 11 years. We estimate that in 2011 17,013,
527 (95% CI 14,518,438 – 19,218,733) children aged up
to 10 years – 6.54% of the total population within this
age group – were infected with dengue for the first time
(see Additional file 2).
Discussion
We conducted a secondary analysis of dengue seropreva-
lence data from pediatric populations in India. We found
that among dengue-naïve children, 11.9% experience
their first dengue infection every year. This means that
50% of children at these sites are infected by dengue at
least once by the age of 5.8 years, and 70% of them are
infected by the age of 10.1 years, although there was sig-
nificant variation in FOI between sites. Our study was
not the first to report estimates of dengue FOI in Indian
populations. Imai et al. used data from 1988 to 89 to
estimate FOI of 0.2% (95% CI: 0.1–0.7%) in the Anda-
man and Nicobar Islands [11, 13]. Rodriguez et al. esti-
mated that the dengue FOI in Chennai from 2004 to
2011 was 23% (95% CI: 16–30%) [8]. The Andaman and
Nicobar Islands are a unique geography; that study de-
tected antibodies against only one of the four serotypes
of dengue (dengue serotype- 2), and was conducted at a
time when dengue endemicity was probably much lower
than today. Rodriguez et al. sampled probabilistically from
Chennai and found high FOI in pediatric populations. We
identified similar FOI from Mumbai, a city with similar
ecological conditions: both are coastal with similar ranges
of temperature and high levels of unplanned infrastruc-
ture, construction sites and slum housing.
We assumed these sites experienced constant FOI for
the 5 years prior to sample collection, representing the
time period when study subjects were infected. A differ-
ent approach would consider FOI to be time-varying, in
which constant FOI is assumed only for a certain period
[9]. Our assumption is broadly consistent with other
studies that have found age-constant models adequately
describe age-related seroprevalence data over a 6–9 year
time horizon [8, 10]. The goodness-of-fit of our constant
model provided some evidence that our assumption of
constant FOI is valid for four of our six sites, but to
more completely explore age-varying FOI, data from a
larger age range of subjects would be needed. Further, a
visual inspection of Fig. 1 suggests some deviation be-
tween the modelled values and the observed data espe-
cially at more extreme ages. This may be due to cyclical
Table 1 Number of subjects, mean age and overall seroprevalence by site [15]
Site name Number of subjects enrolled Mean age in years (standard deviation) Seroprevalence (%)
(95% CI)
Delhi (for 2 sites) 649 8.0 (1.7) 63.3 (59.6–67.0)
Kalyani 323 7.6 (1.4) 23.2 (18.7–28.2)
Wardha 323 8.0 (1.7) 69.0 (63.7–74.0)
Mumbai 301 8.0 (1.5) 80.1 (75.1–84.4)
Hyderabad (for 2 sites) 639 7.8 (1.6) 58.4 (54.5–62.2)
Bangalore 321 7.5 (1.5) 62.6 (57.0–67.8)
Total 2556 7.8 (1.6) 59.6 (57.7–61.5)
Table 2 Annual FOI, goodness-of-fit statistics; and the ages by which 50 and 70% of children seroconverted
Site Annual FOI,
% (95% CI)
Goodness of fit Chi2
statistic; P- value
Age of 50% population
seroconversion, years (95% CI)
Age of 70% population
seroconversion, years (95% CI)
Delhi (2 sites) 12.9 (11.1–15.0) 2.96; 0.94 5.4 (4.6–6.2) 9.3 (8.0–10.8)
Kalyani 3.5 (2.8–4.4) 4.72; 0.79 > 11 > 11
Wardha 15.4 (13.4–17.7) 16.9; 0.03 4.5 (3.9–5.2) 7.8 (6.8–9.0)
Mumbai 21.2 (18.4–24.5) 12.8; 0.12 3.3 (2.8–3.8) 5.7 (4.9–6.6)
Hyderabad (2 sites) 11.5 (11.2–11.8) 20.9; 0.01 6.0 (5.9–6.2) 10.4 (10.2–10.7)
Bangalore 13.2 (11.5–15.3) 10.2; 0.25 5.2 (4.5–6.0) 9.1 (7.9–10.5)
All sites combined 11.9 (8.8–16.2) 20.4; 0.01 5.8 (4.3–7.9) 10.1 (7.4–13.7)
Bhavsar et al. BMC Public Health         (2019) 19:1116 Page 4 of 6
dengue outbreaks in the respective geographies. For ex-
ample, there were documented outbreaks in Mumbai in
2003, and in Wardha and Hyderabad in 2004 [20–22].
Children were disproportionately affected in Mumbai
and Wardha which might provide an explanation for
outliers in our observations i.e. higher seroprevalence in
older children at these sites.
Similar dengue FOI has been estimated from sero-
prevalence data from dengue hyperendemic Southeast
Asian countries. Prayitno et al. estimated the FOI in 1–
18 year old Indonesian children in 2014 to be 14.0%
[23]. Imai et al. estimated FOI in Thailand using data
from 2000 to 01 in school children to be 15.7% [11].
Using 2008–09 data in children under 12 from Col-
ombo, Sri Lanka, Tam et al. estimated the FOI to be
14.1% [10]. Consequently, and because reported dengue
incidence rates in India are so low, we calculated the
resulting number of primary dengue infections, estimat-
ing > 17 million primary infections in India, annually.
Other researchers have estimated between 30 and 50%
of primary infections are symptomatic [24] which would
equate to ~ 5 – ~ 8.5 million cases annually in children
aged < 11. When considering cases in other age groups,
and following secondary or subsequent infections; these
case numbers are broadly within the same range as those
reported in Bhatt et al., that India suffers ~ 35 million
symptomatic episodes per year, and provide additional
evidence of a very significant level of under-reporting of
dengue in India [6]. More detailed estimates of symp-
tomatic episodes are limited by our lack of secondary in-
fection history data; and more complex mathematical
modeling was beyond the scope of our study.
This is the first study to estimate FOI in India using
data from multiple geographies; urban and rural, and
from multiple states. Our results point towards a high
dengue FOI in children in India, which logically equates
to a significant number of secondary infections and bur-
den of symptomatic disease in this age group. With im-
proved surveillance, we may begin to see incidence rates
of dengue in India comparable to those seen in other hy-
perendemic countries. Longitudinal cohort studies,
ideally incorporating fever surveillance and serological
surveys, to more accurately describe the incidence of
dengue and changing infection patterns with age, are
needed [25].
Our study has several limitations. The original sero-
prevalence samples were collected in 2011–12 and the
FOI we have derived corresponds to cumulative expos-
ure experienced by study subjects in the years of their
life before this time. Numbers of reported cases of den-
gue in India have increased significantly from 2011. [3]
This can be attributed to several factors including popu-
lation movement and increased exposure to the virus;
improved dengue surveillance, increasing awareness
among healthcare practitioners, availability of confirma-
tory diagnostics and improvement in access to health-
care resulting in increased reporting [4, 26]. As
demonstrated by Rodriguez et al.in Chennai, it is also
very likely that FOI has increased in India over recent
decades [8]. Despite their geographical spread, study
sites were not sampled to be representative of the whole
of India and our extrapolation to the national level is a
strong assumption which should be validated with more
recent data from other sites. DNG10 also used conveni-
ence sampling for enrollment of subjects, a method
which does not guarantee representativeness. We used
IgG ELISA to ascertain infection history, an assay with
known cross-reactivity to antibodies against other flavi-
viruses. However, dengue infection was confirmed by the
plaque reduction neutralization test (PRNT) and > 97%
of IgG positive samples were also positive by PRNT.
Further, Japanese encephalitis (JE) seropositivity mea-
sured at the study sites using IgG ELISA, was 13.6%
overall and with a similar trend at the site level as
dengue seroprevalence (data not shown). Its confounding
influence is therefore likely to be minimal. Because IgG
ELISA is unable to distinguish primary from secondary in-
fections we measured only the rate of primary seroconver-
sion, and are unable to quantify the burden of secondary
and subsequent dengue infections.
Conclusions
We demonstrate high dengue FOI in multiple Indian
settings. Observed variations are likely reflective of den-
gue epidemiological variation in different parts of India.
These data may be used for benchmarking the dengue
endemicity in other areas in India, and to allow compari-
sons based on other epidemiological indicators.
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Dengue Endemicity, Force of Infection, and Variation in 
Transmission Intensity in 13 Endemic Countries
Joshua Nealon,1,  Alain Bouckenooghe,2 Margarita Cortes,3 Laurent Coudeville,1 Carina Frago,2 Denis Macina,1 and Clarence C. Tam4,5,6 
1Vaccines Epidemiology and Modeling, Sanofi Pasteur, Lyon, France, 2Global Clinical Sciences, Sanofi Pasteur, Singapore, Singapore, 3Global Clinical Sciences, Sanofi Pasteur, Bogota, Colombia, 
4Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, 5National University Health System, Singapore, Singapore, and 6London School of Hygiene and 
Tropical Medicine, London, United Kingdom
Dengue endemicity varies but comparative, multicountry data are extremely limited. An improved understanding is needed to 
prioritize prevention, including vaccination, which is currently recommended only under specific epidemiological conditions. We 
used serological study data from 46 geographical sites in 13 countries to estimate dengue force of infection (FOI, the proportion 
of children seroconverting per year) under assumptions of either age-constant or age-varying FOI, and the age at which 50% and 
80% of children had been infected. After exclusions, 13 661 subjects were included. Estimated constant FOI varied widely, from 
1.7% (Singapore) to 24.1% (the Philippines). In the site-level analysis 44 sites (96%) reached 50% seroconversion and 35 sites (75%) 
reached 80% seroconversion by age 18 years, with significant heterogeneity. These findings confirm that children living in dengue-
endemic countries receive intense early dengue exposure, increasing risk of secondary infection, and imply serosurveys at fine spatial 
resolutions are needed to inform vaccination campaigns.
Keywords.  dengue; epidemiology; seroprevalence; vaccines; endemicity; infectious disease transmission.
Dengue viruses infect approximately 400 million people annu-
ally at frequencies that vary according to environmental, eco-
logical, and behavioral factors [1, 2]. Disease burden estimates 
have historically been unreliable but more recent studies using 
more comprehensive data synthesis and systematic methods 
estimate that dengue viruses likely result in 24–130 million 
symptomatic episodes, 10 000–50 000 deaths, and costs of US 
$4–19 billion, annually [2–4]. Dengue represents a significant 
source of morbidity in affected regions and 50% of the global 
population is at risk of infection, with local variations caused 
by geographical, microclimatic, and ecological factors at the 
subnational and local levels [2, 5, 6].
Following infection, the likelihood of suffering mild or more 
serious symptoms depends on immunological or other factors 
that predispose individuals to more severe disease, particu-
larly during chronological and/or immunological windows of 
enhancement caused by antibody-dependent enhancement 
or other mechanisms arising from infection with heterolo-
gous viral serotypes [7–9]. The risk of suffering a symptomatic 
episode is therefore a complex function of ecological and immu-
nological factors with time-varying risk windows, determined 
by the underlying transmission intensity. A  result is that the 
age distribution of symptomatic dengue disease is dependent 
on the epidemiological setting, with more intense transmission 
resulting in a younger median age of cases [10]. Infection fre-
quency may be constant or may be shaped by individual events 
such as outbreaks or changes in human behavior that affect the 
risk of exposure [11].
Because most dengue infections are asymptomatic, prospective 
measurements of infection rates require longitudinal studies with 
blood samples at multiple time points, which are resource inten-
sive and generally conducted in single study sites with limited geo-
graphical representativeness [12]. However, dengue seroprevalence 
at a given age is an alternative measure of endemicity, which can 
be measured relatively efficiently from age-stratified cross-sec-
tional surveys [13]. Assuming transmission intensity is constant 
over time, the rate at which seroprevalence increases with age can 
provide a measure of the force of infection (FOI) or the rate at 
which susceptible (seronegative) individuals acquire infection [14]. 
Under assumptions of constant or varying endemicity, FOI can be 
used to estimate seroprevalence at a given age, an approach which 
can complement empirical seroprevalence measurements [15, 16].
Reliable estimates of age-stratified dengue seroprevalence 
are particularly important when considering immuniza-
tion, because the efficacy of the world’s first dengue vaccine 
(CYD-TDV, Dengvaxia; Sanofi Pasteur) is dependent on an 
individual’s infection history [17]. World Health Organization 
(WHO) guidelines recommend vaccination only after indi-
vidual screening for dengue antibodies or, if this is not feasible, 
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where seroprevalence in 9  year olds exceeds a threshold of 
80% [18]. Dengue seroprevalence is therefore an important 
determinant of the impact and cost-effectiveness of dengue 
vaccination.
Here, we used age-stratified dengue seroprevalence data 
from healthy children in 13 countries involved in dengue vac-
cine clinical trials and epidemiological studies to describe 
dengue endemicity across a wide range of geographical regions, 
using FOI as an indicator. We estimated the age at which se-
roprevalence reached 50% and 80% in countries overall and at 
each of 46 geographically distinct sites, to inform the feasibility 
and optimum age for efficient dengue vaccination strategies, 




This is a secondary analysis of anonymized data. Ethics 
approval for analyses and publication of study data 
were secured from relevant ethical committees prior to 
the collection of any data (all approval numbers are in 
Supplementary Table 1).
Study Design
We analyzed data from cross-sectional, age-stratified se-
rological surveys in 13 countries collected over 6  years. 
Data and blood samples originated from baseline measure-
ments of clinical trials before any vaccine or placebo were 
administered, or from dedicated cross-sectional seropreva-
lence surveys.
Study Population
Eligible subjects were participants in Sanofi Pasteur dengue 
vaccine clinical trials or epidemiological studies, which col-
lected dengue serological data from healthy, asymptomatic, 
unvaccinated individuals (Table  1). Enrollment methods in 
these studies varied and included investigators directly re-
cruiting subjects under their care or following informational 
events at primary health care centers, schools, or community 
centers, depending on the local health care system and com-
munity organization. For phase 2b or phase 3 vaccine efficacy 
studies, which provided 29% of data, subjects were typically re-
cruited following school-based (in Asia) or community-based 
(in Latin America) meetings held in proximity to participating 
hospital study sites, during which parents were informed 
about upcoming dengue vaccine studies and implications of 
participating [19, 20]. Recruitment for epidemiological studies, 
which provided approximately 42% of data, was conducted at 
multiple sites selected to provide geographical variability across 
countries. After school/community educational events, families 
wishing to participate presented to local health care facilities for 
recruitment [21, 22]. The remaining subjects were enrolled in 
earlier-phase clinical trials and were typically recruited directly 
from medical facilities by study investigators.
Data from all studies were combined into a single data-
base and categorized according to the geographical district 
Table 1. Site Description and Data (Country-Level Analysis)
Country Sites
No. of 





India Delhi, Pune, Ludhiana, Bangalore, West Bengal,  
Wardha, Mumbai, Hyderabad
8 CYD47,a DNG10b 2562 5–18.7 Jan 11 Oct 12
Indonesia Bali, West Java, Jakarta, Aceh, North Sumatera,  
West Sumatera, Jambi, Lampung, Banten,  
Central Java, East Java, East Kalimantan, 
South Sulawesi, Southeast Sulawesi
14 CYD14,c DNG26b 3539 1–18.9 Jun 11 Nov 14
Malaysia Kuala Lumpur, Penang, Ipoh (Perak), Seremban  
(Negeri Sembilan), Kuching
5 CYD14,c CYD32a 547 2–14.8 Dec 10 Sep 11
Philippines San Pablo (Region IV-A) 1 CYD08,a CYD14a 820 0.9–14.9 Jan 10 Jul 11
Singapore Singapore 1 CYD28a 384 2–18 Apr 09 Oct 09
Thailand Ratchaburi, Kamphaeng Phet 2 CYD14,c CYD23c 637 2–14.8 Feb 09 Nov 11
Vietnam Long Xuyen (An Giang), My Tho (Tien Giang) 2 CYD14,c CYD22a 607 2–18.7 Mar 09 Oct 11
Brazil Nordeste, Espirito Santo, Goias, Mato Grosso Sud 4 CYD15,c CYD30a 450 8.9–16.9 Aug 10 Nov 11
Colombia Santander, Quindio, Cundinamarca, Meta,  
Casanare, Cali
6 CYD13,a CYD15,c 
CYD29a
1518 0.9–16.9 Oct 09 Mar 12
Honduras Tegucigalpa 1 CYD13,a CYD15c 455 9–16.9 Oct 09 Sep 11
Mexico San Luis, Veracruz, Morelos, Yucatan, Guerrero,  
Nuevo León 
6 CYD13,a CYD15,c 
CYD33a
1213 0.6–16.9 Nov 09 Jul 12
Peru Peru 1 CYD24,a CYD29a 671 0.9–11.9 Sep 08 Mar 12











ited user on 28 April 2020
Global Dengue Seroprevalence • jid 2020:XX (XX XXXX) • 3
or comparable administrative unit (hereafter, “site”) of each 
participating study center, on the advice of local Sanofi Pasteur 
staff with expertise on local geography. The analysis was re-
stricted to subjects aged 7 months to < 19 years on the day of 
blood sampling, as data on older subjects were limited and 
indicated minimal variation in seroprevalence in older age 
groups. A sensitivity analysis was conducted on the entire pop-
ulation aged > 7 months for India, Singapore, and Vietnam, the 
only countries where subjects > 19 years had been enrolled, 
to assess the impact of excluding older adults from the anal-
ysis. Data from areas that are not dengue endemic (Australia, 
United States, and Mexico City) and from subjects with incon-
clusive dengue serological results were excluded from analysis 
(Figure 1). A country-level analysis was followed by a site-level 
analysis, in which sites with < 10 subjects and those that en-
rolled only subjects aged < 2 years were removed.
Data Collection and Laboratory Analyses
Baseline serum samples, drawn before any vaccine was admin-
istered from both vaccine and placebo arm subjects of clinical 
trials, were collected between September 2008 and November 
2014 (Table  1). Dengue exposure for each subject was ascer-
tained in clinical trials by 50% plaque reduction neutralization 
test (PRNT50) with a lower limit of quantitation titer of 10 (re-
ciprocal dilution) as described previously [23]. For epidemio-
logical studies DNG10 and DNG26, serostatus was determined 
by IgG enzyme-linked immunosorbent assay (ELISA; Panbio 
and Focus Diagnostics); >97% of a positive subset were con-
firmed by PRNT50 providing confidence in the specificity of 
IgG ELISA assays [21, 24]. As the youngest subject was aged 
0.6 years, we assumed declining maternal antibodies had little 
or no impact on our analyses.
Statistical Methods
FOI was estimated using catalytic models in which seropreva-
lence is assumed to increase exponentially with age:
Pa = 1 − e−λa
Here, Pa is the seroprevalence at age a years, and λ represents 
FOI or the annual risk of seroconversion among initially sero-
negative individuals. The parameter λ can be estimated through 
a generalized linear model with complementary log-log link:
ln (− ln (1 − pa)) = ln (λ) + ln(a)
where the logarithm of each subject’s age is included as an offset 
with a coefficient constrained to 1.  This model implicitly as-
sumes that FOI is constant throughout the age range and that 
transmission intensity is stable over time.
FOI estimates were derived for each country and site with 
uncertainty described through generation of exact binomial 
95% confidence intervals (CIs). Intersite variability in countries 
Subjects from 23 studies 
n =  16 033
Subjects with dengue results from 
endemic areas n = 14 083
Country-level analysis:
13 661 subjects in 51 sites; 
in 13 countries 
Symptomatic cases (n = 126)
Nonendemic countries (n = 1462)
Non-endemic parts of Mexico (n = 247)
Dengue equivocal (n = 81) or no dengue 
tests done (n = 34)
Subject not aged 0–18 years, (n = 422)
5 sites with <3 age groups or <10 subjects 
included (n = 916)
Site-level analysis: 
12 745 subjects in 46 sites; 
in 13 countries
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with > 1 site was accounted for by generating robust standard 
errors, assuming sites were independent clusters.
To describe possible changes in FOI within large age strata, 
we also generated age-varying FOI estimates for specific age 
groups using linear piecewise models. We fitted log-binomial 
models with 2 age terms:
−ln(1 − Pa) = λ1a1 + λ2a2
For each study site, we determined the optimal age-varying FOI 
model by sequentially varying the age breakpoint for each whole 
year of data with at least 2 adjacent data points (eg, for countries 
with data starting in 3-year-old children the first possible break-
point was age 5 years) and identifying the model with the lowest 
value for Akaike’s information criterion. For each country, we de-
termined whether constant or age-varying models fit the data better 
by 10-fold cross-validation, taking a random 10% of the sample, 
and selected the model (constant or age varying) with lower root 
mean squared error. Seroprevalence by age, per country, was es-
timated from the resulting models. Graphs of estimated constant 
and age-varying seroprevalence were developed for each country, 
overlaid with observed seroprevalence and their 95% CIs grouped 
by year, using robust variance estimates for countries with > 1 site 
to account for clustering.
We estimated the age at which 50% and 80% (p = 0.5 or 0.8) of 
children seroconverted in each country and site from the optimal 
model for each site, using the following formula in case of constant 








All analyses were conducted using Stata version 15.0.
RESULTS
Dataset
Our database contained information from 16 033 subjects 
participating in 23 clinical trials and epidemiological studies. 
After exclusions, 13 661 subjects from 15 studies were eligible 
in 13 country-level analyses and 12 745 in 46 site-level analyses, 
with a mean of 268 subjects per site (Table  1 and Figure  1). 
Countries with the highest number of sites and subjects were 
Indonesia, India, Colombia, and Mexico. The range of subject 
ages was narrowest in Brazil (7.9 years) and widest in Indonesia 
(17.9 years).
Dengue Force of Infection
Under the assumption of constant FOI, dengue FOI varied be-
tween countries from a low of 1.7% (95% CI, 1.4–2.2) in Singapore, 
increasing to 24.1% (95% CI, 21.8–26.5) in the Philippines (Table 2). 
FOI was lower than 10% in Singapore, Mexico, Peru, and Puerto 
Rico. In most countries, constant and age-varying models predicted 
similar seroprevalence at most ages; constant models fit data better in 
8 countries (Table 2 and Figure 2). In all countries except India and 
Brazil, age-varying FOI was higher in younger children than older 
children, indicating a decreasing rate of first infection as children 
aged. The highest FOI estimates occurred in very young Filipino 
children, with an annual seroconversion risk of 43% up to the age 
of 2 years. Estimated dengue seroprevalence increased with age in 
all scenarios, except for the age-varying Singapore model where esti-
mated seroprevalence declined at age 4 years. In a sensitivity analysis, 
the impact of including adults aged > 19 years from India, Singapore, 
and Vietnam was minimal (constant FOI changed from 11.9 [95% 
CI, 8.7–16.2] to 11.5 [95% CI, 8.4–15.6]; 1.7 [95% CI, 1.4–2.2] to 
2.0 [95% CI, 1.7–2.3]; and 11.4 [95% CI, 10.2–12.8] to 11.4 [95% 
CI, 10.3–12.7], respectively). At the site level, the age-constant FOI 
was > 10% per year at 31 of 46 sites and constant models fit observed 
data better at 36 of 46 sites. FOI estimates at the site level are provided 
in Supplementary Table 2.
Age at 50% and 80% Seroconversion Thresholds
According to the best-fitting model, the estimated age at which 
50% of children had seroconverted was < 10 years in 12 of 13 
countries in our analysis; the youngest was in the Philippines 
(1.6 years; 95% CI, 1.4–3.1, Table 3). In Singapore, a seroprev-
alence of 50% was not reached within the range of our ob-
served data, by age 18 years (Table 2). An 80% seroprevalence 
threshold was reached by the age of 18 years in 10 countries, 3 of 
which reached this threshold by the age of 9 years (Philippines, 
Colombia, and Honduras).
Forty-six sites were included in the site level analysis. We es-
timated 80% of children had been infected by age 18 years (ie, 
within the range of our observed data) at 35 (76%) sites and by 
age 9 years at 14 (30%) sites (Figure 3). The youngest estimated 
age at which 80% of children seroconverted was 5.3 years, ob-
served at Casanare, in Colombia. At least 50% of children were 
estimated to have seroconverted by the age of 18  years at 44 
(96%) sites, and at all 15 sites in Latin America (Supplementary 
Figure 1). In Kalyani (West Bengal, India), median seropreva-
lence was not reached. Seroprevalence at age 9 was also high 
at other sites, notably across Indonesia (Supplementary Table 
2). Within countries, there was considerable variation between 
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DISCUSSION
We analyzed data from over 13 000 children to describe dengue 
transmission intensity at 46 geographically distinct, endemic 
sites in 13 countries in Asia and Latin America. Study subjects 
were in age groups likely to seroconvert, providing the neces-
sary variation in seroprevalence to estimate FOI. Dengue se-
rological status was confirmed with gold-standard diagnostics 
and consistent analyses were used to make comparisons across 
countries and sites.
Across the age ranges sampled, children at most sites were 
at high risk of dengue infection, with FOI exceeding 7% in all 
countries except Singapore. Countries with higher levels of 
transmission included the Philippines, Colombia, Honduras, 
Indonesia, and Thailand, in which ≥ 14% of seronegative 
children were infected each year. In these countries, intense 
dengue exposure results in a steep reduction in dengue-naive 
individuals early in life, providing a large pool of individuals 
at risk of secondary infection. While these data describe the 
force of primary (ie, first) dengue infections, these transmission 
intensities would translate, at the population level, to a signifi-
cant burden of secondary infections, which are more likely to 
be symptomatic and severe. Malaysia and Singapore had lower 
transmission than other Asian countries, which could be an in-
dication of improvements in dengue control measures.
Age-varying models were developed to assess whether clear 
variation in infection risk was observed as children aged. 
Strong evidence for this variation was lacking; seroprevalence 
estimates from constant and age-varying models were broadly 
similar and differences in cross-validation errors from dif-
ferent models were small (Supplementary Table 3). However, 
in age-varying models transmission intensity was more fre-
quently (11 out of 13 countries) higher in younger children, 
perhaps indicating their increased exposure to infectious 
mosquito bites. In Singapore, FOI declined for a significant 
proportion of the study sample (children aged > 3  years), a 
finding which is biologically counter intuitive. This is possibly 
a consequence of intensive and effective vector control activi-
ties and behavior that minimizes exposure to infectious bites 
(eg, use of air conditioning) resulting in low seroprevalence 
throughout childhood. Singapore also tends to experience se-
vere, cyclical epidemics and a recent large outbreak could re-
sult in higher seroprevalence in younger than older children. 
For example, there was a large outbreak in late 2005, approx-
imately 4 years before study subjects were bled, and if young 
children were disproportionately infected this could give the 
impression of declining FOI [25].
According to WHO guidelines, an overall population ben-
efit of dengue vaccination with CYD-TDV dengue vaccine can 
be expected in very high transmission settings, as defined by 
Table 2. Constant and Age-Varying FOI Estimates for Each Country 
Country Constant FOI (95% CI) Age-Varying FOI (95% CI) Corresponding Age Range, y Better Fita





Indonesia 14.7 (12.8–16.9) 15.1 (13.1–17.1)




Malaysia 8.6 (6.7–10.9) 12.2 (11.3–13.1)









Singapore 1.7 (1.4–2.2) 6.6 (4.0–9.2)



















Colombia 18.4 (14.2–23.7) 18.7 (13.1–24.3)









Mexico 7.1 (5.1–9.8) 7.7 (4.8–10.5)









Puerto Rico 8.4 (7.2–9.9) 8.8 (7.1–10.5)




Abbreviations: CI, confidence interval; FOI, force of infection; RMSE, lower root mean squared error.
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seroprevalence of ≥ 80% in subjects aged 9 years of age or older, 
noting that such areas are rare [18]. Here, we estimated that 14 
of 46 (30%) sites met this criterion: 1 in Brazil, 1 in Honduras, 
4 in Colombia, 1 in India, 6 in Indonesia, and at the only site 
included from the Philippines. These data represent transmis-
sion levels when blood samples were drawn, several years ago, 
but indicate several sites may benefit from dengue vaccination 
at the population level.
Another objective of this analysis was to understand vari-
ability in endemicity within countries because few multisite 
dengue seroprevalence studies have been conducted. We identi-
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Figure 2. Observed seroprevalence by age (circles) and 95% confidence interval (CI), adjusted for clustering (spikes) and estimate seroprevalence assuming constant force 
of infection (FOI) (solid line) and 95% CIs (shaded area). Dotted lines correspond to estimated seroprevalence under an assumption of age-varying FOI. (Country-specific se-
roprevalence estimates provided in Supplementary Table 4)
Table 3. Ages at Which 50% and 80% of Children Become Dengue Seropositive, Per Country, Using Constant or Age-Varying Models
Country 
Median Age at Seroconversion, y (95% CI) 80th Percentile Age at Seroconversion, y (95% CI)
Constant Model Age-Varying Model Constant Model Age-Varying Model
India 5.8 (5.5–6.1) 6.5 (6.0–6.9) 13.5 (12.8–14.3) 11.1 (8.8–17.4)
Indonesia 4.7 (4.5–4.9) 4.6 (4.4–4.8) 11.0 (10.5–11.5) 10.6 (10.1–11.2)
Malaysia 8.1 (7.1–9.2) 9.2 (5.9–>18) 18.8 (16.6–21.3) >18
Philippines 2.9 (2.6–3.2) 1.6 (1.4–3.1) 6.7 (6.1–7.4) 8.7 (6.6–12.2)
Singapore >18 >18 >18 >18
Thailand 4.7 (4.2–5.2) 4.2 (3.7–4.9) 10.9 (9.8–12) 12.7 (0–40.2)
Vietnam 6.1 (5.5–6.8) 5.1 (4.3–6.5) 14.1 (12.7–15.7) >18
Brazil 6.5 (5.8–7.3) 7.5 (6.4–9.1) 15.1 (13.4–17.0) 13.3 (11.9–17.4)
Colombia 3.8 (3.5–4.1) 3.7 (3.4–4.1) 8.8 (8.1–9.5) 8.6 (7.9–9.4)
Honduras 4.0 (3.5–4.5) 3.9 (3.3–4.7) 9.2 (8.2–10.3) 9.0 (7.7–10.9)
Mexico 9.8 (8.8–10.9) 9.0 (8.0–10.4) >18 >18
Peru 7.5 (6.5–8.7) 10.6 (6.5–28.8) 17.4 (15.1–20.2) >18
Puerto Rico 8.2 (7.0–9.6) 7.9 (6.6–9.8) >18 >18
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in Indonesia, the median age of first infection varied between 
sites from 2.3 to 10.1 years, and in Brazil this varied from 3.7 to 
11.4 years. We did not have data from multiple sites in all coun-
tries but this implies site-specific seroprevalence assessments 
would be needed prior to dengue vaccine introduction without 
prior serotesting, and such data would be useful to prioritize 
areas where vaccination would be most efficient [18]. However, 
few observed seroprevalence data points fell outside the confi-
dence intervals of our estimated seroprevalence and statistical 
approaches such as this, accounting for uncertainty, could be 
considered complementary to empirical seroprevalence studies 
in endemic countries [13].
Our analysis was confined to exploring FOI and seroprev-
alence as a function of age but, because dengue is a cyclical, 
epidemic disease, calendar time is another, and perhaps more 
plausible, explanation for observed variation in FOI, as ob-
served elsewhere [26]. Our study precluded detailed analysis of 
the effect of time on FOI; although data were available for more 
than 1 time point in some countries, samples for most countries 
were collected within a 2-year timeframe. While higher FOI in 
younger age groups is a finding compatible with higher trans-
mission intensity in more recent years, we could not explore 
specific and granular cohort effects. Future studies would be 
needed to shed further light on the contributions of age, time, 
and geography to variations in dengue endemicity. Another 
limitation of our analysis is that many of our datasets were 
collected for the purposes of clinical research rather than as part 
of geographically representative surveys. These clinical trials, 
from which 58% of our data were collected, often targeted areas 
of high dengue endemicity, cannot be considered nationally 
representative, and, in countries where endemicity is hetero-
geneous, likely represent populations with higher-than-average 
exposure. This is especially relevant for Latin American coun-
tries where dengue is not endemic nationwide; for example, in 
Columbia and Mexico significant proportions of the population 
live in areas where the disease does not circulate [27].
The models used for FOI estimation impose certain con-
straints; notably, the power of age-varying models to detect a 
meaningful breakpoint is partly dependent on the age range of 
the data, which varies between countries. We confined the anal-
ysis to single breakpoints corresponding to whole years of age 
and to years with > 2 years of adjacent data, which is a simplistic 
design, prohibiting additional flexibility. Comparisons between 
countries on this point should therefore be made with caution. 
Akaike’s information criterion was used to identify optimal 
(constant vs age varying) models for each country but in many 
cases both models fit the data well and we identified only weak 
evidence for age-varying effects.
All 4 dengue serotypes circulate in most of these countries 
[28] and we calculated only total (or average) dengue FOI, as-
suming this is relatively stable over time, without more granular 
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Figure 3. Age of 80% seroconversion by site, estimated from best-fitting constant (circles) or age-varying (diamonds) models. Symbol size corresponds to frequency 
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characterized by cyclical introductions of different serotypes 
giving rise to outbreaks, as elegantly demonstrated in an ex-
tremely thorough longitudinal serological analysis from the city 
of Iquitos in Peru [26, 29]. The authors demonstrated high at-
tack rates following the introduction of new serotypes into naive 
populations of up to 89 infections/100 person-years and accom-
panying high, time-varying, serotype-specific FOI fluctuating 
across time and serotypes. From our samples, over 90% tested 
by PRNT50 showed evidence of infection with > 1 serotype 
(possibly due to cross-reaction rather than true infection) and 
calculation of meaningful serotype-specific FOI estimates was 
therefore not possible without making unreliable assumptions 
from PRNT titers. Because total FOI has been shown to approx-
imate the sum of serotype-specific FOI [10], we considered the 
approach was reasonable, and more complex modeling activ-
ities would be needed to further understand serotype-specific 
transmission dynamics. Our data should be considered repre-
sentative of long-term average dengue exposure rates.
The infection history of around 40% of samples was deter-
mined by IgG ELISA. In concordance experiments, we found 
97% of IgG-positive samples were PRNT50 positive, providing 
a high level of confidence in the specificity of these tests but it 
was not possible from our dataset to assess sensitivity of the IgG 
vs PRNT.
We also did not consider the impact of other flavivirus in-
fections but in dengue-endemic areas we considered positive 
dengue diagnostic results, confirmed by PRNT, to be definitive. 
Approximately 45% of samples came from India and Indonesia, 
countries in which large dengue seroprevalence studies had 
been conducted and the proportions of children in Asian 
studies were higher than in Latin America, which could affect 
statistical power.
Nonetheless, these data provide one of the largest dengue 
seroprevalence analyses performed, provide epidemiological 
information across endemic countries, can be used to guide 
public health decision-making, including the benefits/risks of 
vaccination, and inform health economic analyses.
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